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Abstract 
Infection with the parasite Toxoplasma gondii causes foetal abnormalities during 
pregnancy and encephalitis in immunocompromised individuals in both developed and 
developing countries. Inside the host cell, Toxoplasma resides in a protective 
parasitophorous vacuole (PV), allowing it to survive and replicate. Following 
infection, the cytokine interferon gamma (IFNγ) upregulates the p47 immunity-related 
GTPases (IRGs) and the p65 guanylate-binding proteins (GBPs). Both IRGs and GBPs 
are highly expressed in IFNγ-induced cells in vitro and accumulate at the PV of 
avirulent type II and III, but not virulent type I strains of Toxoplasma, mediating the 
disruption of the avirulent PV. Autophagy, the process targeting intracellular cargo for 
degradation by the lysosome, has been shown to be a key player in cell-autonomous 
resistance to Toxoplasma. Inflammasomes, the signalling platforms of the innate 
immunity detecting pathogenic and danger molecules, have been reported to regulate 
non-cell-autonomous restriction of Toxoplasma. However, the mechanisms involved 
in these two defence responses and what happens once the vacuole is disrupted remain 
unclear.  
In this work, I investigate the role of ubiquitin in IFNγ-dependent resistance against 
Toxoplasma infection. I identified the E3 ubiquitin ligase TRIM21 as a novel 
interaction partner of GBP1. TRIM21 and GBP1 were co-recruited to the PV of 
avirulent but not virulent Toxoplasma. I show that avirulent, but not virulent 
Toxoplasma, is ubiquitinated in an IFNγ- and TRIM21-dependent manner, with 
TRIM21 partly mediating Lys63 ubiquitin linkages. TRIM21 differentially regulated 
the transcriptional and protein levels of GBP1 and GBP2, which were identified as 
substrates of the E3 ligase. TRIM21 also substantially upregulated the biosynthesis of 
  8 
cholesterol, for which Toxoplasma is auxotroph. TRIM21-/- mice were highly 
susceptible to Toxoplasma infection and exhibited decreased levels of pro-
inflammatory cytokines in their serum associated with higher parasite burden in the 
periphery and later in the brain. These findings suggest TRIM21 is a crucial, novel 
restriction factor during acute Toxoplasma infection. 
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FCS: fetal calf serum 
GAP: GTPase activating protein 
GBP: guanylate binding protein 
GDP: guanosine di-phosphate 
GEF: guanine nucleotide exchange factors 
GFP: green fluorescent protein 
GKS: glycine-lysine-serine 
GM-CSF: granulocyte-macrophage colony stimulating factor 
GMP: guanosine mono-phosphate 
GMS: glycine-methionine-serine 
GPI: glycophosphatidylinositol 
GTP: guanosine tri-phosphate 
GTPase: GTP hydrolase 
h: hour 
H2O: dihydrogen monoxide (water) 
HCl: hydrochloric acid 
HCV: hepatitis C virus 
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HECT: homology to E6-AP C-terminus 
HEK 293T: human embryonic kidney 293T 
HeLa: Henrietta Lacks 
HFF: human foreskin fibroblast 
HIV: human immunodeficience virus 
HRP: horseradish peroxidase 
IAP: immunoaffinity purification 
IB: immunoblot 
IC100: inhibitory concentration 100% 
IF: immunofluorescence 
IFA: indirect fluorescence antibody assay 
IFN: interferon 
Ig: immunoglobulin 
IgM-ISAGA: Immunoglobulin M-immunosorbent agglutination assay 
IL: interleukin 
IMDM: Iscove's modified Dulbecco's media 
IP: immunoprecipitation 
i.p.: intraperitoneal 
IRF: interferon regulatory factor 
IRG: immunity-related GTPase 
IVIS: in vivo imaging system 
K: lysine 
KO: knockout 
LAMP2: lysosomal membrane-associated protein 2 
LC: liquid chromatography 
LC3: microtubule-associated protein 1 light chain 3 
LIR: LC3-interacting region 
LPS: lipopolysaccharide 
LRR: leucine-rich repeat 
M: molar 
Mb: megabase 
M-CSF: macrophage colony-stimulating factor 
MEF: mouse embryonic fibroblast 
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µg: microgram 
mg: milligram 
MgCl2: magnesium chloride 




mLN: mesenteric lymph node 
m: micrometre 
mM: millimolar 
MOI: multiplicity of infection 
MS: mass spectrometry 
Mx: myxovirus resistance 
NaCl: sodium chloride 
NADPH: nicotinamide adenine dinucleotide phosphate 
NaN3: sodium azide 
NBR1: neighbour of BRCA1 gene 1 protein 
NDP52: nuclear dot protein 52 kDa 
NF-κB: nuclear factor κB 
NH4Cl: ammonium chloride 
NK: natural killer 
NLR: NOD-like receptor 
NLRC: NLR family, CARD-containing 
NLRP: NLR family, pyrin domain-containing 
NO: nitric oxide 
NOD: nucleotide-binding oligomerisation domain 
NP-40: nonyl phenoxypolyethoxylethanol 40 
O/N: overnight 
PAMP: pathogen-associated molecular pattern 
PBA: PBS + 1% BSA 
PBS: phosphate buffered saline 
PCR: polymerase chain reaction 
PE: phosphatidylethanolamine 
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PEC: peritoneal exudate cell 
PI3K: phosphatidylinositol 3-kinase 
PLA: proximity ligation assay 
PP: Peyer’s patches 
PRR: pattern recognition receptor 
Pru: Prugniaud 
PTM: post-translational modification 
PV: parasitophorous vacuole 
PVM: parasitophorous vacuole membrane 
PYD: pyrin domain 
qPCR: quantitative polymerase chain reaction 
RabGDI: Rab dissociation inhibitor 
RBCC: RING, B-box, coiled-coil domain 
RIG-I: retinoic acid-inducible gene-I 
RIN: RNA integrity number 
RING: really interesting new gene 
RNA: ribonucleic acid 
RNase: ribonuclease 
ROP: rhoptry protein 
RPMI: Roswell Park Memorial Institute medium 
RT: room temperature 
SCB: sodium cacodylate buffer 
SCV: Salmonella-containing vacuole 
SCX: strong cationic exchange 
SDS-PAGE: sodium dedocyl sulfate polyacrylamide gel electrophoresis 
sec: second 
SeV: Sendai virus 
SILAC: stable isotope labelling with amino acid in cell culture 
SNARE: soluble N-ethylmaleimide-sensitive factor attachment protein receptor 
STAT: signal transducer and activator of transcription 
T3SS: type III secretion system 
TAE: Tris-Acetate-EDTA 
TFA: trifluoroacetic acid 
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TLR: Toll-like receptor 
TNF: tumor necrosis factor 
Tom: tomato 
Toxoplasma: Toxoplasma gondii 
TRAF: TNF receptor-associated factor 
TRIM: tripartite motif-containing protein 
U: unit Ub: ubiquitin 
UV: ultraviolet 
VH: variable region heavy chain 
VL: variable region light chain 
VLIG: very large inducible GTPase 
Vps: vacuolar protein sorting 
VSV: vesicular stomatitis virus 
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1.1 Toxoplasmosis in the 21st century 
1.1.1 Toxoplasmosis: a global health problem 
Toxoplasmosis refers to an infectious disease that is caused by an opportunistic 
parasite called Toxoplasma gondii (Toxoplasma) and is considered one of the most 
common parasitic zoonoses in the world. It is estimated that up to a third of the human 
population is infected with Toxoplasma, arguably rendering it the most successful 
parasite. However, the seroprevalence varies greatly between countries, with incidence 
rates ranging between almost 0% and 90% (Figure 1.1).  
In European countries such as Austria, Belgium, France, Germany, Poland, Spain and 
the United Kingdom, seroprevalence has been estimated to range between 9.1% and 
63.2% in pregnant women. Seroprevalence is higher in Latin American countries such 
as Argentina, Brazil, Columbia and Venezuela (6.1-77.5%) or African countries such 
as Ethiopia, Ghana and Democratic Republic of Congo (25.3-92.5%). Seroprevalence 
is lower in Asian countries such as China, India, Japan, Korea and Thailand (0.88-
45%) (Table 1.1). However, the true magnitude of the disease is most likely unknown 
as toxoplasmosis remains asymptomatic in most cases and pregnant women and 
immune-compromised patients mainly constitute the cohorts of seroprevalence 
studies. The differences in toxoplasmosis incidence in various countries can be 
attributed to a preference for eating raw or undercooked meat, but also to a 
geographical localisation in a warm and low altitude climate favouring the survival of 
Toxoplasma oocysts. Indeed, epidemiologic studies have identified several risk factors 
for Toxoplasma infection: being in proximity to seropositive cats in farming areas 
(Weigel et al., 1999); cleaning an infected cat litter box (Kapperud et al., 1996); eating 
raw or undercooked meat including pork, mutton, lamb, beef or mincemeat products 
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(Kapperud et al., 1996; Baril et al., 1999; Weigel et al., 1999; Cook et al., 2000); 
gardening or being in contact with soil (Weigel et al., 1999; Cook et al., 2000); eating 
raw or unwashed vegetables and fruits and having poor hand hygiene (Baril et al., 
1999).  
Toxoplasmosis is responsible for high morbidity. In the United States (US), where 
Toxoplasma infects a predicted 1.1 million persons every year (Jones and Holland, 
2010), studies investigating foodborne illness have estimated toxoplasmosis to be the 
major foodborne disease leading to hospitalisation (Mead et al., 1999; Vaillant et al., 
2005; Scallan et al., 2011; Batz et al., 2012), the second cause of death among 
foodborne infections (Scallan et al., 2011; Batz et al., 2012) and a leading contributor 
to the loss of quality-adjusted life years (Havelaar et al., 2007; Scallan et al., 2011; 
Batz et al., 2012). Toxoplasmosis is a zoonotic disease that has impact from both a 
medical and a veterinary point of view. Economically, Toxoplasma infection is 
considered to be one of the most important diseases in animals and causes a variety of 
clinical manifestations in humans requiring different levels of health care. The annual 
economic impact of toxoplasmosis in the US, determined by medical costs, income 
losses and costs incurred by special education or residential care required as a result 
of a handicap caused by congenital toxoplasmosis, is estimated to be $7.7 billion 
(Roberts et al., 1994; Buzby and Roberts, 1996).  
1.1.2 Toxoplasmosis: clinical manifestations 
In immune-competent individuals, most Toxoplasma infections are asymptomatic. It 
is estimated that 10% to 20% of Toxoplasma-infected immune-competent adults and 
children will develop symptoms of toxoplasmosis (Remington, 1974). Since the 
description of the lymphadenopathic form of toxoplasmosis (Gard and Magnusson, 
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1951), it has been recognised as the most common clinical manifestation of the disease 
in humans. Fever, malaise, night sweats, myalgia, sore throat and abdominal pain 
might accompany lymphadenopathy. Thus, the signs of infection mimic the symptoms 
of very common infectious diseases. If present, the symptoms usually resolve within 
a few months and they rarely continue over a year. In less frequent cases, immune-
competent individuals will develop encephalitis (Hemsath and Pinkerton, 1956), 
pneumonitis (Ludlam and Beattie, 1963), pericarditis (Jones et al., 1965), hepatitis 
(Vischer et al., 1967), myocarditis (Theologides and Kennedy, 1969; Cunningham, 
1982; Montoya et al., 1997) or myositis (Greenlee et al., 1975; Montoya et al., 1997). 
Infection with Toxoplasma has been identified as a major cause of uveitis (Montoya 
and Remington, 1996; Holland et al., 1999), and it is responsible for more than 85% 
of chorioretinitis cases in Brazil (Silveira et al., 1988). Symptoms of acute toxoplasmic 
chorioretinitis include blurred vision, pain, and photophobia, and can result in partial 
or complete loss of vision. More recently, serological surveys have suggested chronic 
toxoplasmosis may be a risk factor for the development of schizophrenia or other 
human behavioural disorders (Yolken et al., 2001; Hinze-Selch et al., 2010; Okusaga 
et al., 2011; Gale et al., 2014; Markovitz et al., 2015; Celik et al., 2015; Monroe et al., 
2015). 
Congenital infection occurs when seronegative women acquire toxoplasmosis during 
pregnancy and transmit the infection to the foetus. Clinical manifestations of 
congenital toxoplasmosis depend on the time the infection was acquired in utero: they 
are most severe if transmission of infection occurs before 24 weeks of gestation, 
whereas transmission after week 26 results in subclinical disease that will develop later 
in life (Desmonts et al., 1985; Daffos et al., 1988). Clinical manifestations of 
congenital toxoplasmosis often affect the retina and the central nervous system with 
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symptoms including chorioretinitis, strabismus, blindness, epilepsy, psychomotor or 
mental retardation, encephalitis, microcephaly, hydrocephalus and pneumonitis 
(Remington et al., 2011). 
Immune-deficient individuals are at high risk of severe Toxoplasma infection. This 
specific group of hosts includes patients receiving immunosuppressive therapy with 
corticosteroids or cytotoxic drugs, and individuals with organ transplant or acquired 
immune deficiency syndrome (AIDS). Severe clinical manifestations are usually the 
consequence of a reactivation of a latent infection and are usually fatal if not 
recognised and treated (Gallino et al., 1996). After the appearance of the AIDS 
epidemic, the frequency of Toxoplasma encephalitis increased (Horowitz et al., 1983; 
Roué et al., 1984; Velimirovic, 1984; Enzensberger et al., 1985; Suzuki et al., 1988; 
Israelski and Remington, 1988). Toxoplasma encephalitis was a major cause of death 
in HIV patients before the introduction of anti-retroviral therapy (Luft et al., 1983; 
1984; 1993). In the setting of AIDS, patients with reactivated toxoplasmosis most 
often present symptoms of encephalitis (Luft and Remington, 1992) but also less 
frequently symptoms of pulmonary disease (Oksenhendler et al., 1990; Derouin et al., 
1990; Rabaud et al., 1996) and eye disease (Holland et al., 1988). Recipients of heart, 
kidney and liver transplantation have also been diagnosed with reactivated 
toxoplasmosis (Aubert et al., 1996; Renoult et al., 1997; Giordano et al., 2002). 
Infection usually develops within three months after transplantation, and clinical 
symptoms may arise in the central nervous system, retina or lung as observed in AIDS 
patients (Fernàndez-Sabé et al., 2012). 
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1.1.3 Toxoplasmosis: diagnosis, treatment and prevention 
Possible reactivation of latent toxoplasmosis and the discovery of Toxoplasma cysts 
in asymptomatic carriers enforced the need to develop accurate methods to diagnose 
toxoplasmosis, especially in expecting mothers and immune-compromised 
individuals. As clinical signs of human toxoplasmosis are often absent or non-specific, 
definite diagnosis of the disease is performed by serological, histological or molecular 
methods. Sabin and Feldman developed the first significant serological toxoplasmosis 
diagnosis, the dye test, in 1948. This test relies on antibody-mediated killing of live 
Toxoplasma in the presence of complement-activated antibodies. Intact, live 
Toxoplasma parasites retain a vital dye and appear blue under the microscope when 
incubated with methylene blue in the presence of normal serum. However, if incubated 
in the presence of serum containing anti-Toxoplasma antibodies from an infected 
patient, the parasite membrane is lysed by the complement-activated neutralising 
antibodies and does not retain the vital blue dye (Sabin and Feldman, 1948). Although 
highly sensitive and specific, the dye test requires Toxoplasma parasites to be 
constantly maintained in the analysis laboratory. The development of new methods to 
allow for detection of Toxoplasma-specific antibodies enabled circumvention of this 
issue. The first Toxoplasma-specific IgM assay was developed in 1968 by Remington 
et al. and proved to be a useful tool to diagnose congenital toxoplasmosis because IgM 
antibodies do not cross the placental barrier whereas IgG antibodies do (Remington et 
al., 1968). Other serological tests allowing detection of Toxoplasma-specific IgM 
antibodies include the indirect fluorescent antibody assay (IFA) (Miller et al., 1969), 
the enzyme-linked immunosorbent assay (ELISA) (Naot and Remington, 1980), the 
IgM-immunosorbent agglutination assay (IgM-ISAGA) (Desmonts et al., 1981) and 
by 1989, serological tests were successfully adapted to automated systems (Schaefer 
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et al., 1989). In immune-competent individuals, serological tests are the method of 
choice. However, serological diagnosis has been complemented with histological or 
molecular tests in immune-deficient individuals who might not reliably produce 
antibodies. Developed in 1989 by Burg et al. (Burg et al., 1989), the detection of 
Toxoplasma DNA by polymerase chain reaction (PCR) amplification in body fluids 
such as blood or amniotic and cerebrospinal fluids as well as in tissues has shown to 
be effective and more sensitive than any other technique (Romand et al., 2001). 
There is no effective treatment available to date that can eradicate chronic 
toxoplasmosis. As a result, immune-competent individuals latently infected with 
Toxoplasma are usually not treated. However, in rare cases when symptoms arise, after 
organ transplantation or in immune-compromised individuals, prophylaxis must be 
undertaken. The standard treatment in these cases consists in a combined therapy with 
sulphonamides and pyrimethamine. Although individual efficacy of sulphonamides 
(Sabin and Warren, 1942) has been established, its effectiveness is eight-fold higher 
when synergised with pyrimethamine (Eyles and Coleman, 1953). Because it does not 
cross the placenta, spiramycin can be used prophylactically during pregnancy in order 
to reduce transmission of the parasite from the mother to the foetus (Garin and Eyles, 
1958; Desmonts and Couvreur, 1974). 
To date, drug treatment can only control the active proliferation of the parasite but 
does not eradicate infection. Thus, Toxoplasma vaccines -ideally for the various life 
cycle stages- would be extremely valuable in order to limit acute parasitemia and 
protect against congenital toxoplasmosis, to reduce tissue cysts in livestock and to 
reduce oocysts secretion in felids. The live but cystless Toxoplasma strain S48 has 
been used to develop an ovine vaccine. It has been shown to reduce the rate of abortion 
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in sheep to a limited extend (O'Connell et al., 1988; Wilkins et al., 1988). The 
protection conferred by this vaccine has been evaluated up to 18 months after the initial 
vaccination (Buxton et al., 1993). The resulting commercially available ovine vaccine, 
ToxovaxTM, is administered as a single shot prior to mating but needs to be repeated 
after 2 years (Buxton and Innes, 1995). This vaccine is only licenced for veterinary 
purposes, as it consists of a live Toxoplasma, which could potentially regain virulence. 
There is currently no vaccine available to prevent Toxoplasma infection in humans. 
However, several measures can be adopted to prevent or minimise the risks of 
contamination. These include hygienic methods such as avoiding contact with or 
washing hands after contact with cats and their litters, wearing gloves while gardening 
and washing raw fruits and vegetables thoroughly before consumption. Studies 
revealed Toxoplasma tissue cysts in meat can be killed by cooking at 67°C (Dubey et 
al., 1990), freezing at -13°C (Kotula et al., 1991) or exposing to 0.5 krad of gamma 
irradiation (Dubey and Thayer, 1994). Domestic cats should also be fed thoroughly 
cooked meat as an alternative to dry or canned food. The easiest and most economical 
method to reduce contamination through meat remains freezing fresh meat overnight 
before human or animal consumption. Recommendations for prevention of 
toxoplasmosis among pregnant women and HIV patients have been published (Centers 
for Disease Control and Prevention, 2000; USPHSIDSA, 1999). 
1.2  Biology of Toxoplasma gondii 
1.2.1 Toxoplasma: a brief history of its discovery 
It has been more than a century since the discovery of Toxoplasma at the Pasteur 
Institute in Tunis. In 1908, while performing research on leishmaniasis using a 
hamster-like rodent called Ctenodactylus gundi, Nicolle and Manceaux discovered a 
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new protozoan in the tissues of two dead animals (Nicolle and Manceaux, 1908). At 
the same time, Splendore reported the existence of a similar organism in the tissues of 
a rabbit in Brazil (Nicolle and Manceaux, 1909; Splendore, 1908). As reported during 
a meeting at the ‘Académie des Sciences’ in Paris on the 26th of October that year, 
Nicolle and Manceaux first thought they had identified a new species of Leishmania 
and initially called the protozoan Leishmania gondii (Nicolle and Manceaux, 1908). 
They soon realised their mistake and created a new genus of protozoan in 1909 called 
Toxoplasma gondii based on the morphology of the parasite –toxo meaning arc or bow 
in Greek- and its initial host (Nicolle and Manceaux, 1909). As early as 1937 Sabin 
and Olitsky, two virologists working with guinea pig brains, noticed that Toxoplasma 
multiplication was only possible inside a living cell, describing it as an obligate 
intracellular parasite for the first time. They were also able to successfully passage 
Toxoplasma from animal to animal via intracranial, intraperitoneal or subcutaneous 
infections of brain inoculum. At a time when the possibility of an insect vector was 
still being investigated, Sabin and Olitsky reported the possibility that ‘one method of 
natural dissemination may be by means of the eating of toxoplasma-contaminated 
tissues’ after mice fed on Toxoplasma-infected mice also became infected. 
Interestingly, they noted the serum of recovering rhesus monkeys contained 
“neutralising” or “protective” antibodies (Sabin and Olitsky, 1937). The first reference 
of toxoplasmosis in humans came several decades after the parasite’s discovery, when 
Janku described the case of a blind, deceased 11-month old baby who suffered from 
hydrocephalus and chorioretinitis and harboured parasitic cysts in his right eye (Janku, 
1923). In 1939, three pathologists -Wolf, Cohen and Paige- firmly identified free and 
intracellular Toxoplasma parasites in tissues from a deceased congenitally infected 
newborn girl. Brain parasites isolates were successfully used to infect rabbits and mice 
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that developed encephalitis (Wolf et al., 1939a; b; 1940). These two cases were the 
first reports of human congenital toxoplasmosis. In 1941, Sabin described the case of 
a six year-old boy with the initials R.H. who was admitted to hospital several days 
after being hit with a baseball bat. Following his death, brain homogenate was injected 
into mice who died 21 days post-infection, and Toxoplasma gondii strain RH isolated 
from this child is still being used in the laboratory (Sabin, 1941). The same year, 
Pinkerton and Weinman isolated Toxoplasma from the tissues of two adults and were 
able to passage them in animals (Pinkerton and Henderson, 1941). These two cases 
were the first reports of acquired acute toxoplasmosis in young and adult humans. As 
the parasites were mainly found during post-mortem histopathology in patients 
suffering from encephalitis and/or chorioretinitis, toxoplasmosis was thought to only 
lead to acute infection. Kean and Plaut were the first to note the presence of 
Toxoplasma cysts in the heart and brain of deceased asymptomatic patients, suggesting 
for the first time the possibility of a chronic asymptomatic Toxoplasma infection (Kean 
and Grocott, 1945; Plaut, 1946; Kean and Grocott, 1947). These combined studies 
confirmed Toxoplasma as an obligate intracellular parasite, capable of congenital as 
well as acquired infections in humans (Table 1.2). 
1.2.2 Life cycle of the parasite  
Toxoplasma has a complex life cycle that consists of two discrete phases. The sexual 
part of the life cycle occurs in members of the feline family, which are the only known 
definitive hosts of Toxoplasma and therefore the main reservoirs of infection (Figure 
1.2). The asexual part of the life cycle takes place in the intermediate host that can be 
any warm-blooded animal, including humans (Figure 1.3). Both stages are essential to 
the life cycle of the parasite.  
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The feline host becomes infected with tissue cysts of Toxoplasma through predation 
of infected animals. After ingestion, the tissue cyst wall is dissolved by proteolytic 
enzymes in the stomach and small intestine. As the cyst breaks, the discharged 
parasites actively invade the epithelial cells of the small intestine. In the feline 
intestine, Toxoplasma first undergoes an asexual development of five different stages 
before gametogony begins. Thus, the sexual cycle starts in the cat 2 days after 
inoculation, and gamonts can be found in the small intestine and ileum from 3 to 15 
days after ingestion of the tissue cyst. An oocyst wall is formed around the parasite 
after fertilisation, the infected epithelial cells rupture and the oocysts are released into 
the intestinal lumen. Millions of unsporulated oocysts are finally shed 3 to 10 days 
after initial ingestion of tissue cysts (Frenkel et al., 1970; Dubey et al., 1970; Dubey 
and Frenkel, 1972). Although infected cats only shed oocysts for a limited period of 
time, the oocysts already sporulate and become infectious 1-5 days after shedding. 
Under laboratory conditions, these sporulated oocysts survived storage at 4°C for up 
to 54 months and freezing at −10°C for 106 days, while they survived at least 32 days 
at 35°C and 9 days at 40°C (Dubey, 1998). Toxoplasma sporulated oocysts released in 
the environment can thus survive for up to several years under the right climate 
conditions.  
Intermediate hosts like livestock and humans can subsequently become ‘accidentally’ 
infected with Toxoplasma in several ways: ingestion of contaminated uncooked meat 
or unwashed vegetables (Kapperud et al., 1996; Baril et al., 1999; Weigel et al., 1999; 
Cook et al., 2000), faecal contamination of drinking water or hands by soil contact 
(Baril et al., 1999), transmission between humans through organ transplant (Aubert et 
al., 1996; Renoult et al., 1997; Giordano et al., 2002), and transmission from the 
infected mother to the unborn child (Wolf et al., 1939a; b; 1940). There are three 
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possible infectious stages of Toxoplasma in the intermediate host: the tachyzoites, the 
bradyzoites and the sporozoites. The latter refer to the parasites contained within the 
oocysts. The tachyzoites (tachos meaning speed in Greek) refer to the rapidly 
multiplying parasites in any nucleated cell of the intermediate host. The bradyzoites 
(brady meaning slow in Greek) describe the slowly replicating parasite within a tissue 
cyst. After ingestion of parasites by an intermediate host, the sporozoites or 
bradyzoites break the oocyst or tissue cyst wall, respectively. Toxoplasma parasites 
released in the small intestine must spread into the organism. They do so either by a 
transmigration route across the intestinal epithelium (Barragan and Sibley, 2002), or 
by parasitising neutrophils within the lumen that are capable of migrating through the 
intestinal epithelium to the lamina propria (Coombes et al., 2013), where they 
encounter more neutrophils, inflammatory monocytes and dendritic cells (DCs) 
(Gregg et al., 2013). They then use these leucocytes, especially hypermotile DCs, as 
“Trojan horses” to migrate via the intestinal lymphatic system to the secondary 
lymphoid organs, including the spleen and the lymph nodes (Zenner et al., 1998; Da 
Gama et al., 2004; Lambert et al., 2006; Bierly et al., 2008; Fuks et al., 2012; Weidner 
et al., 2013). Toxoplasma parasites continue their dissemination in the blood stream in 
order to reach other secondary organs (Unno et al., 2008; Silveira et al., 2011). In the 
blood, Toxoplasma parasites are preferentially found in monocytes if not free 
(Channon et al., 2000; Courret et al., 2006; Unno et al., 2008; Silveira et al., 2011). 
This defines the acute phase of the infection. Finally, Toxoplasma tachyzoites 
predominantly migrate to the brain and eye by a mechanism that still remains to be 
described. Studies have shown Toxoplasma-infected monocytes can cross an in vitro 
model of blood-brain barrier (Lachenmaier et al., 2011) and can also deliver the 
parasites to the mouse brain (Courret et al., 2006). Parasitised DCs are able to 
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transmigrate across the retinal endothelium (Furtado et al., 2012). Free tachyzoites can 
directly infect brain microvascular endothelial cells (Lachenmaier et al., 2011) and 
cross multiple layers of ex vivo retinal cultures (Furtado et al., 2013). Once in the brain, 
Toxoplasma may infect microglia, the resident macrophages in the brain, in order to 
potentiate their spread (Dellacasa-Lindberg et al., 2011). Finally, Toxoplasma 
tachyzoites convert into the slow-replicating and long-lasting bradyzoites organised in 
tissue cysts, distributed homogenously in the brain (Berenreiterová et al., 2011). This 
defines the chronic phase of the infection.  
1.2.3 Ultrastructure of the parasite 
The three infectious stages of Toxoplasma –namely the tachyzoite, the bradyzoite and 
the sporozoite– present the same basic morphological features with only minor 
variations. However, due to its ease to cultivate both in vitro and in vivo, the tachyzoite 
has been the most widely used and described. The Toxoplasma tachyzoite is a 2x7 µm 
crescent shaped cell that presents a pointed anterior end and a rounded posterior end. 
The anterior end is defined by the direction of motility and is also called apical or 
conoidal end. The ultrastructure of Toxoplasma tachyzoites was extensively 
investigated thanks to the advancement of electron microscopy (EM). In 1954-1956, 
Gustafson et al. and then Meyer and De Mendonça carried out the first EM studies of 
Toxoplasma tachyzoites (Gustafson et al., 1954; Meyer and De Mendonça, 2007; 
Meyer and Porter, 2008). Their work revealed that the parasite displays the same 
features as any eukaryotic organism, namely a nucleus, endoplasmic reticulum, Golgi 
apparatus and ribosomes (Figure 1.4). Toxoplasma also harbours two endosymbiosis-
derived organelles, a mitochondrion and an apicoplast. The whole cell is enclosed 
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within a pellicle, a complex membrane comprising an outer plasmalemma and an inner 
layer formed by two closely applied membranes.  
Electron microscopy also allowed the identification of three specialised organelles – 
rhoptries (Garnham et al., 1962), micronemes (Garnham et al., 1961; 1962) and dense 
granules (Ogino and Yoneda, 1966)– that are characteristic features of Apicomplexan 
parasites. Rhoptries are excretory structures situated between the anterior tip and the 
nucleus. There are 8 to 10 of these long club-shaped organelles, each consisting of an 
anterior narrow neck up to 2.5 µm long and a saclike posterior end up to 0.25x1 µm 
long. Micronemes are short rod-shaped structures (250x50 nm) mainly located at the 
most anterior end of the parasite. Dense granules (0.3 µm diameter) are found 
throughout the cell but mostly at the posterior end of the parasite. These three specific 
Apicomplexan organelles play a major and sequential role during invasion of the host 
cell. 
Toxoplasma contains a nuclear genome of about 87 Mb organised on 11 chromosomes 
(Wilson and Williamson, 1997; Sibley et al., 1992). Phylogenetic analyses have shown 
that Toxoplasma comprises three major genotypic lineages referred to as types I, II 
and III, the majority of human isolates belonging to type II (Sibley and Boothroyd, 
1992; Howe and Sibley, 1995; Johnson, 1997). Although these three strains vary in 
their virulence in mice, there are no appreciable structural differences among the three 
different isolates of Toxoplasma. 
1.2.4 Host cell invasion 
Toxoplasma is able to infect any nucleated host cell in any warm-blooded animal, 
including humans. Toxoplasma tachyzoites can enter the host cell by either active 
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penetration through the plasmalemma, or by phagocytosis. In the first instance, the 
process is entirely driven by the parasite, whose successful entry into the host cell will 
enable it to avoid host cellular defences such as acidification or endolysosomal 
hydrolases. Toxoplasma first glides on the potential host cell using an intricate linear 
motor system, and probes the host cell with its conoidal tip. Once it has targeted a cell 
to invade, adhesion molecules stored in the vesicular micronemes are the first proteins 
discharged in a calcium-dependent fashion in order to tighten attachment areas with 
the cell to be invaded (Carruthers and Sibley, 1997; Carruthers et al., 1999; Huynh et 
al., 2003; Cérède et al., 2005). The second wave of secretion involves the rhoptry neck 
proteins (RON), interacting with the microneme-derived AMA1 protein and forming 
a so-called moving junction that constitute an intimate binding interface of less than 6 
nm (Mital et al., 2005; Alexander et al., 2005; Lebrun et al., 2005). Another secretion 
of rhoptry proteins (ROP) into the host cytoplasm triggers the invagination of the host 
cell plasma membrane and is instrumental in the formation of a parasitophorous 
vacuole (PV), where Toxoplasma tachyzoites reside and replicate inside the host cell 
(Suss-Toby et al., 1996; Carruthers and Sibley, 1997). Some ROP proteins including 
ROP2, ROP3, ROP4 and ROP7 remain associated with the PV membrane (PVM), 
while other ROP proteins remain soluble and may target to other sites in the host cell 
(Saffer et al., 1992; Carruthers and Sibley, 1997). Finally, as the PVM pinches off and 
separates from the host cell membrane, the dense granule proteins GRA1, GRA2, 
GRA3, GRA4, GRA5 and GRA6 are released into the PV as soon as its formation is 
complete (Ossorio et al., 1994; Carruthers and Sibley, 1997; Mercier et al., 1998a; b). 
De novo formation of the rather large 30-33 µm2 PVM occurs in an estimated 10-20 
seconds interval. It has thus been postulated and demonstrated that the majority of 
lipids composing the PVM are host cell derived (Suss-Toby et al., 1996). On the other 
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hand, other host cell proteins are completely excluded from the Toxoplasma PVM. 
Indeed, the parasite regulates the contents of the PVM by preventing host proteins like 
SNAREs accumulating on the PVM (Suss-Toby et al., 1996). Thus, the PV never fuses 
with endolysosomes (Jones et al., 1972; Mordue and Sibley, 1997) and is resistant to 
acidification (Sibley et al., 1985), enabling the PV to provide a safe and protective 
place for the parasite to survive in the host cell, allowing it to persist despite a vigorous 
immune response.  
The Toxoplasma route of entry into the host cell is critical to the fate of the vacuole. 
Apart from the active, parasite-driven invasion, Toxoplasma can also be phagocytosed 
by host cells. Toxoplasma tachyzoites can be opsonised with neutralising antibodies, 
leading to the acidification of the PV (Sibley et al., 1985) and its fusion with the 
lysosome in macrophages (Jones et al., 1972; Mordue and Sibley, 1997) or CHO cells 
expressing Fc receptors (Joiner et al., 1990). In this instance, the absence of a 
protective PV leads to neutralisation of the parasite, highlighting the importance of the 
PV in the immune escape mechanism inside the host cell. Nevertheless, Toxoplasma 
replication in vivo is restricted. The molecular mechanisms underlying the host-
pathogen interactions by which the parasite maintains the delicate and intricate balance 
between induction and suppression of host immune responses to guarantee survival 
and host defence are not fully understood. 
1.2.5 Division inside the host cell 
Once the parasite has invaded the host cell and established the protective PV, it can 
start replicating by a specific event called endodyogeny. This highly complex process 
is unique as it enables indefinite proliferation. In this form of reproduction, the parasite 
grows and divides to form two progenies. Briefly, the Golgi apparatus is the first 
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organelle to divide, forming two complexes at the anterior end of the nucleus. The 
Toxoplasma nucleus then takes the shape of a horseshoe, and each end of the nucleus 
moves into the apical end of the developing progeny. The inner membrane complex 
continues to grow and encircle one half of the nucleus, eventually pinching it in two. 
The newly obtained daughters formed by endodyogeny are in turn able to undergo 
repeated cycles of asexual reproduction, giving rise to rosette-like structures within 
the PV. The host cell ruptures and releases the tachyzoites when it can no longer 
accommodate the replication of Toxoplasma parasites (Goldman et al., 1958; Garnham 
et al., 1962; Gavin et al., 1962; Sheffield and Melton, 1968).  
1.3 Host defence mechanisms against intracellular pathogens 
1.3.1 The immune system 
Vertebrates are possible targets of infection by numerous pathogens, including viruses, 
bacteria and parasites. These pathogens vary greatly in their mode of pathogenesis, but 
also in their size, structure and complexity. To combat them, vertebrates have evolved 
a dynamic and intricate immune system able to distinguish between self and non-self 
that comprises two different sets of mechanisms: the early, unspecific innate 
immunity, and the slower, long-term adaptive immunity. The successful immune 
response will result in the control or clearance of the pathogen, whilst limiting off-
target impact and damage to the host. The constituents of the innate immunity are for 
the most part constitutively present and thus provide an immediate and maximal 
response to infection. In contrast, the adaptive immune system is pathogen-specific 
and hence requires time to develop an effective response. However, it involves the 
capacity for immunological memory, allowing a more rapid and specific response in 
the case of a future re-infection (Janeway, 2001). 
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Innate immunity is the first line of defence against infective pathogens. It is 
orchestrated by several cell types including macrophages, dendritic cells (DCs), 
natural killer (NK) cells and neutrophils. These cells carry receptors called pattern 
recognition receptors (PRRs) that can be triggered by different sensing mechanisms. 
PRRs are able to recognise and bind distinct molecular signatures associated with 
infections. These signatures can be pathogen-associated molecular patterns (PAMPs) 
or danger-associated molecular patterns (DAMPs). PAMPs are immunostimulatory 
invariant structures shared by large groups of microorganisms. They represent 
essential components for the function and survival of pathogens, are absent from the 
host organism and hence direct the targeted host cell to discriminate self from non-
self. Classical PAMPs recognised by the PRRs are microbial nucleic acids (including 
DNA (Hemmi et al., 2000; Hornung et al., 2009; Fernandes-Alnemri et al., 2009), 
double- or single-stranded RNA (Kanneganti et al., 2006; Sabbah et al., 2009; Sander 
et al., 2011)), but also microbial lipoproteins (Aliprantis et al., 1999; Hirschfeld et al., 
1999), surface glycoproteins (Opitz et al., 2001) or membrane components such as 
peptidoglycans (Yoshimura et al., 1999; Schwandner et al., 1999) or 
lipopolysaccharide (Poltorak et al., 1998; Hoshino et al., 1999). On the contrary, 
DAMPs are host components that are presented in an abnormal cellular context, such 
as host molecules released from stressed or damaged cells (uric acid (Shi et al., 2003), 
chromatin protein HMGB1 (Scaffidi et al., 2002), cytoplasmic DNA (Hornung et al., 
2009; Fernandes-Alnemri et al., 2009; Sun et al., 2013a; Wu et al., 2013)) or 
components from damaged pathogen-containing vacuoles (extracellular hyaluronan 
fragments (Scheibner et al., 2006) or luminal glycans (Dupont et al., 2009; Paz et al., 
2010; Thurston et al., 2012)). Various PRRs are targeted to specific subcellular 
compartments. Toll-like receptors (TLRs) are membrane-bound sensors and can bind 
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to ligands that are present on the cell surface or in endosomal vesicles (Yang et al., 
1998; Kirschning et al., 1998; Qureshi et al., 1999; Schwandner et al., 1999; Underhill 
et al., 1999; Yoshimura et al., 1999; Campos et al., 2001; Opitz et al., 2001; Debierre-
Grockiego et al., 2007; Alexopoulou et al., 2001; Poltorak et al., 1998; Hoshino et al., 
1999; Hayashi et al., 2001; Takeuchi et al., 2001; Hemmi et al., 2000; Foureau et al., 
2010). By contrast, NOD-like receptors (NLRs) (Chamaillard et al., 2003; Girardin et 
al., 2003b; a), DExD/H box (Asp–Glu–x–Asp/His box) helicases (Kang et al., 2002; 
Kato et al., 2005; Yoneyama et al., 2004; Rothenfusser et al., 2005; Saito et al., 2007; 
Satoh et al., 2010), and PYHIN (pyrin and HIN200 domain-containing) proteins 
(Hornung et al., 2009; Fernandes-Alnemri et al., 2009; Jones et al., 2010) are cytosolic 
sensors and can bind to ligands present in the cytosol. Ligand binding and subsequent 
activation of most PRRs leads to an inflammatory state that is characterised by the 
secretion of inflammatory cytokines and chemokines. These proteins work as 
mediators of the immune and inflammatory reactions by alerting the neighbouring 
cells of the infection (Janeway, 2001). 
Adaptive immunity is triggered at a later stage of the infection and is orchestrated by 
two classes of effector cells called B lymphocytes and T lymphocytes. Both cell types 
recognise specific pathogen-derived antigens. B cells are central to humoral adaptive 
immunity and produce antibodies specific to the antigen they bind. T cells are only 
able to recognise antigen peptides that are presented by antigen presenting cells via the 
major histocompatibility complex (MHC). There are two subtypes of T cells: CD4+ 
helper T cells detect peptides presented by MHC II molecules and then activate 
macrophages and promote B cell antibody production, while CD8+ cytotoxic T cells 
recognise peptides displayed on MHC I molecules and once activated, kill infected 
cells (Janeway, 2001). 
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1.3.2 Compartmentalisation as a mean to escape the host immune system 
Many intracellular microorganisms, including bacteria and protozoan parasites, have 
evolved specialised mechanisms to reside and replicate inside the host cell within 
plasma membrane-derived compartments called vacuoles. These vacuoles are formed 
during the uptake of the pathogen and separate it from the host cytosol. The uptake 
process can either be active if the pathogen itself drives invasion into the host cell, or 
it can occur by passive internalisation if the mechanism is host-driven in the case of 
phagocytosis. Regardless of the uptake mechanism, vacuolar pathogens will reside in 
a compartment that provides them with a secure niche. It is likely that vacuole-bound 
pathogens have developed a sequestered lifestyle in the vacuolar niche over residing 
in the nutrient rich cytoplasm to avoid host immune surveillance pathways (Randow 
et al., 2013). Several potential mechanisms can be deployed in order to establish the 
protective pathogenic vacuole. Shortly after invasion, many intracellular vacuolar 
pathogens hijack the host endomembrane system, thereby preventing or delaying the 
fusion with lysosomes. Originally, the vacuole is composed of host-derived 
membranes and shares molecular components of early endosomes. However, to resist 
acidification and avoid endolysosomal fusion, these compartments are gradually 
modified by pathogen-derived proteins and lipids translocated via secretion systems, 
leading to a decreased fusogenicity with host vesicules and organelles. The specificity 
of membrane fusion events is dictated by the presence of Rab proteins, SNAREs and 
tethering factors. Many vacuolar pathogens alter their recruitment to the vacuole to 
establish the replicative niche (Alix et al., 2011). For example, Mycobacterium-
containing vacuoles present features of early endosomes and arrest the phagosome 
maturation process via the action of secreted bacterial factors such as SapM, ManLAM 
and PtpA that inhibit the recruitment and activity of phosphatidyl inositol 3-phosphate 
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effectors and Rab7 at the vacuole (Vergne et al., 2005; Bach et al., 2008). Legionella 
intercepts early secretory vesicles exiting the endoplasmic reticulum (ER) to modulate 
the features of its vacuole, hence avoiding lysosomal compartments. Arf1, which is 
implicated in vesicle budding and recycling at the Golgi apparatus, is recruited to the 
Legionella-containing vacuole by the bacterial protein RalF (Kagan and Roy, 2002). 
Sar1, which is involved in the formation of vesicles that exit from the ER and Sec22b, 
which is involved in the docking of ER-derived vesicles at the Golgi apparatus, are 
also recruited to the Legionella-containing vacuole, although the mechanism of 
recruitment remains unclear (Kagan and Roy, 2002; Kagan et al., 2004). Finally, as 
described previously, Toxoplasma-containing vacuoles are completely devoid of any 
host membrane feature and are thus disconnected from the classical host vesicular 
trafficking pathways (Jones et al., 1972; Jones and Hirsch, 1972).  
Other potential mechanisms may also be employed for the critical maintenance of the 
integrity and stability of pathogenic vacuoles. Several microorganisms modulate their 
hosts’ cytoskeletal functions to maintain and stabilise the intracellular vacuole. For 
example, Salmonella and Chlamydia species inject bacterial effectors into the host 
cytosol via secretion systems, inducing local polymerisation of actin and intermediate 
filaments to consolidate their vacuole. The Salmonella secreted effector SteC is 
required for the remodelling of the F-actin filament network around the Salmonella-
containing vacuole (Poh et al., 2008). The Chlamydia secreted effectors RhoA and 
CPAF contribute to the formation of a dynamic scaffold of host cytoskeletal structures 
consisting of F-actin and intermediate filaments of vimentin and cytokeratin 
surrounding the Chlamydia-containing vacuole (Kumar and Valdivia, 2008). 
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Pathogenic secretion systems and virulence factors help to maintain vacuolar integrity 
and stability essential for its protective property. However, they can also constitute an 
opportunity for the host to detect the presence of an invading organism. Mammalian 
hosts have evolved multiple strategies to unmask the pathogen hiding in its vacuole, 
thereby leading to the engagement of powerful antimicrobial responses and the onset 
of robust inflammatory responses. 
1.3.3 Cytosolic recognition of pathogens: the autophagy pathway 
Autophagy is a fundamental cell survival mechanism that consists of capturing 
cytosolic organelles and proteins into double-membrane vesicles called 
autophagosomes in order to deliver them by fusion to lysosomes for degradation or 
elimination. Meaning ‘self-eating’ in Greek, autophagy enables the cell to generate an 
autonomous source of amino acids and energy when facing nutritional deprivation 
(Takeshige et al., 1992; Kuma et al., 2004), but also to prevent cell death in the 
presence of protein aggregates or faulty organelles (Elmore et al., 2001; Ravikumar et 
al., 2002; Fortun et al., 2003; Narendra et al., 2008). The process of autophagy can be 
deconstructed into four steps (nucleation, expansion, fusion and degradation) and 
involves 35 autophagy-related (ATG) proteins and other autophagy interaction 
network components (Figure 1.5). First, the initiation stage is characterised by the 
formation of a crescent-shaped isolation membrane called phagophore (Mizushima et 
al., 2001). The phagophore can be formed from rough endoplasmic reticulum 
(Hayashi-Nishino et al., 2009; Ylä-Anttila et al., 2009), Golgi apparatus (Yen et al., 
2010), mitochondria (Hailey et al., 2010) and plasma cell membrane (Ravikumar et 
al., 2010). The vacuolar protein sorting 34 (Vps34), a class III phosphatidylinositol 3-
kinase (PI3K), complexes with Beclin 1, ATG14 and p150 and phosphorylates lipids 
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on the targeted membranes destined to become the phagosome (Volinia et al., 1995; 
Panaretou et al., 1997; Mizushima et al., 2003b; Blommaart et al., 1997; Liang et al., 
1999; Petiot et al., 2000; Kihara et al., 2001a; b; Itakura et al., 2008). Second, the small 
nascent phagophore elongates by recruiting effector proteins such as WD-repeat 
protein interacting with phosphoinositides 1 (WIPI1) that triggers the expansion of the 
developing membrane (Proikas-Cezanne et al., 2004). This expansion step is also 
promoted by the action of two ubiquitin-like conjugation systems. The first is an 
ATG12-ATG5-ATG16 complex (Suzuki et al., 2001; Mizushima et al., 2001; 2003b; 
a), that is formed by conjugation of ATG12 with ATG5 mediated by the E1-like 
enzyme ATG7 and the E2-like enzyme ATG10. ATG12-ATG5 subsequently 
complexes with ATG16. This forms an E3-like system that mediates the conjugation 
of the second complex between the microtubule-associated protein 1 light chain 3 
(LC3) and phosphatidylethanolamine (PE), complex also termed LC3II (Kabeya et al., 
2000). At this stage, most of the proteins involved in the genesis of the autophagosome 
(unconjugated LC3I and ATG12-ATG5-ATG16 complex) are recycled back into the 
cytosol, and LC3II remains the major protein located at the inner membrane of the 
phagophore (Kabeya et al., 2000; Fujita et al., 2008). LC3II has the ability to bind 
autophagy receptors such as p62 (Komatsu et al., 2007) and NDP52 (Thurston et al., 
2009), allowing selection of the cargo to be engulfed in the forming autophagosome. 
Third, the autophagosome fuses with a lysosome in the presence of lysosomal 
membrane-associated protein 2 (LAMP2) and become an autolysosome (Huynh et al., 
2007). Finally, as lysosomes are vesicles containing a wide range of hydrolases 
maintained at an acidic pH, the autolysosome allows the degradation of the luminal 
content through acidification and hydrolysis. The degradation products are 
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translocated out of the autolysosome by lysosomal transporters such as ATG22 to 
allow reuse in metabolic processes, and the membrane is recycled (Yang et al., 2006). 
Mammalian cells have evolved the fundamental biological process of autophagy to 
apply it to the clearance of invading microorganisms, including vacuolar pathogens. 
This autophagy-mediated breakdown of pathogens has been called “xenophagy”, from 
the Greek “to eat foreign matter” (Levine, 2005). In the context of an intracellular 
infection, the process of selective xenophagy is triggered by the detection of PAMPs 
or DAMPs by PRRs, leading to the recruitment of autophagy receptors or adapters that 
deliver the cytoplasmic or vacuolar microorganisms to the lysosome for clearance. For 
example, recognition of viral RNA or bacterial lipopolysaccharide by TLRs activates 
autophagy (Xu et al., 2007; Sanjuan et al., 2007; Delgado et al., 2008). Similarly, 
detection of bacterial peptidoglycan by NLRs also triggers autophagy activation 
(Travassos et al., 2010b; Cooney et al., 2010; Travassos et al., 2010a). The selectivity 
of xenophagy is conferred by the help of cytosolic autophagy sensors called 
sequestasome-like receptors (SLRs) or LC3-interacting regions (LIR) proteins. These 
autophagy receptors, including the proteins p62 (Pankiv et al., 2007), NBR1 (Thurston 
et al., 2009), NDP52 (Thurston et al., 2009), and optineurin (Wild et al., 2011) 
recognise and capture ubiquitinated targets via their ubiquitin-binding domain (UBD) 
for delivery to the LC3-positive nascent autophagosome via their LIR (Thurston et al., 
2009; Dupont et al., 2009; Zheng et al., 2009; Orvedahl et al., 2010). Intracellular 
vacuolar pathogens known to be targeted by xenophagy include Mycobacterium 
(Gutierrez et al., 2004; Alonso et al., 2007), Legionella (Amer and Swanson, 2005; 
Khweek et al., 2013) and Chlamydia (Al-Zeer et al., 2009; 2013). The best-
characterised xenophagy system so far remains for the targeting and clearance of 
Salmonella and will be discussed in more details.  
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Salmonella typhimurium is a facultative intracellular bacterium that resides and 
replicates within a containing vacuole called SCV. However, following type III 
secretion system (T3SS)-mediated damage of the SCV, a small proportion of 
Salmonella resides in damaged vacuoles or escapes in the cytosol of the host cell 
(Beuzón et al., 2000; Brumell et al., 2002; Perrin et al., 2004). Autophagy has been 
shown to restrict the cytosolic replication of Salmonella in vitro (Birmingham et al., 
2006), and this can be achieved by not less than 6 different host mechanisms (Figure 
1.6). One possible autophagy activation signal is the production of diacylglycerol 
(DAG) in response to the secretion of bacterial proteins into the host cytosol via the 
T3SS. DAG acts as a specific lipid second messenger to initiate the recruitment of LC3 
to the SCV (Shahnazari et al., 2010). The E3 ubiquitin ligase LRSAM1 has been 
shown to directly recognise Salmonella via its LRR domain, leading to ubiquitination 
associated with the bacterium. LRSAM1 also participates in the recruitment of LC3-
positive autophagosome by binding to the autophagy receptor NDP52 via its LRR 
domain (Huett et al., 2012). Both cytosolic and damaged SCV can be targeted by 
ubiquitination (Perrin et al., 2004; Fujita et al., 2013), providing the recognition signal 
for the autophagy receptors p62, NDP52 and optineurin which link the ubiquitinated 
target to LC3-positive autophagosome for clearance through LIR (Thurston et al., 
2009; Zheng et al., 2009; Wild et al., 2011). In all three studies, RNA silencing 
demonstrated restriction of Salmonella by autophagy is dependent on p62, NDP52 or 
optineurin. Finally, galectin-8 has recently been identified as a danger receptor that 
can detect damaged SCV. Galectin-8 is a lectin that binds to β-galactoside sugars that 
are usually localised inside endosomal or lysosomal vesicles. The disruption of the β-
galactosides-containing SCV provides access to the newly exposed host glycans. 
Galectin-8 binds to these sugars and subsequently recruits the autophagy receptor 
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NDP52 to the site of Salmonella infection, thereby directing autophagy that translates 
into the recruitment of LC3-positive autophagosome (Thurston et al., 2012).  
Autophagy has also been linked to resistance during Toxoplasma infection. 
Interestingly, electron microscopy showed ultrastructral evidence of the autophagic 
elimination of Toxoplasma in IFNγ-stimulated macrophages. Following vacuolar 
disruption, released Toxoplasma are engulfed in autophagosome-like vesicles that 
subsequently fuse with lysosomes (Ling et al., 2006). ATG5 is required for IFNγ-
dependent disruption of the PV, and ATG5 mediates the control of Toxoplasma 
replication both in vitro and in vivo (Zhao et al., 2008; Selleck et al., 2013). More 
recently, the autophagy proteins ATG3, ATG7 as well as the ATG12-ATG5-ATG16 
complex were reported to mediate the disruption of avirulent Toxoplasma PV by LC3 
and IFNγ effector proteins (Choi et al., 2014). 
1.3.4 Cytosolic recognition of pathogens: the inflammasome pathway 
Following invasion by a pathogen, cytosolic NLRs detect the presence of the intruder 
or a disruption of the cellular compartment integrity and mediate the activation of a 
specific innate immune response called the inflammasome. Inflammasomes are 
multimeric complexes that comprise a sensor protein, an adaptor protein and the 
inactive zymogen procaspase-1. The sensor protein can be an NLR receptor or an 
AIM2-like receptor (ALR). The adaptor protein is an apoptosis-associated speck-like 
protein containing a C-terminal CARD (caspase activation and recruitment domain) 
termed ASC. After activation by microbial products, the NLRs or ALRs oligomerise 
via their NACHT or HIN200 domain, respectively, and recruit ASC via an interaction 
involving the pyrin domain (PYD) of the adaptor protein and the PYD of the receptor 
(Vajjhala et al., 2012). Finally, ASC recruits the zymogen procaspase-1 in the complex 
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through its CARD domain (Cai et al., 2014; Lu et al., 2014) (Figure 1.7). This 
assembled molecular platform promotes the cleavage of inactive procaspase-1 into the 
active enzyme caspase-1, which further cleaves and activates the inactive 
inflammatory cytokines pro-IL-1β and proIL-18 into their active counterparts: IL-1β 
and IL-18 (Kostura et al., 1989; Black et al., 1989; Thornberry et al., 1992; Walker et 
al., 1994; Ayala et al., 1994; Li et al., 1995; Alnemri et al., 1996; Gu et al., 1997). 
Activation of the inflammasome also leads to a programmed cell death called 
pyroptosis, resulting in the release of the produced inflammatory cytokines. After 
pyroptosis, the inflammatory response can be amplified and prolonged by the 
accumulation of released ASC oligomers into the extracellular environment, where 
they will continue to activate caspase-1 for subsequent processing of extracellular IL-
1β (Franklin et al., 2014; Fink et al., 2008; Baroja-Mazo et al., 2014). 
Although NLRs and ALRs are able to detect the presence of microbial products, a 
direct interaction with their pathogenic stimuli has not been shown so far. 
Inflammasomes can be activated by extracellular, vacuolar or intracellular bacteria, 
viruses and protozoans. The nature of the microbial stimuli determines the specific 
sensor that will be activated to induce the inflammasome cascade and to translate it 
into a successful inflammatory response leading to clearance of the microorganism. In 
the case of vacuolar pathogens (Figure 1.8), Legionella and Salmonella have been 
shown to induce the activation of the NLRC4 inflammasome via the bacterial flagellin 
or protein components of the bacterial secretion systems (Amer et al., 2006; Lightfield 
et al., 2008; Molofsky et al., 2006; Franchi et al., 2006; Miao et al., 2006). Until 
recently, the NLRP1 inflammasome was thought to only be activated by a single 
signal, the anthrax lethal toxin secreted by Bacillus anthracis (Boyden and Dietrich, 
2006; Fink et al., 2008). This NLRP1 activation does not require the adaptor protein 
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ASC, but necessitates ubiquitination of caspase-1 (Van Opdenbosch et al., 2014; Broz 
et al., 2010). However, Toxoplasma has now also been shown to activate the NLRP1 
inflammasome in both human and rodent cell lines, leading to the restriction and 
killing of the parasite as well as the upregulation of the protective pro-inflammatory 
cytokine IL-1β (Lees et al., 2010; Witola et al., 2011; Ewald et al., 2013). More 
recently, both the NLRP1 and the NLRP3 inflammasomes have been reported to 
confer resistance to Toxoplasma infection in vivo, mediating the protective production 
of the pro-inflammatory cytokine IL-18 in the serum of mice (Gorfu et al., 2013). 
1.3.5  Cytosolic recognition of pathogens: the antibody-dependent intracellular 
neutralisation (ADIN) pathway 
Immunoglobulins (Ig), or antibodies (Ab), are a critical player in the defence against 
invading pathogens. Their importance is highlighted by the fact that an inability to 
mount an effective humoral response often leads to a persistent, or even fatal, 
infection. Immunoglobulins are glycoproteins produced by plasma B cells that can 
either be membrane-associated on B cells, or secreted as soluble circulating antibodies. 
Their function consists in recognising and binding to specific antigens, thereby helping 
eliminating the antigen or the microorganism harbouring this antigen (Male et al., 
2006). 
Immunoglobulins are constructed in a uniform manner, characterised by the 
combination of four polypeptide chains: two identical heavy chains and two identical 
light chains (Figure 1.9). The immunoglobulin molecule presents a variable region 
encompassing the N-terminal domains of each heavy and light chain (VH and VL, 
respectively) that is involved in antigen binding and is called Fab (fragment antigen 
binding). The C-terminal domains of the heavy and light chains form the constant 
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region (CH and CL, respectively) that distinguishes the five classes of immunoglobulin 
and is termed Fc (fragment crystallisable) (Porter, 1959; Inbar et al., 1972). The Fab 
fragment of the immunoglobulin provides the specificity for the recognition of the 
three-dimensional conformation of the antigen, called epitope. The Fc fragment of the 
immunoglobulin is recognised by Fc receptors expressed on the surface of innate 
immune cells such as monocytes, macrophages, neutrophils and NK cells (Jondal and 
Pross, 1975; West et al., 1977; Anderson, 1982; Fleit et al., 1982; Cohen et al., 1983). 
There are five classes of immunoglobulins in mammals: IgG (70% of total serum Igs), 
IgA (15% of total serum Igs), IgM (10% of total serum Igs), IgD and IgE. Their 
interaction with an Fc receptor triggers the immune response such as phagocytosis –
termed antibody-dependent cellular phagocytosis (ADCP) (Leslie, 1980; Mellman, 
1982; Mellman et al., 1983)–, or cell killing –called antibody-dependent cellular 
cytotoxicity (ADCC) (Rosenberg et al., 1972; Oldham and Herberman, 1973; 
Rakebrandt et al., 2014; Herberman et al., 1975a; b; Kiessling et al., 1975a; b)–. 
Since their discovery in 1890 (Behring and Kitasato, 1890; Behring, 1890) and until 
recently, immunoglobulins were believed to provide protection exclusively in the 
extracellular environment. Pathogens were considered safe from immunoglobulins 
once inside the host cell. Recently, antibodies have been shown to mediate antiviral 
and antibacterial protection inside the host cell (McEwan et al., 2013; Mallery et al., 
2010; Rakebrandt et al., 2014). This newly identified mechanism has disputed the 
dogma that antibodies do not have an intracellular function and has been termed 
antibody-dependent intracellular neutralisation or “ADIN” (Figure 1.10). Mallery et 
al. showed that adenovirus, a non-enveloped virus, is coated with immunoglobulins in 
the extracellular medium and carries them into the host cell after invasion. Following 
release from the endosomal compartment, antibody-coated viruses are sensed by a 
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newly discovered and ubiquitously expressed cytoplasmic antibody receptor called 
tripartite motif-containing protein 21 (TRIM21) (Mallery et al., 2010). McEwan et al. 
as well as Rakebrandt et al. demonstrated that TRIM21 also binds to antibodies 
surrounding intracellular, IgG-opsonised Salmonella (McEwan et al., 2013; 
Rakebrandt et al., 2014). Structural and biochemical studies have revealed that 
TRIM21 is characterised by a C-terminal B30.2/PRYSPRY domain that is able to 
strongly bind to the Fc part of immunoglobulins (Rhodes and Trowsdale, 2007; Keeble 
et al., 2008; Mallery et al., 2010). TRIM21 binds symmetrically to the 
immunoglobulin, allowing TRIM21 dimers to bind both heavy chains of the antibody 
at the same time. The formation of this TRIM21-immunoglobulin complex leads to an 
exceptionally high binding affinity, as TRIM21 is the strongest IgG receptor so far 
described in humans with an affinity of about 0.2-0.5 nanomolar (nM) (Keeble et al., 
2008; Mallery et al., 2010). Additionally, TRIM21 has been shown to be able to bind 
to other classes of immunoglobulins such as IgM (17 nM) (Mallery et al., 2010) and 
IgA (50 nM) (Bidgood et al., 2014). The IgG receptor binding property was shown to 
be conserved and functionally interchangeable through murine, canine, primate and 
human species, suggesting an important biological role for TRIM21 (Keeble et al., 
2008). In all the above investigations, restriction of the pathogen was dependent on the 
presence of both TRIM21 and antibodies. The TRIM21- and antibody-dependent 
mediation of adenoviral infection is also important in vivo, as TRIM21 KO mice 
injected with protective antisera still succumb viral infection (Vaysburd et al., 2013). 
These studies position TRIM21 as a potential new DAMP receptor, alerting the cell of 
the presence of misplaced antibodies in the cytosol. However, in both viral and 
bacterial infections that were investigated, TRIM21 function did not solely consist of 
the recognition of antibody-bound pathogens. TRIM21 also possesses a really 
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interesting new gene (RING) domain exhibiting an E3 ubiquitin ligase activity 
(Meroni and Diez-Roux, 2005), and uses it to label the adenovirus and Salmonellae 
for degradation by the proteasome or possibly autophagy, respectively (Mallery et al., 
2010; Rakebrandt et al., 2014). TRIM21 has also been shown to trigger a non 
pathogen-specific immune signalling that involves the activation of nuclear factor κB 
(NF-κB), activating protein-1 (AP-1) and interferon regulatory factors IRF3, IRF5 and 
IRF7 (McEwan et al., 2013). As antibody-coated latex beads can be detected by 
TRIM21, be subsequently labelled with ubiquitin (Mallery et al., 2010) and prompt 
the activation of  TRIM21 immune signalling (McEwan et al., 2013), TRIM21 could 
be an important intracellular receptor mediating resistance against pathogens yet to be 
identified.  
1.4 Early immune responses to Toxoplasma infection 
1.4.1 Innate immunity against Toxoplasma infection 
Mice are natural intermediate hosts of Toxoplasma and are widely used as laboratory 
animal models to study the mechanisms of host resistance to the parasite. Moreover, 
human clinical presentation of Toxoplasma is diverse, but can be mimicked in animal 
models by choosing the appropriate genetic background of mice combined with 
varying strains of Toxoplasma (Munoz et al., 2011). In the mouse model, the acute 
phase of infection lasts approximately 10 days. After invasion of the host cell, 
Toxoplasma activates the two surface PRRs Toll-like receptors TLR2 and TLR4 on 
monocytes and macrophages through its glycophosphatidylinositol (GPI) anchors 
(Debierre-Grockiego et al., 2007), as well as the endosomal PRRs termed TLR11 and 
TLR12 in dendritic cells through a protein called profilin (Yarovinsky, 2005; Raetz et 
al., 2013) (Figure 1.11). These activated cells are then triggered to produce cytokines 
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such as IL-12 and tumor necrosis factor alpha (TNFα). Production of IL-12 promotes 
differentiation and proliferation of both CD4+ and CD8+ T cells as well as natural killer 
cells, leading to an enhanced secretion of interferon gamma (IFNγ) (Khan et al., 1994; 
Gazzinelli et al., 1993; Hunter et al., 1994). This type II interferon, the major mediator 
of resistance against Toxoplasma, in turn activates the host’s non-haematopoietic cells 
as well as haematopoietic cells, amongst them macrophages, to elicit antimicrobial 
activities. In order to hinder the replication of the parasite, the production of nitric 
oxide (NO) is triggered (Murray et al., 1985; Adams et al., 1990). This has been shown 
to be important during the chronic phase of the infection only (Scharton-Kersten et al., 
1997). Moreover, type II interferon mediates the transcriptional upregulation of two 
classes of large GTPases called p47 immunity related GTPases or IRGs (Taylor et al., 
2004; Taylor, 2007)  and p65 guanylate binding proteins or GBPs (Virreira Winter et 
al., 2011; Yamamoto et al., 2012; Degrandi et al., 2007) that will be discussed in more 
details. 
1.4.2 The family of IFNγ-inducible large GTPases 
In mammals, interferon γ was identified as a major pro-inflammatory cytokine that 
mediates resistance against many intracellular pathogens, including Toxoplasma. 
Among the hundreds of genes that are upregulated by interferons after infection (de 
Veer et al., 2001), four families of large GTPases are of particular interest: myxovirus 
resistance (Mx) proteins (Nakayama et al., 1991), very large inducible GTPases called 
VLIGs (Klamp et al., 2003), p47 immunity-related GTPases termed IRGs (Gilly and 
Wall, 1992; Carlow et al., 1995; Lafuse et al., 1995; Sorace et al., 1995) and p65 
guanylate-binding proteins called GBPs (Cheng et al., 1983; Staeheli and Sutcliffe, 
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1988). These IFNγ-inducible GTPases play important roles during pathogen 
infections.  
The family of Mx proteins comprises two human proteins (MxA and MxB) encoded 
by genes mapped to chromosome 21 (Horisberger et al., 1988; Petersen et al., 1991), 
and their murine orthologs (MX1 and MX2) encoded by genes localised on 
chromosome 16 (Staeheli et al., 1986a; Staeheli and Sutcliffe, 1988; Reeves et al., 
1988). The Mx proteins are mainly upregulated by type I interferons IFNα/βand type 
III interferon  λ. The Mx proteins were discovered in an inbred mouse strain that 
exhibited a natural resistance to infection with influenza A viruses (Lindenmann, 
1964; Horisberger et al., 1983). Expression of the MX1 protein was shown to confer 
selective resistance to viral infection by intrinsic antiviral activity, both in vitro and in 
vivo (Staeheli et al., 1986b; Arnheiter et al., 1990). Mice naturally susceptible to 
influenza infection have been reported to carry a defective Mx1 gene (Staeheli et al., 
1988), and IFNαR−deficient mice constitutively expressing human MxA were shown 
to survive lethal viral infections (Hefti et al., 1999). Since these first discoveries, 
human and mouse Mx proteins have been shown to be involved in resistance to a wide 
range of viruses, including orthomyxoviridae (influenza virus (Lindenmann, 1964; 
Krug et al., 1985; Staeheli et al., 1986b; Pavlovic et al., 1995; Hefti et al., 1999), 
Thogoto virus (Haller et al., 1995; Pavlovic et al., 1995; Frese et al., 1995; Kochs and 
Haller, 1999; Hefti et al., 1999), Dhori virus (Thimme et al., 1995), Batken virus 
(Collazo et al., 2001; Leroy et al., 2006; Klamp et al., 2003; Frese et al., 1997; Li et 
al., 2009a)}), rhabdoviridae (vesicular stomatitis virus (Pavlovic et al., 1995; 1990), 
rabies virus (Leroy et al., 2006)), bunyaviridae (Hantaan River virus (Jin et al., 2001), 
La Crosse virus (Frese et al., 1996; Hefti et al., 1999; Kochs et al., 2002; Reichelt et 
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al., 2004)), paramyxoviridae (measles virus (Schnorr et al., 1993; Schneider-Schaulies 
et al., 1994)), hepadnaviridae (hepatitis B virus (Gordien et al., 2001; Yu et al., 2008)) 
and more recently, retroviridae (HIV-1 (Goujon et al., 2013; Kane et al., 2013; Liu et 
al., 2013)). The broad range of antiviral action the Mx proteins exhibit implies that 
intricate and various mechanisms are involved. Several studies on the mode of action 
against a few viruses have demonstrated the Mx proteins may inhibit viral replication 
through direct interaction with essential viral components (Staeheli et al., 1986c; 
Haller et al., 2015).  
The family of VLIGs comprises 4 putative active members and 7 pseudogenes mapped 
on murine chromosome 7. The two human orthologous genes, localised on 
chromosome 11, are deemed pseudogenes (Klamp et al., 2003; Li et al., 2009a). The 
murine protein VLIG1 is the only family member characterised so far, and its 
expression has been shown to be upregulated in the liver following infection with 
Listeria monocytogenes. As IFNγR-/--infected mice did not exhibit an increased 
expression of VLIG1 in the liver, its regulation is dependent on IFNγ (Klamp et al., 
2003). No further studies on its role during infection, or on the other putative VLIGs, 
have been undertaken so far. 
The family of p47 IRGs has been more widely studied in mouse during diverse 
pathogen infections. Indeed, murine IRGs have been shown to possess essential 
antimicrobial activity during infection involving intracellular pathogens such as 
Listeria (Collazo et al., 2001), Mycobacterium (MacMicking et al., 2003), Chlamydia 
(Bernstein-Hanley et al., 2006), Salmonella (Henry et al., 2007), Trypanozoma 
(Santiago et al., 2005) and Toxoplasma (Taylor et al., 2000; Collazo et al., 2001; 
Halonen et al., 2001). Collazo et al. showed Irgm1-/- mice fail to control Listeria 
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monocytogenes infection, exhibiting a high bacterial burden 3 days post-infection in 
the spleen and the liver, as well as an increased level of the cytokine IL-12 in the serum 
(Collazo et al., 2001). Similarly, MacMicking et al. reported Irgm1-/- mice to be highly 
susceptible to Mycobacterium tuberculosis infection. They showed Irgm1-/- 
macrophages exhibit a decreased bacterial killing compared to WT controls, which 
was attributed to an impaired lysosomal fusion and subsequent acidification of the 
Mycobacterium-containing phagosome (MacMicking et al., 2003). Bernstein-Hanley 
et al. demonstrated that both Irgb10 and Irgm3 are required to restrict Chlamydia 
trachomatis growth in vitro (Bernstein-Hanley et al., 2006). Henry et al. showed 
Irgm1-/- mice fail to control infection with Salmonella typhimurium due to an impaired 
bacterial killing and cell mobility in Irgm1-/- macrophages (Henry et al., 2007). 
Santiago et al. reported Irgm1-/- mice also exhibit high susceptibility to infection with 
Trypanosoma cruzi, accompanied with unchecked parasite replication, defective 
hematopoiesis and reduced parasite killing in macrophages (Santiago et al., 2005). 
Three independent studies demonstrated the role of several IRGs in resistance against 
Toxoplasma. Irgm3-/- mice exhibit an increased susceptibility to the parasitic infection, 
characterised by an uncontrolled parasite burden and increased production of the 
inflammatory cytokines IFNγ and IL-12 (Taylor et al., 2000). Irgm3 has also been 
shown to control Toxoplasma replication in astrocytes (Halonen et al., 2001). Irgm1-/- 
mice were also reported to exhibit an enhanced susceptibility to Toxoplasma, 
characterised by an increased parasitemia (Collazo et al., 2001).  
The family of p47 IRGs can be divided in two categories, based on the sequence in the 
first nucleotide-binding site (G1). The three IRGM proteins bear the non-canonical 
glycine-methionine-serine sequence (GMS) and the remaining IRG proteins harbour 
the conserved canonical glycine-lysine-serine sequence (GKS) (Intemann et al., 2009; 
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Ling et al., 2006; Bekpen et al., 2005; Boehm et al., 1998; Che et al., 2010; Zhao et 
al., 2009a; Khaminets et al., 2010). In IFNγ-induced cells in vitro, many GKS IRGs 
assemble together at the PV of Toxoplasma and mediate killing of the parasite by 
vesiculation and ultimately disruption of the vacuolar compartment (Butcher et al., 
2005; Martens et al., 2005; Zhao et al., 2009b). IRG proteins Irgb6, Irgb10 and Irga6 
sequentially localise to PVs containing avirulent type II and III strains of Toxoplasma 
but not virulent type I strain (Ling et al., 2006; Zhao et al., 2009a; Khaminets et al., 
2010). These observations suggest virulent type I parasites escape from disruption of 
the PV and death by preventing the substantial accumulation of IRGs on the PV. 
Recently, the Toxoplasma virulence factor ROP18 from virulent type I Toxoplasma 
has been shown to phosphorylate two members of the IRG family, Irga6 and Irgb6, 
thereby preventing their recognition of the vacuole (Steinfeldt et al., 2010; Fentress et 
al., 2012). The pseudokinase ROP5 mediates ROP18 action by blocking the target IRG 
proteins in their inactive GDP-bound form, allowing the active kinase ROP18 to access 
the threonine phosphorylation sites (Fleckenstein et al., 2012). ROP18 forms a 
complex with the pseudokinases ROP2 and ROP8 as well as with the dense granule 
GRA7. The latter also binds to Irga6 and increases its turnover, probably preventing it 
from recruiting to the PV (Alaganan et al., 2014). This summer, GRA7 has been 
localised to avirulent Toxoplasma PV in complex with ROP5, hence allowing the 
specific phosphorylation and inactivation of Irga6 by ROP18 (Hermanns et al., 2015). 
Recently, the subfamily of GMS proteins has been reported to regulate the recruitment 
of their GKS counterparts to the PV. Localisation studies of the two groups have 
shown GMS proteins are present on endomembranes and largely absent from foreign 
membranes such as the PVM, while GKS proteins mainly recognise and recruit to 
GMS-free endomembrane components (Haldar et al., 2013). How exactly murine 
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IRGs accumulate at the PV, as well as which cellular functions and molecular 
mechanisms this class of GTPases regulate in Toxoplasma infection remains unknown. 
So far, 23 genes corresponding to IRGs have been identified in the mouse genome, 
localised on chromosomes 7, 11 and 18 (Bekpen et al., 2005) (Figure 1.12). Despite 
their presence in several mammals, IRG genes appear to be degenerated in humans 
with only two members localised on chromosomes 5 and 19 (Bekpen et al., 2005). As 
both human IRGC and IRGM genes do not entail any interferon responsive elements 
and do not respond to stimulation by interferons in vitro, their role in infection was 
considered non-existent. However, IRGM has been reported to be required for 
induction of autophagy in human macrophages in both normal conditions by mediating 
the conversion of LC3I into LC3II, and during infection with Mycobacterium 
tuberculosis by regulating the maturation of the phagosome (Singh et al., 2006). 
Human population genetic studies revealed that two single nucleotide polymorphisms 
(-261TT and -1208AA) of the human gene encoding IRGM provide protection against 
Mycobacterium tuberculosis infection (Intemann et al., 2009; Che et al., 2010).  
In contrast to the p47 IRGs, the homologous IFNγ-induced GTPases, the p65 GBPs, 
are highly conserved throughout the vertebrate lineage with 13 copies in the mouse 
genome clustered on chromosomes 3 and 5, and 7 copies in the human genome on 
chromosome 1 (Kresse et al., 2008; Shenoy et al., 2008). Both the mouse and human 
p65 GBPs are inducible by interferons, rendering them interesting from a medical 
point of view.  
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1.4.3 The p65 guanylate binding proteins 
The p65 guanylate binding proteins are 67-73kDa proteins that were identified for the 
first time in 1979 by Gupta et al. in IFNγ-stimulated human fibroblasts (Gupta et al., 
1979). In 1983, Cheng et al. discovered their murine orthologs in IFNγ-stimulated 
mouse fibroblasts (Cheng et al., 1983). Although IFNγ is the major inducer of GBP 
expression, their upregulation has also been reported by type I interferons (IFNα/β), 
interleukin-1β (IL-1β) and TNFα in rodents and humans (Lubeseder-Martellato et al., 
2002; Tripal et al., 2007). Multiple sequence alignments of either human or murine 
GBPs highlighted regions of conservations within their amino acid sequences 
(Olszewsky et al., 2006). The N-terminal region of the GBPs is the most conserved 
and contains the GTP (guanosine triphosphate)-binding domain, comprising the four 
consensus sequences: the G1 or P-loop (GxxxxGKS, where “x” is any amino acid) 
coordinating the phosphates, the G2 or Switch1 (a single T residue) and the G3 or 
Switch2 (DxxG) involved in catalysis and moving during nucleotide hydrolysis, and 
the G4 motif (TLRD). In contrast, the C-terminal region is the most diverse and 
interestingly, some human and mouse GBPs (hGBP1, hGBP3, hGBP5, mGBP1, 
mGBP2 and mGBP5) share an amino acid motif called “CaaX” sequence with 
members of the Ras superfamily of GTPases. This “CaaX” motif (“C” represents 
cysteine, “a” is an aliphatic residue and “X” is any residue) encodes a potential site for 
prenylation, a posttranslational modification consisting of the addition of an isoprenyl 
lipid, allowing the protein to anchor to cellular membranes (Maltese, 1990) (Figure 
1.13).  
In the last 30 years, several studies have been carried out in order to characterise the 
structural and biochemical properties of the GBPs. Crystal structures have been 
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obtained for full-length hGBP1 in either the free state (Prakash et al., 2000a), bound 
to a non-hydrolysable analog of GTP (GppNHp) (Prakash et al., 2000b), in complex 
with GDP/AIF3 or GMP/AIF4 (Ghosh et al., 2006). The N-terminal catalytic domain 
is globular and is linked to an elongated C-terminal series of α-helices via a short 
middle region consisting of a two-stranded beta-sheet and a helix (Figure 1.14).  
GTPases are enzymes catalysing the hydrolysis of GTP to GDP (guanosine di-
phosphate). GTPases are referred to as inactive when in a GDP-bound state while 
active when GTP is bound. hGBP1 has been observed to oligomerise in a nucleotide-
dependent manner (Figure 1.15), so that active GTP-bound hGBP1 dimerises whereas 
inactive GDP-bound does not (Prakash et al., 2000a; Voepel et al., 2014). hGBP1 has 
been of great interest from a biochemical point of view due to its unique ability to bind 
GTP, GDP and GMP (guanosine mono-phosphate) with an equivalent low affinity 
(Cheng et al., 1983; Praefcke et al., 1999). hGBP1 has also been shown to catalyse the 
hydrolysis of GTP to GDP as well as to GMP in a two-step fashion, GMP being the 
major end product of the reaction (Schwemmle and Staeheli, 1994). As the affinity for 
GMP is low, these reactions are performed at a high nucleotide dissociation rate or 
turn-over and at a fast hydrolysis rate of up to 80-100 min-1, suggesting that the GBPs 
are not regulated by GTPase activating proteins (GAPs) or guanine nucleotide 
exchange factors (GEFs) like small GTPases are. However, the structures of the N-
terminal GTPase domain of hGBP1 in complex with GTP, GDP and GMP obtained 
by X-ray crystallography implied GBPs are self-activating upon dimerisation (Ghosh 
et al., 2006; Kunzelmann et al., 2006). Moreover, the intermediate helical domain of 
hGBP1 has been shown to play a key role in the structural stabilisation by allosteric 
interaction of residues during dimerisation and in the regulation of the GTPase activity 
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of the protein, and has as such been referred to as an internal GAP (Abdullah et al., 
2009; 2010).  
1.4.4 Implication of the p65 GBPs in infections 
Although the GBPs have been known for more than 30 years, little is known about 
their biological relevance after infection. Research with mice lacking either type I 
interferon receptor or type II interferon receptor demonstrated type I interferons are 
involved in antiviral responses, whereas type II interferon is important for resistance 
against intracellular bacteria and parasites (van den Broek et al., 1995). As the p65 
GBPs can be induced by both types of interferons, their role is likely to encompass 
antiviral, antibacterial and antiparasitic host defence. Most of the studies on the 
implication of the GBPs have been carried out in the mouse, mainly due to technical 
challenges involved with working with human cells and generating knockout systems. 
However, recent investigations have allowed for more insights into the contribution of 
the GBPs during infection. 
1.4.4.1 Implication of human GBPs in infection 
Members of the family of human p65 GBPs have been shown to be involved in 
mediating resistance against intracellular viral and bacterial infections. 
Overexpression of hGBP1 in human Henrietta Lacks (HeLa) cells confers modest 
resistance against vesicular stomatitis virus (VSV) and encephalomyocarditis virus 
(EMCV) as seen by a reduction in morphological changes induced by the viral 
infections and a decreased viral replication. The combination of hGBP1-silencing and 
induction with type I IFNα or type II IFNγ in HeLa cells showed hGBP1 is involved 
in the IFNα-mediated response against EMCV and in the IFNγ-mediated response 
against both VSV and EMCV (Anderson et al., 1999). Another overexpression study 
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of hGBP1 in human hepatoma Huh7 cells showed a decrease in hepatitis C virus 
(HCV) replicon replication by almost 40%, while knock down of hGBP1 increased it 
by more than 45% (Itsui et al., 2006). This antiviral effect against HCV has later been 
attributed to the GTPase activity of hGBP1, as in normal conditions the viral NS5B 
protein interacts with hGBP1 to inhibit the GTPase activity and repress the inhibition 
of viral replication (Itsui et al., 2009). hGBP1 has also been reported to participate in 
the host defence against dengue virus (DENV), as silencing of hGBP1 lead to a higher 
viral load accompanied with an impaired NF-κB signalling and a downregulation of 
inflammatory cytokines (Pan et al., 2012). Overexpression of hGBP1, hGBP3 and of 
a new hGBP3∆C splice variant were shown to reduce influenza viral titers in human 
A549 cells. The most potent anti-influenza GTPase, hGBP3∆C, inhibits the activity of 
the viral polymerase complex upon binding to, but not hydrolysis of, guanosine 
triphosphate (Nordmann et al., 2012). 
As far as bacterial infections are concerned, both hGBP1 and hGBP2 participate in the 
defence against Chlamydia trachomatis. Tietzel et al. demonstrated that hGBP1 and 
hGBP2 localise at the Chlamydia inclusion membranes and restrict the growth of the 
bacteria in HeLa cells when harbouring a functional GTPase domain (Tietzel et al., 
2009). Interestingly, hGBP5 has been shown to promote the activation of the NLRP3 
inflammasome following infection with live Salmonella and Listeria in IFNγ-
stimulated human THP-1 macrophages. Tetramerised hGBP5 binds to the PYD 
domain of the sensor protein NLRP3, which subsequently assembles with the adaptor 
protein ASC to activate procaspase-1, thereby triggering its autoproteolysis into 
caspase-1 and production of the inflammatory cytokines IL-1β and IL-18 (Shenoy et 
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al., 2012). The involvement of human GBPs in defence against other bacterial models 
has not been investigated so far. 
Human p65 GBPs have recently been studied during the course of infection with 
Toxoplasma. Using an antibody recognising hGBP1-5 (commercially available from 
Santa Cruz), Niedelmann et al. showed hGBPs do not recruit to the Toxoplasma PVs 
(<1%) in IFNγ-stimulated HFFs, and individual knock down of either hGBP1 or 
hGBP2 in HFFs does not increase the susceptibility to the parasite (Niedelman et al., 
2013). Using the same antibody for their immunofluorescence studies, Ohshima et al. 
reported the recruitment of endogenous hGBPs to the parasitophorous vacuole of 
avirulent Toxoplasma in human HAP1 cells in an IFNγ-dependent manner at 6h post-
infection. However, this accumulation of the hGBPs was observed for only about 6% 
of the parasite PVs, and the knock down of the clusters of hGBPs in the cell line did 
not lead to any enhanced susceptibility to Toxoplasma infection (Ohshima et al., 2014). 
The low accumulation of hGBPs to the PV could be explained by the absence of p47 
IRGs found to be recruited in the mouse system. The function of all the hGBPs, either 
at the Toxoplasma PV or acting elsewhere in the cell without localisation to the PV, 
remains to be assessed in different hematopoietic and non-hematopoietic cell types.  
1.4.4.2 Implication of mouse GBPs in infections 
More extensive research on the family members of the murine p65 GBPs has 
highlighted their importance in host defence against viruses, bacteria and protozoa. 
The putative murine ortholog of hGBP1, mGBP2, has also been shown to have 
antiviral activities during infection with the viruses VSV and EMCV, as seen by a 50% 
and 60% reduction in viral load, respectively, following overexpression of mGBP2 in 
mouse NIH3T3 cells. However, the GTP-binding domain was required for the 
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inhibition of EMCV replication, but not VSV (Anderson et al., 1999; Carter et al., 
2005). mGBP4 has been reported as a novel regulator of antiviral response during 
Sendai virus (SeV) infection by dampening the production of IFNα. Indeed, mGBP4 
interacts with the inhibitory domain of interferon regulatory factor 7 (IRF7), a 
transcription factor that mediates the production of IFNα. This interaction inhibits 
IRF7 SeV-induced phosphorylation and TRAF6-induced ubiquitination, hence 
negatively regulating IRF7-mediated antiviral response (Hu et al., 2011). 
Various mouse GBPs have been implicated in host recognition and/or defence against 
bacteria such as Chlamydia trachomatis, Salmonella enterica, Listeria monocytogenes 
and Mycobacterium tuberculosis (Haldar et al., 2013; Rupper and Cardelli, 2008; Kim 
et al., 2011). mGBP1 and mGBP2 were found to accumulate at Chlamydia inclusion 
membranes, characterised by the absence of GMS p47 IRGs, in IFNγ-stimulated 
mouse embryonic fibroblasts (MEFs) (Haldar et al., 2013). Although the accumulation 
of mGBPs at the Chlamydia inclusions is known to be regulated by the autophagy 
proteins ATG3 and ATG5 (Haldar et al., 2014), the role they exert at the inclusions 
has not been elucidated yet. Following Salmonella infection, mGBP5 is recruited to 
bacteria-containing phagosomes. Moreover, overexpression of mGBP5 in IFNγ-
stimulated RAW264.7 macrophages leads to an increased pyroptosis following 
Salmonella infection, while knock down of mGBP5 results in a higher susceptibility 
to the Salmonella-induced programmed cell death (Rupper and Cardelli, 2008). The 
mechanisms by which mGBP5 potentiates Salmonella-induced pyroptosis still require 
elucidation. Four members of the mGBPs have been found to mediate immunity 
against listerial and mycobacterial infections, some of them acting both in vitro and in 
vivo. Using a family-wide shotgun strategy combining three loss-of-function 
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approaches, mGBP1, mGBP6, mGBP7 and mGBP10 were reported to mediate cell-
autonomous defence against Listeria and Mycobacterium in IFNγ-stimulated 
macrophages, translated by an increased bacterial load following gene silencing. In 
addition, mGBP1/3/7/10 were recruited to Listeria- and Mycobacterium-containing 
vacuoles. Protein interaction studies revealed mGBP1 and mGBP7 to complex with 
proteins involved in oxidative killing and autophagy. mGBP1 was found to assemble 
with the ubiquitin-binding protein p62, thereby promoting delivery of ubiquitinated 
bacteria to autolysosomes. mGBP7 interacted with the nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase that generates superoxide, possibly helping 
its assembly on bacterial phagosomes. mGBP7 also interacted with the autophagy 
protein ATG4B, thus prompting the extension of the phagophore around damaged 
bacteria-containing vacuoles. At the organismal level, the study showed GBP1-/- mice 
failed to control Listeria or Mycobacterium replication and succumbed to the infection 
(Kim et al., 2011). Finally, mGBP5 was demonstrated to participate in the defence 
against Listeria infection in vitro and in vivo. Similarly to hGBP5, mGBP5 activates 
the NLRP3 inflammasome and promotes its assembly following live bacteria 
infection. mGBP5-/- bone marrow-derived macrophages exhibit impaired association 
between NLRP3, ASC and procaspase-1, leading to an absence of caspase-1 
production and IL-1β and IL-18 secretion. mGBP5-deficient mice present a higher 
bacterial burden accompanied with a 50 to 80% decrease in active caspase-1-
expressing macrophages in the mesenteric lymph nodes (Shenoy et al., 2012). Earlier 
this year, several mGBPs were shown to regulate the activation of the AIM2 
inflammasome during infection with the cytosolic bacterium Francisella novisida. 
Infection of BMDMs lacking the mGBPs clustered on chromosome 3 (comprising 
mGBP1, 2, 3, 5 and 7, called hereafter GBPch3) led to a decreased cell death 
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accompanied with lower levels of active caspase-1, IL-1β and IL-18. Individual gene 
silencing narrowed the involved mGBPs to be mGBP2 and mGBP5. Both mGBP2 and 
mGBP5 were recruited to Francisella bacteria that were subsequently lysed, releasing 
the bacterial DNA into the cytosol for recognition and activation of the AIM2 
inflammasome (Meunier et al., 2015; Man et al., 2015). mGBP2-/- as well as mGBP5-
/- macrophages failed to control bacterial replication in vitro (Man et al., 2015), and 
mice lacking GBP2 or GBPch3 were highly susceptible to Francisella infection and 
exhibited a high bacterial burden (Meunier et al., 2015).  
Apart from regulating the canonical NLRP3 and AIM2 inflammasomes, mGBPs have 
been implicated in the activation of the non-canonical caspase-11 inflammasome 
pathway during Legionella and Salmonella infection. The non-canonical caspase-11 
inflammasome leads to the activation of caspase-11 that triggers rapid cell death, 
independently of caspase-1 activation (Kayagaki et al., 2011; Casson et al., 2013; 
Kayagaki et al., 2013). GBPchr3 BMDMs showed lower levels of caspase-11 activation, 
decreased Legionella-induced pyroptosis and failed to control bacterial load. Induction 
of the caspase-11 inflammasome was reported to be triggered by the presence of 
cytosolic Legionella LPS (Pilla et al., 2014). Similarly, GBPchr3 were reported to 
regulate caspase-11 inflammasome activation during Salmonella infection by 
localising to the SCV and promote its lysis, thereby releasing the bacteria into the 
cytosol and rendering the LPS visible to inflammasome sensor. However in this study, 
cytosolic Salmonella LPS or Escherichia coli LPS did not trigger the activation of the 
caspase-11 inflammasome (Meunier et al., 2014). In both infection systems, the 
caspase-11 sensor still remains to be identified. 
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As far as Toxoplasma is concerned, several mGBPs are highly expressed in IFNγ-
induced cells in vitro upon infection with the parasite (Degrandi et al., 2007). 
Following IFNγ stimulation, mGBP1, 2, 3, 5, 6, 7 and 9 actively accumulate at the PV 
of avirulent type II and III, but not virulent type I strains of Toxoplasma (Degrandi et 
al., 2007; Virreira Winter et al., 2011). Moreover, some mGBPs (namely mGBP1, 
mGBP2 and mGBP5) have been reported to interact at the PV in an IFNγ-dependent 
manner, suggesting they act jointly with each other and effector proteins in order to 
combat Toxoplasma (Virreira Winter et al., 2011). In an elegant in vivo study involving 
the GBPchr3 knockout mouse, Yamamoto et al. demonstrated GBPchr3 are required for 
IFNγ-mediated control of Toxoplasma spread and proliferation in vivo, as well as for 
clearance and inhibition of Toxoplasma burden ex vivo by affecting the recruitment of 
p47 IRGs to the PV and its subsequent disruption (Yamamoto et al., 2012). Another 
study revealed that a GBP2-/- mouse is susceptible to Toxoplasma infection as a result 
of a defect in controlling parasite replication (Degrandi et al., 2013). However, 
reintroduction of GBP2 in GBPchr3 cells did not rescue resistance to Toxoplasma 
(Yamamoto et al., 2012), suggesting that mGBP2 alone does not suffice to control 
Toxoplasma infection.  
Invasion of Toxoplasma into the host cell triggers the secretion of proteins from three 
different parasitic organelles, micronemes, rhoptries, and dense granules, a process 
essential to intracellular survival and replication of the parasite (Carruthers, 1999). As 
mentioned in section 1.3.2, some of these secreted proteins have been shown to 
mediate the recruitment of IRGs to the PV of Toxoplasma. The rhoptry protein ROP18, 
a kinase from virulent type I Toxoplasma, is able to selectively phosphorylate 
conserved threonine residues within the switch loop 1 of certain IRGs, preventing them 
from being recruited to the PV of the parasite (Steinfeldt et al., 2010). In previous work 
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by Eva Frickel, ROP18 from virulent type I Toxoplasma can mediate the evasion of 
mGBP1 recruitment to vacuoles of avirulent type III parasites. In the same study, 
expression of the virulent type I Toxoplasma rhoptry protein ROP16, a tyrosine kinase, 
in an avirulent type II strain of Toxoplasma also significantly reduces the recruitment 
of mGBP1 to the PV of the parasite. Deletion of the avirulent type II dense granule 
protein GRA15 leads to a decreased recognition of the PV by mGBP1 (Virreira Winter 
et al., 2011). A few host proteins have also been reported to mediate the recruitment 
of mGBPs to avirulent Toxoplasma. Last year, Ohshima et al. showed that deletion of 
the autophagy proteins ATG7 and ATG16L leads to a reduction in the accumulation 
of mGBPs to avirulent PV following IFNγ-stimulation, as well as an inability to 
control parasite replication (Ohshima et al., 2014). Choi et al. reported the autophagy 
proteins ATG3, ATG7 and the ATG12-ATG5-ATG16 complex mediate the disruption 
of Toxoplasma PV by LC3 and IFNγ effector proteins (Choi et al., 2014). This 
summer, Ohshima et al. showed that the Rab dissociation inhibitor alpha (RabGDIα) 
is a negative regulator of mGBP recruitment to avirulent Toxoplasma. RabGDIα 
interacts with mGBP2, and deletion of RabGDIα leads to an increased resistance to 
Toxoplasma infection both in vitro and in vivo. This was associated with an increased 
accumulation of mGBP2 and mIrga6 at the vacuole (Ohshima et al., 2015). The precise 
mechanism of negative regulation of mGBP2 and mIrga6 by RabGDIα is still unclear. 
Despite all these findings, which place the mGBPs at the avirulent PV of Toxoplasma 
to participate in its clearance, the comprehensive cellular functions of the p65 mGBPs 
during infection with Toxoplasma remain unknown. 
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1.5 Aim of this work 
 
Parasitic infections are characterised by a constant race between the host and the 
pathogen to evolve and adapt in order to survive. The vacuolar parasite Toxoplasma 
actively invades any nucleated host cell, where it safely resides and replicates by 
avoiding fusion with lysosomes and subsequent acidification. Its conversion from the 
fast replicative form called tachyzoite, to the slowly replicative form termed 
bradyzoite, allows the establishment of a chronic, life-long infection within the host. 
The murine host has developed immune strategies to counteract Toxoplasma, which 
have to be deployed timely and orchestrated effectively in order to successfully contain 
the parasite without causing lethal inflammation (Figure 1.16). 
IFNγ is the major mediator of the host defence against Toxoplasma, activating a wide 
range of antimicrobial processes in both immune and non-immune cells. In monocytes 
and macrophages, the production of nitric oxide can lead to parasite damage, but this 
is only effective during chronic infection. In contrast, members of the autophagy 
proteins as well as the two families of large GTPases named p47 IRGs and p65 GBPs, 
contribute to the clearance of the parasite in hematopoietic and non-hematopoietic 
cells during the acute phase of the infection. Both IRGs and GBPs have been shown 
to mediate destruction of Toxoplasma. Both have also been shown to interact with 
autophagy and inflammasome proteins, which also contribute to resistance against 
Toxoplasma. Interestingly, Toxoplasma has been shown to carry monoclonal 
antibodies inside the host cell, which could possibly be detected after vacuolar 
disruption (Zapata et al., 2005; Karunajeewa et al., 2001; Rosso et al., 2008; 
Dubremetz et al., 1985). Thus, the three cytosolic recognition pathways described in 
sections 1.3.3 to 1.3.5 could act jointly to combat Toxoplasma infection.  
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The molecular mechanisms occurring at the interface of host-pathogen interaction –
namely the PV– involving both the IFNγ-induced host response by GBPs and evading 
tactics mediated by secreted parasitic proteins, remain unknown. How are mGBPs 
recruited to the PV of Toxoplasma? What happens after PV disruption, leading to 
Toxoplasma being exposed in the host cytosol? What detection mechanisms are 
triggered? What sensor molecules are involved? How do parasitic secretory proteins 
allow virulent type I Toxoplasma to evade recognition by GBPs at its PV? What are 
the molecular and organismal consequences of vacuolar recognition by GBPs and 
other effectors? Answering these questions will advance our understanding of the 
molecular function of the GBPs in the resistance to Toxoplasma infection. The work 
described in this thesis aimed at identifying what host factors play a role at the PV and 
in mediating resistance against Toxoplasma (Figure 1.17). As the study has been 
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Figure 1.1: Global human seroprevalence of Toxoplasma.  
Low seroprevalence (<30%) is shown in light orange, medium seroprevalence (30-50%) is shown in 
orange and high prevalence (>50%) is shown in dark orange. Adapted and reprinted with permission 
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Country Year Prevalence (%) 
Australia 2001 23 (Karunajeewa et al., 2001) 
Austria 2011 31 (Sagel et al., 2011) 
Belgium 2004 48.7 (Breugelmans et al., 2004) 
Brazil 2012-2008 49.5 (Fonseca et al., 2012)-77.5 (Porto et al., 2008) 
Burkina Faso 2006 25.3 (Simpore et al., 2006) 
China 2013 11.8 (Sun et al., 2013b) 
Columbia 2008 45.8 (Rosso et al., 2008)-63.5 (Castro et al., 2008) 
Costa Rica 2005 55 (Zapata et al., 2005) 
Cuba 2003 61.8 (Sanchez-Gutierrez et al., 2003) 
Czech 
Republic 2007 19.8 (Kanková and Flegr, 2007) 
Denmark 1999 27.8 (Lebech et al., 1999) 
Ethiopia 2013-2015 81.4 (Gebremedhin et al., 2013)-65.8 (Tilahun et al., 2015) 
Finland 1992 20.3 (Lappalainen et al., 1992) 
France 1996 54.3 (Ancelle et al., 1996) 
Germany 1999 63.2 (Fiedler et al., 1999) 
Ghana 2009 92.5 (Ayi et al., 2009) 
Greece 2004 29.4 (Antoniou et al., 2004) 
India 2007-2004 41.6 (Borkakoty et al., 2007)-45 (Singh and Pandit, 2004) 
Iran 2008-2007 33.5 (Fallah et al., 2008)-48.3 (Saeedi et al., 2007) 
Italy 2008-2013 22.7 (De Paschale et al., 2008)-30.2 (Mosti et al., 2013) 
Japan 2012 10.3 (Sakikawa et al., 2012) 
Jordan 2005 47.1 (Jumaian, 2005) 
Mexico 2006 6.1 (Alvarado-Esquivel et al., 2006) 
Morocco 2007 50.6 (Mansouri et al., 2007) 
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New Zealand 2004 35.4 (Morris and Croxson, 2004) 
Norway 1998 10.9 (Jenum et al., 1998) 
Poland 2002-2006 35.8 (Niemiec et al., 2002)-41.3 (Nowakowska et al., 2006) 
RDC 2014 80.3 (Doudou et al., 2014) 
Singapore 2000 17.2 (Wong et al., 2000) 
slovakia 2008 22.1 (Studenicová et al., 2008) 
Slovenia 2002 34 (Logar et al., 2002) 
South Korea 2005 0.8 (Song et al., 2005)-3.7 (Han et al., 2008) 
Spain 2004-2015 
18.8 (Gutiérrez-Zufiaurre et al., 2004)-35.2 (Asencio et al., 
2015) 
Sudan 2003 34.1 (Elnahas et al., 2003) 
Sweden 2001 18 (Evengård et al., 2001) 
Switzerland 2006 35 (Signorell et al., 2006) 
Taiwan 2008 31 (Lin et al., 2008) 
Thailand 2013-2001 2.6 (Sakae et al., 2013)-21.5 (Tantivanich et al., 2001) 
Turkey 2004 60.4 (Harma et al., 2004) 
UK 2005 9.1 (Nash et al., 2005) 
US 2014 9.1 (Jones et al., 2014) 
Venezuela 2006 38 (Triolo-Mieses and Traviezo-Valles, 2006) 
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Date Finding 
1908 New protozoa discovered in the rodent Ctenodactylus gundi in North Africa and in a rabbit in Brazil 
1909 Name Toxoplasma gondii proposed for the first time 
1937 Toxoplasma isolated from and passaged in animals for the first time 
1937 Toxoplasma described as an obligate intracellular parasite 
1939 Toxoplasma isolated from human for the first time 
1939-1940 Congenital transmission demonstrated in human 
1941 Acquired acute infection demonstrated in human child 
1941 Acquired acute infection demonstrated in human adults 
1945-1947 Chronic asymptomatic infection demonstrated in human adults 







































Figure 1.2: Sexual life cycle of Toxoplasma. 
Felines (shown here as a cat) are Toxoplasma’s definitive host, where the parasite can sexually replicate 
in the gut. Oocysts are shed in the cat’s feces and undergo sporulation to become infectious. Asexual 
replication occurs in the intermediate host (shown here as a rodent). Acute infection is characterised by 
the fast replication of Toxoplasma tachyzoites disseminated throughout the body. Chronic infection is 
characterised by the presence of slow-replicating Toxoplasma bradyzoites within tissue cysts. Ingestion 
of tissue cysts leads to infection of a new intermediate or definitive host, reinitiating the asexual or 
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Figure 1.3: Asexual life cycle of Toxoplasma.  
All warm-blooded animals may serve as intermediate hosts, wherever the Toxoplasma asexual life cycle 
occurs. Intermediate hosts, including humans and livestock, are infected by ingestion of food (meat, 
fruits and vegetables), soil or water contaminated by oocysts. The intermediate phase of the Toxoplasma 
life cycle also occurs by transmission from the acutely infected mother to the unborn foetus or by an 
organ transplant, as well as by carnivorism between intermediate hosts. Reprinted with permission from 
(Robert-Gangneux and Dardé, 2012). 
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Figure 1.4: Schematic representation of the ultrastructure of a Toxoplasma tachyzoite. 
Toxoplasma tachyzoites are comprised of eukaryotic universal organelles (nucleus, Golgi apparatus, 
endoplasmic reticulum and ribosomes), Apicomplexan secretory organelles (rhoptries, micronemes and 
dense granules) and endosymbiosis-derived organelles (mitochondrion and apicoplast) enclosed in a 
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Figure 1.5: The autophagy pathway in mammalian cells. 
The first step of the autophagy process involves the nucleation of a crescent-shaped isolation membrane 
called phagophore, arising from the endoplasmic reticulum (ER), the Golgi apparatus or the plasma cell 
membrane. The nucleation step is mainly driven by the complexation of Vps34, Beclin-1, ATG14 and 
p150 leading to the phosphorylation of lipids on the nascent membrane. Second, two ubiquitination-
like systems mediate the expansion of the isolation membrane that will eventually fuse to form a new 
double-membraned vesicle termed the autophagosome. The large multimeric complex ATG12–ATG5–
ATG16 is thought to act as a structural support for membrane expansion, and the microtubule-associated 
protein light chain 3 (LC3) is conjugated with phosphotidylethanolamine (PE). LC3 also has the ability 
to bind autophagy receptors, such as p62, NDP52 or NBR1, which permits selective autophagy. Third, 
LAMP2 mediates the fusion of the autophagosome with the acidic and hydrolase-containing lysosome, 
forming a so-called autolysosome. Finally, the luminal content is degraded, and the obtained products 
are translocated to the cytoplasm for reuse in metabolic processes and the membrane is recycled. 
































Figure 1.6: Autophagy receptors and adapters in the context of Salmonella  typhimurium infection.  
Inside the host cell, Salmonella resides in a specialised compartment called Salmonella-containing 
vacuole (SCV). However, the SCV can be damaged and break, releasing free bacteria in the cytosol and 
exposing the content of the intraluminal membrane. (i): Autophagy can be activated by the secretion of 
bacterial effectors into the cytosol via the type III secretion system (T3SS). This induces the formation 
of diacylglycerol (DAG) that recruits LC3 to the SCV. (ii): LRSAM1 is an E3 ubiquitin ligase that binds 
to free cytosolic Salmonella via its LRR domain and to the autophagy receptor NDP52, recruiting LC3 
to the site of infection. LRSAM1 might also target the free bacterium by ubiquitination (ub: ubiquitin, 
black circles). (iii-v): Ubiquitination at the surface of Salmonella can recruit the autophagy receptors 
p62, NDP52 and optineurin, which in turn bind to LC3-positive autophagosomes. (vi): Disruption of 
the SCV exposes luminal host glycans for recognition by galectin-8, which recruits NDP52 and thereby 



























Figure 1.7: Schematic representation of the structure of the NLRP3 inflammasome.  
Following activation, the sensor NLRP3 oligomerises via its NACHT domains and recruits the adaptor 
protein ASC through their respective pyrin domains (PYD). ASC finally recruits the inactive 































Figure 1.8: Inflammasomes implicated in the recognition of vacuolar pathogens.  
NLRC4 detects Salmonella or Legionella flagellin as well as proteins from their respective secretion 
systems. NLRP1 is a known sensor for Bacillus anthracis lethal toxin, and Toxoplasma has recently 
been shown to trigger its activation as well. Once activated, these sensors can complex with the adaptor 
protein ASC and recruit procaspase-1, which is autoprocessed into active caspase-1. Caspase-1 cleaves 
the inflammatory precursors pro-IL-1β and pro-IL-18 into their active forms IL-1β and IL-18 and thus 


































Figure 1.9: Stylised structure of an IgG.  
Colouring shows heavy chains (H) in blue and light chains (L) in pink. Constant regions (C) are in dark 
colour and variable regions (V) are in light colour. The antibody-binding fragment (Fab) is made of the 
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Figure 1.10: Schematic representation of the antibody-dependent intracellular neutralisation of 
pathogens.  
In the extracellular environment, viruses and bacteria are coated with antibodies. Following invasion, 
the pathogens retain the immunoglobulins on their surface, which can be detected by the cytosolic Fc 
receptor TRIM21. Using the E3 ubiquitin ligase activity conferred by its RING domain, TRIM21 labels 
the pathogens for degradation and triggers innate immune signalling. Figure by Leo Hillier reprinted 


















































Figure 1.11: Early immune responses to Toxoplasma gondii infection. 
Following invasion, Toxoplasma is recognised by monocytes, macrophages and dendritic cells (DCs) 
via their Toll-like receptors (TLRs). These activated cells secrete IL-12 as well as tumor necrosis factor 
(TNF), which stimulate the production of the cytokine interferon gamma (IFNγ) by natural killer (NK) 
cells and T cells. IFNγ, the main mediator of the anti-Toxoplasma immune response, triggers a wide 
range of antimicrobial processes in both hematopoietic and non-hematopoietic cells. These responses 
include the production of nitric oxide (NO) and the transcriptional upregulation of the immunity-related 
GTPases (IRGs) and guanylate-binding proteins (GBPs), leading to the destruction of the parasite. 
Reprinted with permission from (Hunter and Sibley, 2012).  
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Figure 1.12: Genomic organisation of human and mouse p47 IRGs and p65 GBPs.  
(A) Schematic representation of the human p47 IRG (blue) and p65 GBP (green) genes on chromosomes 
1, 5 and 19. (B) Schematic representation of the mouse p47 IRG (blue) and p65 GBP (green) genes on 
chromosomes 3, 5, 7, 11 and 18. Blue and green boxes represent putative pseudogenes. Red boxes 
indicate genes unrelated to the GTPases. Gene orientation is given by the direction of the arrow. The 
gene nomenclature is shown above the arrows, and the NCBI gene identification numbers are shown 
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Figure 1.13: Multiple sequence alignment of the mouse p65 GBPs.  
Red boxes highlight the four N-terminal consensus sequences within the GTP-binding domain and the 
C-terminal CaaX motif. The consensus sequences are shown above the aligned areas. Residues marked 
with an asterisk (*) are invariant, fully conserved amino acids. Residues marked with a colon (:) indicate 
amino acids with strongly similar properties. Residues marked with a period (.) indicate amino acids 
with weakly similar properties. Dashes indicate gaps in the aligned sequences. Multiple sequence 














Figure 1.14: Ribbon representation of the overall structure of human GBP1:GppNHp.  
The structure was determined by X-ray crystallography at a resolution of 1.7Å (PDB entry 1F5N). The 
N-terminal domain containing the GTP-binding site is globular, the C-terminal domain is elongated. 
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Figure 1.15: Model representation of human GBP1 dimerisation.  
The presumed head-to-head dimer in presence of the GTP analog GppNHp. The expected distance 
between the respective K567 and Q577 residues is indicated in red arrows and numbers. Reprinted 
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Figure 1.16: Battle between the host immune defence and Toxoplasma survival strategy. 
Toxoplasma actively invades the host cell and resides in a parasitophorous vacuole as the fast replicative 
form called the tachyzoite. Its conversion to the slowly replicative form termed bradyzoite allows the 
establishment of a chronic, life-long infection within the host. The infected host must develop immune 
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Figure 1.17: Known key players involved in the resistance against Toxoplasma gondii and 
outstanding questions to be answered.  
Following infection with Toxoplasma, interferon gamma (IFNγ) is the main cytokine produced. 
Signalling through its receptor (IFNγR), IFNγ activates the signal transducer and activator of 
transcription 1 (STAT1). This nuclear transcription factor in turn upregulates the expression of two 
defence proteins called immunity-related GTPases (IRGs) and guanylate-binding proteins (GBPs), 
which recruit to the Toxoplasma parasitophorous vacuole (PV) and mediate its disruption and the killing 
of the parasite. Autophagy has also been linked to the clearance of Toxoplasma. As Toxoplasma can be 
coated with antibodies and retains them once it has invaded the cell, the breakage of the PV could 
release the immunoglobulins in the host cytosol where they could serve as danger-associated molecular 
pattern (DAMP). How the GBPs exert their function at the PV remains unknow, as well as what signals 
trigger the activation of the autophagy pathway. The aim of this thesis is to identify what other factors 
play a role at the PV and in mediating the resistance against Toxoplasma. 
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2.1 Tissue culture: cells and parasites 
2.1.1 Culture of mammalian cells 
All cell lines were grown in an incubator maintained at 37°C with 5% CO2. Human 
foreskin fibroblasts (HFFs, ATCC, Manassas, VA, USA), Raw 264.7 macrophages 
(ATCC), human embryonic kidney 293T cells (HEK 293T, ATCC) and primary 
mouse embryonic fibroblasts (MEFs, home-made) were cultivated in Dulbecco's 
Modified Eagle Medium (DMEM, Gibco, Life Technologies, Carlsbad, CA, USA) 
supplemented with 10% fetal calf serum (FCS, Gibco). 
Raw 264.7 cells were split every 3-4 days when confluency was about 90%. Cells were 
washed once with PBS and scraped in 1mL PBS. After resuspension in culture 
medium, cells were passaged at a 1:20 ratio into new 10 cm dishes (Corning, Corning, 
NY, USA). 
HFFs, MEFs and HEK 293T were split about every week when confluency was 90%. 
Cells were washed once with PBS and treated with 0.05% trypsin-EDTA (Gibco) for 
3 min at 37°C. Cells were resuspended in culture medium and centrifuged at 900 g for 
5 min. The pellet was then resuspended in culture medium and cells were split into 
new flasks (for HFFs) or new 10 cm dishes (for MEFs and HEK 293T). 
2.1.2 Culture of Toxoplasma gondii parasites 
2.1.2.1 Toxoplasma gondii cell lines 
Unless stated otherwise, the virulent type I strain RH and the nonvirulent type II strain 
Prugniaud (Pru) were used. Both strains were either WT or genetically modified to 
express a fluorescent protein in their cytoplasm. Virulent type I RH parasites express 
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tomato while avirulent type II Prugniaud (Pru) parasites express GFP and firefly 
luciferase (kind gifts from Marc-Jan Gubbels and Jeroen Saeij) (Yoshimi et al., 2009; 
Wang et al., 2006; Roos et al., 1994; Kim et al., 2007). 
2.1.2.2 Toxoplasma gondii passage 
All strains of Toxoplasma were maintained by serial passage on monolayers of HFFs 
as described previously (Garnham et al., 1962). Briefly, HFFs with Toxoplasma 
vacuoles were scraped off the flask and were passed through a 25 or 27 gauge needle 
(Terumo, Somerset, NJ, USA) to disrupt cells. A few drops of medium containing the 
parasites were transferred to a new, confluent flask of HFFs to passage the parasites. 
2.1.3 Induction with interferon gamma 
Cells were induced with interferon gamma (IFN-γ) by supplementing the culture 
medium with 100 U/mL murine IFNγ (R&D Systems, Minneapolis, MN, USA) for 16 
h. 
2.1.4 Infection of mammalian cells with Toxoplasma gondii parasites 
To infect cells, parasites were isolated from HFF cultures as described above. After 
needle lysis, the collected parasites were centrifuged at 1230 g for 7 min and the pellets 
containing Toxoplasma were resuspended in a small volume of DMEM. 
Concentrations of parasites were determined by counting them in a disposable 
FastRead102 counting chamber. For infections, cells were incubated with Toxoplasma 
at a multiplicity of infection (MOI) ranging from 0.5-10 and dishes were centrifuged 
at 900 g for 2 min and incubated for 1 h at 37°C with 5% CO2 before cells were lysed 
or fixed. 
Chapter 2: Experimental Procedure 
 98 
2.2 Primers  
All primers used for the generation of constructs described or used in this work, as 
well as for the sequencing of plasmids or the genotyping of animals, are listed in the 
below. The nucleotide sequence is indicated from 5’ to 3’ direction. 
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Table 2.1: List of primers used for any application described in this thesis. 
 
2.3 Molecular cloning 
2.3.1 Origin of DNA templates for polymerase chain reaction 
The DNA templates for the polymerase chain reaction (PCR) were either full-length 
constructs already available in the lab or full-length cDNA clones commercially 
available. 
Gene name IMAGE ID Sequence accession nb cDNA type 
Trim21 3584654 BC010580 Mouse verified Full-Length cDNA 
Table 2.2: List of the cDNA clone. Information available from the I.M.A.G.E Consortium online at 
http://www.imageconsortium.org/.  
 
2.3.2 DNA amplification by polymerase chain reaction 
Coding sequences of mGBP1, mGBP2, mGBP5, mTRIM21, mSEC23A, mSEC23B, 
mSEC24A, mSEC24B and mIRF8 were amplified by PCR. Primers were purchased 
from Sigma-Aldrich (St. Louis, MO, USA) and were used to introduce FLAG or HA 
epitope tags as well as recognition sites for restriction endonucleases. The two 
restriction sites are not complementary to prevent the vector from re-annealing to form 
transformable circular DNA and to allow control of the correct orientation of the 
inserted PCR product. Short overhangs were placed 5’ to the recognition sites to allow 
more efficient cutting of linear DNA by restriction enzymes. The content of the PCR 
reaction mix is listed in Table 2.3 and the PCR program is shown in Figure 2.1.  
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DNA template 100 ng 
Forward primer (10µM) 2.5 µL 
Reverse primer (10µM) 2.5 µL 
dNTPs mix (10mM) 1 µL 
5x buffer HF 10 µL 
Phusion DNA polymerase 0.5 µL 
H2O to 50 µL 
Total 50 µL 









Figure 2.1: PCR cycling conditions. 
 
Amplification of the genes of interest was verified on a 1% agarose gel (Bio-Rad 
Laboratories, Hercules, CA, USA) containing the fluorescent dye ethidium bromide 
by electrophoresis in 1X Tris-Acetate-EDTA (TAE) buffer (TAE Buffer 50X, 
National Diagnostics, Atlanta, GA, USA) at 100V until the migration was completed. 
DNA samples were visualized under UV light.  
2.3.3 Preparation of the inserts and vectors 
2.3.3.1 Cloning into the pMSCVneo vector 
Both the PCR amplicons and the pMSCVneo vector were double digested for 1 h at 
37°C as indicated in Table 2.4. The restriction enzymes (Fermentas, Thermo Scientific 
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Molecular Biology, Waltham, MA, USA) were inactivated for 5 min at 80°C and the 
digested products were run on a 0.8% agarose gel as described above. The linearised 
vector and digested inserts were purified in 20 µL final using the Nucleospin PCR & 
Gel Clean-Up kit (Macherey-Nagel, Düren, Germany) according to the manufacturer’s 
instructions.  
 
The inserts and plasmids were ligated using T4 DNA ligase (Thermo Scientific) for 1 
h at RT as listed in Table 2.5. Finally, 5 μl of the ligation mix was used for 
transformation as described below (see section 2.3.5). 
Linearised pMSCVneo variable 
Cut purified insert variable 
10x buffer 1 µL 
T4 DNA ligase 0.5 µL 
H2O to 10 µL 
Total 10 µL 
Table 2.5: Ligation into pMSCVneo reaction mix. 
 
2.3.3.2 Cloning into the pGEM-T vector 
pGEM-T vector (Promega, Madison, WI, USA) is an open vector exhibiting a T-
overhang, enabling for ligation with A-overhang inserts. As the PCR amplicons 
Enzyme 1 2 µL  Enzyme 1 1 µL 
Enzyme 2 2 µL  Enzyme 2 1 µL 
PCR amplicon 20 µL  Vector  1 µg 
10x FastDigest buffer 3 µL  Alcaline phosphatase 1 µL 
H2O 1 µL  10x Fast Digest buffer 2 µL 
Total 30 µL  H2O to 20 µL 
   Total 20 µL 
Table 2.4: Restriction digest reaction mixes for the inserts and vectors. 
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produced by a high fidelity DNA polymerase are blunt-ended, a normal Taq 
polymerase was used to add an additional A at the end of the PCR fragments for 30 
min at 72°C as indicated in Table 2.6. 
Purified PCR amplicon 6.2 µL 
10x buffer 1 µL 
MgCl2 (25mM) 0.8 µL 
dATP (2mM) 1 µL 
Taq polymerase (5U/µL) 1µL 
Total 10 µL 
Table 2.6: A-tailing reaction mix. 
 
The inserts and plasmids were ligated using T4 DNA ligase (Thermo Scientific) 
overnight (O/N) at 4°C as listed in Table 2.7. Finally, 2 μl of the ligation mix was used 
for transformation as described below (see section 2.3.5). 
pGEM-T 50ng/µL 1 µL 
A-tailed insert 3 µL 
2x buffer 5 µL 
T4 DNA ligase 1 µL 
Total 10 µL 
Table 2.7: Ligation into pGEM-T reaction mix. 
 
2.3.4 Site-directed mutagenesis 
Site-directed mutagenesis was used to introduce the R48A and K51A mutations into 
mGBP2 and mGBP5. The retroviral vectors pMSCVhygro-HA-mGBP2 and 
pMSCVhygro-HA-mGBP5 were used as templates for the PCR reactions. Primers 
were designed to encompass the sequence surrounding the mutation to be introduced, 
according to the instructions of the QuikChange II Site-Directed Mutagenesis Kit 
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(Agilent Technologies Inc., Santa Clara, CA, USA) and are described in Appendix 9.2. 
The polymerase, buffers and deoxynucleotides (dNTPs) were all purchased from New 
England Biolabs (Ipswich, MA, USA). 
DNA template 100 ng 
Forward primer (10μM) 1.5 μL 
Reverse primer (10μM) 1.5 μL 
5x Q5 buffer 10 μL 
5x GC enhancer buffer 10 μL 
dNTPs (10mM) 1 μL 
Q5 polymerase 1 μL 
H2O to 50 μL 
Total 50 μL 









Figure 2.2: Site-directed mutagenesis PCR cycling conditions. 
 
The generated PCR products were then directly digested with 1 μL DpnI endonuclease 
that recognises methylated parental vector. Finally, 2 μL of the remaining mutated 
retroviral vectors generated by PCR were used for transformation as described below. 
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2.3.5 Transformation into E. coli and plasmid preparation 
For each transformation, 2-5 µL DNA of the ligation reaction was added to 50 µL 
chemically competent DH5α library-efficient cells (Invitrogen Life Technologies, 
Paisley, UK). After incubation on ice for 30 min, chemical transformation was 
performed by heat shock for 45 sec at 42°C followed by 2 min incubation on ice. Cells 
were recovered in 950 mL SOC medium and shaken at 225 rpm for 1 h at 37°C. After 
spreading onto selective plates, cells were incubated at 37°C overnight.  
The constructs were first screened by restriction digestion analysed on a 1% agarose 
gel. Briefly, an overnight culture of a single positive colony was grown at 37°C to 
extract plasmid DNA using the NucleoSpin Plasmid Kit (Macherey-Nagel) according 
to the manufacturer’s instructions. Concentration of DNA was measured by UV 
spectrometry with a NanoDrop (ThermoScientific) and 1 μg DNA was digested with 
the appropriate restriction enzyme as described previously. Presence of an insert of the 
right size was assessed by gel electrophoresis. DNA of positive bacterial clones was 
sequenced by GATC Biotech (Konstanz, Germany). Sequences were analysed with 
the SeqMan Pro program (DNAStar Lasergene, Madison, WI, USA). 
2.4 Production of retroviruses 
HEK 293T cells are a human cell line that can be transfected with plasmid DNA at 
high efficiency. The cell line was derived from the HEK293 cell line by the addition 
of the SV40 large T-antigen, leading to an increased production of some viral vectors, 
including retroviruses. For optimal efficiency, 293T cells were freshly thawed and kept 
in a low passage number. 24 h before transfection, HEK 293T were seeded in 10 cm 
dishes to achieve 80% confluency the next day. Cells were then transfected with the 
appropriate plasmid using TransIT®-293 Transfection Reagent (Mirus, Madison, WI, 
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USA) as follow. DNA and transfection reagents were separately mixed with Opti-
MEM® (Invitrogen), briefly vortexed and incubated 10 min at RT.  
Retroviral vector 4 µg  Opti-MEM® 200 µL 
VSV-G 3 µg  TransIT®293 30 µL 
gag-pol 3 µg  Total 230 µL 
Opti-MEM® 10 µL    
Total 20 µL    
Table 2.9: Transfection mixes for the production of retroviruses. 
DNA and transfection reagents were then mixed, vortexed, and incubated for 15 min 
at RT before transfection mixes were added uniformly drop by drop to the HEK 293T 
cells. Dishes were swirled and incubated at 37°C and 5% CO2 for 8 h before medium 
was changed to DMEM + 10% FCS. Supernatants containing viruses were collected 
48 h and 72 h post-transfection and pooled together. After centrifugation at 900 g for 
5 min at 4°C, 1 mL aliquots of the supernatants were frozen at -80°C for long-term 
storage or used for viral transduction immediately. 
2.5 Determination of the IC100 for specific antibiotics 
Transduced cells having incorporated the gene of interest can be segregated from non-
transduced cells by selection with an antibiotic whose resistance gene is encoded on 
the introduced plasmid, thus generating stable cell lines for the gene of interest. To 
determine the right concentration of the antibiotic to use for the selection of transduced 
cells, the inhibitory concentration 100% (IC100) was assessed for hygromycin B 
(Invitrogen), puromycin (Sigma-Aldrich) and geneticin (G-418, Gibco). Raw 264.7 
were seeded at 50% confluency in 6-wells plates and incubated with rising 
concentrations of each antibiotic. The IC100 corresponds to the minimum 
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concentration of antibiotic leading to the death of all Raw 264.7 cells. Table 2.10 
shows the IC100 concentrations for Raw 264.7 cells found for the three antibiotics. 
Antibiotics Concentration 
Hygromycin B 150 μg/mL 
Geneticin 850 μg/mL 
Puromycin 2.5 μg/mL 
Table 2.10: Concentration of antibiotics for selection of Raw 264.7.  
 
2.6 Generation of stable cell lines 
24 h before transduction, Raw 264.7 cells were seeded in a 6-wells plate to achieve 
50% confluency the next day. For each viral construct, 2 ml of virus-containing 
supernatants were added to a well. 8 μg/ml Polybrene (Santa-Cruz Biotechnology, 
Dallas, TX, USA) was added to each well to improve attachment of viral particles to 
the cells. Plates were then centrifuged at 600g for 90min and incubated at 37°C and 
5% CO2 for 16 h before the medium was replaced with DMEM + 10% FCS. After 24h, 
the medium was supplemented with the appropriate antibiotics. After successful 
selection of cells that stably expressed the transduced constructs, aliquots of cells were 
frozen at -80°C and subsequently moved to liquid nitrogen storage or cells were used 
for experiments. 
2.7 Generation of primary cell lines 
2.7.1 Generation of mouse embryonic fibroblasts 
The uterus was taken out of a female 13.5 or 14.5 days post-coïtum and put in iodine 
solution (poly(vinylpyrrolidone)-iodine complex at 100 mg/mL in PBS; Sigma-
Chapter 2: Experimental Procedure 
 107 
Aldrich). The uterus was incubated sequentially for 1min twice in iodine solution, 
twice in 70% ethanol and twice in PBS. The embryos were taken out of the uterus one 
by one by carefully removing the amnion and the placenta. Each embryo was 
transferred into 150 mm dish (Corning) and placed looking to the right to see the liver. 
The liver, the intestine and the heart were carefully removed, as well as the head, but 
the neck and the arms were kept. The embryo was placed in a new 150 mm dish and 
100 µL of 0.15% trypsin were added. The embryo was finely chopped with two 
scalpels and placed in the incubator at 37°C, 5% CO2 for 5-10 min. The homogenate 
was loosened from the plate in 5 mL DMEM supplemented with 15% FCS, 50 μM 
beta-mercaptoethanol (Sigma-Aldrich), 1X non-essential amino-acids (PAA 
Laboratories, Pasching, Austria) and penicillin/streptomycin. Cells were then 
resuspended in an additional 20 mL of medium and were incubated for 3 days at 37°C, 
5% CO2 without touching or moving the dishes. At day 3, 15 mL medium was taken 
off each plate and replaced with fresh media. Cells were grown until confluent and 
frozen in liquid nitrogen. 
2.7.2 Generation of mouse bone marrow-derived macrophages 
Both mouse leg bones were isolated and kept on ice in sterile PBS (Sigma Aldrich). 
Cells were extracted from bones by crushing in a mortar in sterile PBS. After filtering 
through a 70 μm filter (Sartorius, Göttingen, Germany) and spinning at 900 g for 5 
min at RT, cells were resuspended in 20 mL DMEM supplemented with 
Penicillin/Streptomycin, 10% FCS and 100 U/mL M-CSF (=macrophage complete 
medium). Total bone marrow progenitor cells count was determined using a 
haemocytometer and the cell concentration was adjusted to a final concentration of 
4x106 in macrophage complete medium. Cells were seeded at a density of 4x106 in 10 
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cm sterile culture dishes and incubated for at 37°C, 5% CO2. After 3 days, 5 mL of 
complete macrophage medium was added to each dish. After another 4 days, culture 
supernatants were discarded and cells were washed with 5 mL pre-warmed PBS. Cells 
were then incubated for 10-15 min in ice-cold PBS at 4°C and cells were detached by 
pipetting up and down. Cells were pooled together, spun at 900 g for 5 min at RT and 
resuspended in 3-5 mL DMEM supplemented with Penicillin/Streptomycin and 10% 
FCS (=DMEM/F12-10). Cells were then either frozen at 4x106 per vial or seeded for 
experiments at 2x105 cells per well in 24-well plates or 1x106 cells per well in 6-well 
plates. 
2.8 Immortalisation of primary BMDMs 
Both mouse leg bones were isolated and kept on ice in sterile PBS. Cells were extracted 
from bones by crushing in a mortar in IMDM supplemented with 15% FCS. After 
filtering through a 70 μm filter  and spinning at 900 g for 5 min at RT, cells were 
resuspended in 5 mL red blood cell lysis solution (Sigma Aldrich)at RT for no longer 
than 5 min. The solutions was neutralised with 10 mL PBS, cells were span at 900 g 
for 5 min, resuspended in 20 mL PBS and filtered through a 40 μm filter. Total bone 
marrow progenitor cells count was determined using a haemocytometer. 100 µL of 
separation buffer (PBS, 0.5% BSA, 2mM EDTA) and 10 µL of anti-CD117-biotin 
antibody (Miltenyi Biotec, Bergisch Gladbach, Germany) were added per 1.107 cells. 
After incubation at 4°C for a minimum of 10 min, cells were resuspended in 10 mL 
PBS and span at 900 g for 5 min. 100 µL of separation buffer and 10 µL of anti-biotin 
beads (Miltenyi Biotec) were added per 1.107 cells. After incubation at 4°C for 15 min, 
cells were resuspended in 10 mL PBS and span at 900 g for 5 min. The pellet was 
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resuspended in 500 mL separation buffer and CD117-positive macrophage progenitors 
were separated on a MACS purification column. 
The cells were loaded on a MACS purification column previously equilibrated with 
3x3 mL of separation buffer. Unbound material was washed with 3x3 mL of separation 
buffer. BMDMs were eluted with 2 mL separation buffer in a new collection tube by 
flushing out the magnetic beads vigorously with the plunger. PBS was added to obtain 
a final volume of 10 mL. Successful purification was assessed by determining the cell 
concentration, which should yield 1/3 of the initial cell load. Cells were span at 900 g 
for 5 min, washed once in 10 mL IMDM  + 15% FCS, span at 900 g for 5 min before 
final resuspension in 8 mL IMDM + 15% FCS supplemented with IL-3 (10 ng/mL), 
IL-6 (20 ng/mL) and SCF (25 ng/mL). The cells were split in two wells of a 6-well 
pate and incubated for 48h at 37°C, 5% CO2. 
Homeobox protein 8 (HOXB8) has been shown to block differentiation of myeloid 
progenitors {(Schroeder et al., 2006; Yoshimi et al., 2009; Wang et al., 2006). Infection 
of bone marrow cells with retroviruses encoding oestrogen-dependent HOXB8 
enables generation of myeloid progenitors, which can be cultured in presence of 
granulocyte-macrophage colony stimulating factor (GM-CSF) and oestrogen. After 
incubation for 2 days, non-adherent cells were span at 900 g for 5 min and resuspended 
in 1 mL of IMDM + 15% FCS supplemented with IL-3, IL-6 and SCF. Cells were 
transduced with 2 mL of HOXB8 retroviruses in presence of 8 µg/mL polybrene and 
span at 600 g for 90 min. Cells were washed once to remove any trace of remaining 
polybrene and extracellular retroviruses, resuspended in 4 mL IMDM + 15% FCS 
supplemented with IL-3, IL-6 and SCF and incubated 48h at 37°C, 5% CO2. 
Transduced non-adherent progenitor cells were selected by replacing the medium with 
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IMDM + 15% FCS supplemented with 1 µM fresh estradiol, 10 ng/mL GM-CSF and 
1.5 µg/mL puromycin. Cells were selected and expanded for a minimum of 15-19 days 
before induction of differentiation. 
Selected positively-transduced myeloid progenitors can be differentiated into 
immortalised macrophages by removing oestrogen from the culture medium. Cells 
were washed three times in RPMI 1640 + 10% FCS to remove the estradiol. Cells were 
finally transferred in RPMI1640 + 10% FCS supplemented with 10 ng/mL GM-CSF 
for 3-4 days until they differentiated into macrophages and became adherent. 
2.9 Protein biochemistry 
2.9.1 Antibodies 
Primary antibodies used for immunoprecipitation, immunoblot or 
immunofluorescence were: rabbit polyclonal anti-GBP1 (Virreira Winter et al., 2011), 
goat polyclonal anti-TRIM21 (#sc-21365, Santa-Cruz Biotechnology), mouse 
monoclonal anti-myc (#2276, Cell Signalling, Danvers, MA USA), mouse monoclonal 
anti-ubiquitin FK2 (#PW8810, Enzo Life Sciences, Farmingdale,NY, USA), rabbit 
monoclonal anti-ubiquitin Lys48 (#05-1307, Merck Millipore, Billerica, MA, USA), 
rabbit monoclonal anti-ubiquitin Lys63 (#05-1308, Merck Millipore) and mouse 
monoclonal anti-p62 (#56416, Abcam, Cambridge, UK). Secondary antibodies for 
immunoblotting were from KPL (Gaithersburg, MD, USA): goat anti-mouse HRP 
(#474-1806), goat anti-rabbit HRP (#474-1506) and rabbit anti-goat (#14-13-06). 
Secondary antibodies for immunofluorescence were from Molecular Probes: 
AlexaFluor®488 chicken anti-rabbit (#A21441), AlexaFluor®488 chicken anti-goat 
(#A21467), AlexaFluor®568 goat anti-rabbit (#A11011), AlexaFluor®568 donkey 
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anti-goat (#A11057) and AlexaFluor®568 goat anti-mouse (#A11004). The dilution 




Immunoblot Immunoprecipitation Immunofluorescence 
anti-GBP1 1:10000 1:1000 1:500 
anti-TRIM21 1:200 2 µg/mL 1:200 
anti-myc tag 1:1000 1:1000 / 
anti-Flag tag 1:500 3 µg/mL / 
anti-ubiquitin FK2 / / 1:500 
anti-ubiquitin Lys48 / / 1:500 
anti-ubiquitin Lys63 / / 1:500 
anti-p62 / / 1:250 
anti-mouse HRP 1:5000 / / 
anti-goat HRP 1:5000 / / 
anti-rabbit HRP 1:5000 / / 
AlexaFluor®488 
anti-rabbit 
/ / 1:5000 
AlexaFluor®488 
anti-goat 
/ / 1:5000 
AlexaFluor®568 
anti-rabbit 
/ / 1:5000 
AlexaFluor®568 
anti-goat 
/ / 1:5000 
AlexaFluor®568 
anti-mouse 
/ / 1:5000 
Table 2.11: Concentration or dilution of antibodies for biochemistry and cell biology use. 
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2.9.2 Cell lysis 
Cells were washed twice in ice cold PBS and lysed in 600 L per well ice cold lysis 
buffer (25 mM TrisHCl pH 7.4; 5 mM MgCl2; 150 mM NaCl; 0.5% NP-40; 1 tablet 
protease inhibitor cocktail (Roche, Basel, Switzerland) per 10 mL). After rocking for 
1 h minimum at 4°C, lysates were centrifuged for 20 minutes at 16200 g to separate 
soluble from insoluble fractions. The supernatants containing the soluble proteins were 
kept for protein quantification and further experiments. 
2.9.3 Protein quantification 
Protein concentration of the cell lysates were determined using Pierce® BCA Protein 
Assay Kit (Thermo Scientific) according to the manufacturer’s instructions. For each 
sample, an undiluted sample as well as a 1:5 dilution sample were used to guarantee a 
fit within the standard curve.  
2.9.4 Immunoprecipitation 
All steps were performed at 4°C or on ice. Cells were washed twice in PBS and lysesd 
in ice cold lysis buffer (25 mM TrisHCl pH 7.4; 5 mM MgCl2; 150 mM NaCl; 0.5% 
NP-40; cOmplete EDTA-free protease inhibitor cocktail (Roche)). After rocking for 1 
h minimum, lysates were centrifuged for 20 min at 11 000 g. Total protein was 
quantified by the Bradford Dye assay (Pierce® BCA Protein Assay Kit, Thermo 
Scientific). Following pre-clearing for 3 h with protein G sepharose (Sigma Aldrich), 
supernatants containing 0.5-1 mg proteins were incubated overnight with anti-myc or 
anti-TRIM21 antibody and protein G beads. Immunoprecipitated proteins were eluted 
from the beads at 92°C for 10 min in 1X NuPAGE protein loading buffer (NuPAGE 
4X, Invitrogen) supplemented with 1mM dithiothreitol (DTT, Sigma Aldrich). 
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2.9.5 SDS-PAGE gel electrophoresis 
Proteins were separated according to their size by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE). SDS-PAGE gels consisting 
of Tris-glycine separating and stacking gels were prepared (Protogel 30%; 4X 
ProtoGel Resolving Buffer; Protogel Stacking Buffer; National Diagnostics) on the 
day of use in a Bio-Rad casting system. After polymerization, gels were placed in the 
appropriate Bio-Rad electrophoresis system, and Tris-glycine running buffer (National 
Diagnostics) was added. 5-10 µg of protein lysate samples or 7.5 µL of the 40 μL of 
immunoprecipitated samples were added into each lane. Each marker lane was filled 
with 10 μl of Precision Protein Plus Dual Color Standards (Bio-Rad Laboratories, 
Hercules, CA, USA). Proteins were separated by running the gel at 125V until the dye 
front reached the end of the gel. Gels were then used for immunoblot. 
2.9.6 Immunoblot 
Immunoblot was used to quantitatively detect specific protein bands after separation 
of proteins on 12% NuPAGE Bis-Tris SDS-PAGE gels (Life Technologies). Proteins 
were transferred onto nitrocellulose membrane by dry-blotting (iBlot®, Life 
Technologies). Blots were blocked at RT 1 h in a 5% non-fat dried milk/PBS solution 
(Blotto). The membrane was then incubated with primary antibody in Blotto + 0.1% 
Tween 20 for a minimum of 1 h at RT or overnight at 4°C. On the next day, blots were 
washed three times for 10 min in Blotto + 0.1% Tween 20 (except α-GBP1 required 
3x1 h washes). Blots were incubated for 1 h with HRP-conjugated secondary 
antibodies in Blotto + 0.1% Tween 20. Blots were washed three times for 15 min in 
Blotto + 0.1% Tween 20 (except α-GBP1 required 3x1 h washes). Finally, blots were 
developed with Pierce ECL Western Blotting Substrate (Thermo Scientific) or 
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Immobilon Western Chemiluminescent HRP Substrate (Merck Millipore). After 
incubation at RT for 1 min or 5 min respectively, blots were exposed to CL-XPosure 
film (Thermo Scientific) and films developed. 
2.10 Immunofluorescence 
Immunofluorescence was performed on 12 mm, 1.5 mm coverslips (Thermo Fisher) 
in 24-well plates (Nunc). Cells were stimulated with 100 U/mL recombinant murine 
IFNγ (R&D) overnight and infected with Toxoplasma at an MOI of 5-10. After the 
indicated infection time, cells were washed three times with PBS and fixed in 3% 
paraformaldehyde (Sigma Aldrich) at RT for 20 min. Cells were permeabilised for 15 
min at RT with 50 mM NH4Cl/0.2% saponin/PBS and kept at 4°C for up to a week in 
0.2% fish skin gelatin/0.02% saponin/0.02% NaN3/PBS (PGAS) until antibody 
staining. Briefly, coverslips were incubated with appropriate primary antibody in a 
humid chamber at RT for 1 h. Coverslips were then washes three times in PGAS and 
subsequently incubated with appropriate secondary antibody in a humid chamber at 
RT for 1 h in the dark and washed three times in PGAS solution followed by three 
washes in PBS. Nuclei were stained with 1 g/mL Hoechst 33442 solution (Sigma-
Aldrich). Coverslips were mounted on Superfrost® Plus glass slides (Thermo 
Scientific) with 50 µL Mowiol® 4-88 solution (Sigma-Aldrich) and kept in the dark 
at 4°C. The frequency of Toxoplasma-positive vacuoles was determined by counting 
100 PVs per technical replicate using an AxioPlan II fluorescent microscope (Carl 
Zeiss) equipped with DAPI, GFP and rhodamine filters. Images were captured with a 
Leica TCS-SP5 inverted confocal microscope (Leica Microsystems, Wetzlar, 
Germany) fitted with conventional photomultiplier tubes and hybrid detectors and 
using a 100x Leica HCX PL APO CS (numerical aperture 1.4) oil immersion objective. 
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Images were processed in Fiji/ImageJ software (National Institute of Health, Bethesda, 
MD, USA). 
2.11 Proximity ligation assay 
The DuoLink In situ proximity ligation assay (Olink Bioscience, Uppsala, Sweden) 
was used according to the manufacturer’s instructions. Briefly, MEFs were seeded, 
infected, washed, fixed and permeabilised as described in Immunofluorescence. 
Coverslips were incubated with primary antibodies (rabbit anti-GBP1 1:500 and goat 
anti-TRIM21 1:200) for 1 h at 37°C and washed three times in PGAS. Coverslips were 
then incubated with PLA probes anti-rabbit PLUS/MINUS and anti-goat 
PLUS/MINUS diluted 1:5 in PGAS for 1 h at RT and washed 2x5min in 1x wash 
buffer A. Ligation solution at a 1:5 dilution supplemented with ligase at a 1:40 dilution 
was then added onto the coverslips and incubated for 30 min at 37°C. After 2x2 min 
washes in 1x wash buffer A, amplification solution at a 1:5 dilution supplemented with 
polymerase at a 1:80 dilution was added onto the coverslips for 100 min at 37°C. 
Coverslips were washed 2x10 min in 1x wash buffer B and 1x1 min in 0.01x wash 
buffer B. After drying for 15 min at RT in the dark, coverslips were mounted in 
DuoLink In situ mounting medium with DAPI and stored at -20°C until analysis on a 
Leica TCS-SP5 inverted confocal microscope fitted with conventional photomultiplier 
tubes and hybrid detectors and using a 100x Leica HCX PL APO CS (numerical 
aperture 1.4) oil immersion objective. Images were processed in Fiji/ImageJ software. 
2.12 In vitro plaque assay 
MEFs were passaged 24 h before infection in 24-well plates at a seeding density of 
2x105 and induced with 100 U/mL IFNγ 16h before infection. The next morning, cells 
were infected with 100 GFP-expressing Pru tachyzoites per well. The plates were left 
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untouched for 3 days and the number of fluorescent plaques was subsequently counted 
using an Olympus CKX41 (Olympus, Center Valley, PA, USA) epifluorescent 
microscope. 
2.13 Transmission electron microscopy 
WT and TRIM21 KO MEFs were induced with IFNγ for 16h and infected with 
avirulent Pru Toxoplasma as described previously (see 2.1.4). Preparation of the 
samples and ultrastructural analysis of Toxoplasma-infected WT or TRIM21 KO 
MEFs was subsequently performed by Liz Hirst in the dedicated service provided 
within the Crick at Mill Hill Laboratory. Cells were washed three times in PBS before 
0.05% tryspin-EDTA treatment. After centrifugation at 900 g for 5 min, cells were 
immersion fixed in 2% glutaraldehyde/2% paraformaldehyde in 0.1M sodium 
cacodylate buffer, pH7.2, embedded in 2% agarose and spun for 3 min at 13000 rpm 
before being returned to 2% glutaraldehyde/2% paraformaldehyde in 0.1 M sodium 
cacodylate buffer, pH7.2 O/N. Samples were washed in sodium cacodylate buffer 0.1 
M pH7.2 (SCB) for 10 min, post-fixed in 1% osmium tetroxide/SCB for 1.5 hour, 
washed in SCB for 10 min and stained on bloc in 1% aqueous uranylacetate for 1.5 
hour. Samples were dehydrated in 50% ethanol, 75% ethanol and 90% ethanol for 10 
min each, 3x10 min in 100% ethanol and 2x30 min in propylene oxide. Samples were 
embedded in epon resin (Agar Scientific, Stansted, UK) for 5 changes over 8 h and 
polymerised at 70°C O/N. 50 nm sections were mounted on pioloform-coated slot 
grids and stained with uranyl acetate for 30 min and with Reynold’s lead citrate for 7 
min. Samples were observed with a JEOL 1200 EX transmission electron microscope 
(JEOL, Tokyo, Japan) equipped with an Orius 1000 CCD camera (Gatan, Pleasanton, 
CA, USA).  
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2.14 Fluorescence Activated Cell Sorting of cultured cells 
After IFNγ induction for 16h, WT and TRIM21-deficient MEFs were infected for 1 h 
15 min with type II avirulent tomato-expressing Prugniaud at an MOI of 5. Cells were 
washed three times in PBS and treated with 0.05% tryspin-EDTA for 1 min at 37°C. 
Cells were resuspended in culture medium and centrifuged at 900 g for 5 min at 4°C. 
The pellet was then resuspended in PBS to eliminate any phenol red remaining from 
the culture medium and centrifuged at 900 g for 5 min at 4°C. 
Unstained samples were resuspended in 200 μL phenol red-free RPMI supplemented 
with 2% FCS and filtered twice through 40 μm FACS strainers to a final volume of 
500 μL RPMI 2% FCS supplemented with 2.5 mM EDTA. 
All other samples were resuspended in 100 μL PBS and stained with LIVE/DEAD® 
fixable near IR dead cell stain kit (Life Technologies) on ice for 20 min. After washing 
once in 100 μL PBS, cells were spun at 900 g for 5 min at 4°C and the pellet was 
resuspended in 200 μL phenol-free RPMI supplemented with 2% FCS. Cells were 
finally filtered twice through 40 μm FACS strainers to a final volume of 500 μL RPMI 
2% FCS supplemented with 2.5 mM EDTA. 
Cells were kept on ice until sorting on a cat.2 Influx cell sorter. Live uninfected control 
samples were gated on APC-Cy7-/PE TexasRed- cells and live Toxoplasma-infected 
samples were gated on APC-Cy7-/PE TexasRed+ cells. For each sample, 110000 cells 
were collected and a purity check was performed to check for any contamination. Cells 
were then span at 900 g for 5 min at 4°C and the pellet was resuspended in 500 μL 
Trizol before storage at -80°C. 
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Sample Number of cells sorted Purity of the sort 
WT uninfected triplicate 1 110000 92.24% 
WT uninfected triplicate 2 110000 93.68% 
WT uninfected triplicate 3 110000 96.37% 
WT infected triplicate 1 36396 93.95% 
WT infected triplicate 2 38752 91.60% 
WT infected triplicate 3 36491 90.85% 
TRIM21 KO uninfected triplicate 1 110000 70.77% 
TRIM21 KO uninfected triplicate 2 110000 97.53% 
TRIM21 KO uninfected triplicate 3 110000 96.65% 
TRIM21 KO infected triplicate 1 110000 92.14% 
TRIM21 KO infected triplicate 2 109667 93.73% 
TRIM21 KO infected triplicate 3 103394 98.89% 
Table 2.12: Number of cells and purity obtained for each FACS-sorted sample. 
 
2.15 RNA extraction of FACS-sorted cells 
All steps were performed with RNAse-free tubes and using lab equipment previously 
cleaned with RNaseZap (Ambion, Life Technologies). Pellets were thawed on ice and 
200 μL chloroform was added per tube. After vigorous vortexing for 5 sec and 
incubation at RT for 10 min, the mix was spun at 13 000 rpm for 15 min at 4°C. The 
upper aqueous phase containing the extracted RNA was transferred to a new tube 
containing 500 μL ethanol. The mix was then purified using the miRNeasy kit (Qiagen, 
Venlo, The Netherlands), according to the manufacturer’s instructions. Briefly, the 
mix was transferred to a mini spin column and span at 13 000 rpm for 1 min at 4°C. 
Membranes were washed once with 500 μL RW1 buffer and twice with RPE buffer 
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before dry-spinning at 13 000 rpm for 1 min at 4°C. The RNA was eluted with 14 μL 
RNA-free water into a new tube and samples were stored at -80°C. 
2.16 RNA sequencing 
The following steps were performed by the High-Throughput Screening facility 
service provided within the Crick at Mill Hill Laboratory. 
2.16.1 Verification of RNA quality 
The quality of RNA was assessed using an Agilent 2100 Bioanalyser (Agilent 
Technologies, Santa Clara, CA, USA). All RNA samples present an RNA integrity 
number (RIN) higher than 7 (Figure 2.3), meaning the RNA was not degraded and of 
high quality (Schroeder et al., 2006). 
2.16.2 Preparation of samples for RNA sequencing 
The RNA samples isolated from 3 technical replicates were poly-A purified and 
converted into cDNA libraries using the Illumina TruSeq Library Preparation kit v2. 
Samples were sequenced using the Illumina HiSeq 2500 platform with paired-end read 
lengths of 100 nucleotides. 
2.16.3 RNA sequencing analysis 
The following steps were performed by Helena Alhfors (Babraham Institute, 
Babraham, UK). The quality of the sequencing data was assessed using the FastQC 
tool version 0.11.2 (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). 
Reads were aligned using Tophat version 2.0.12, allowing a maximum of 2 
mismatches (Kim et al., 2013). The aligned data was sorted and indexed using 
SAMtools version 0.1.18 (Li et al., 2009b). HTSeq-count version 0.5.4 (Anders et al., 
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2015) was used to count the reads mapping to genes using gtf file version 78. The 
quality of the count data was analysed using SeqMonk version 0.30.0 
(http://www.bioinformatics.babraham.ac.uk/projects/seqmonk/) and DESeq2 (R 
package). The differentially expressed genes were identified from the count data using 
DESeq2. Data visualisation was performed with R/bioconductor. 
2.17 Stable Isotope Labelling by Amino acids in Cell culture 
In order to incorporate the heavy-labelled isotopes into WT and TRIM21 KO MEFs, 
cells were cultivated for a minimum of 5 doublings (equivalent to 4-5 passages) with 
DMEM supplemented with 84 mg/L heavy 13C-arginine and 146 mg/L heavy 13C-
lysine in presence of 10% FCS (SILAC dialysed, 1000 Da cut-off, Dundee Cell 
Products, Dundee, UK) and 40 mg/L unlabelled proline to avoid arginine-to-proline 
conversion. Unlabelled cells were cultivated in parallel in DMEM supplemented with 
84 mg/L light 12C-Arg and146 mg/L light 12C-Lys in presence of 10% FCS (SILAC 
dialysed, 1000 Da cut-off) and 40 mg/L unlabelled proline. Labelled and unlabelled 
cells were induced with IFNγ for 16h and infected with avirulent Pru Toxoplasma as 
described previously (see 2.1.4). Cells were trypsinised and washed three times in 
PBS. Pellets were mixed at a 1:1 ratio as a forward sample (WT heavy/TRIM21 KO 
light) and as a reverse sample (WT light/TRIM21 KO heavy). Both sample pellets 
were flash-frozen in liquid nitrogen and kept at -80°C.  Preparation of the samples was 
then performed by Dr. Vesela Encheva in the dedicated service provided within the 
Crick in Clare Hall Laboratory. Analysis of the raw data was performed with the help 
of Dr. Vesela Encheva using the Perseus software. 
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2.17.1 Quantitative diGly Proteomics  
Cells were lysed in 9 M urea, 20 mM HEPES, pH=7.8, supplemented with 100 
units/ml of benzonase and sonicated to reduce viscosity (3 mm probe, 50% amplitude, 
3 x 15 sec bursts, on ice). Between 30-40 mg of protein per sample were used as 
estimated by Bradford protein assay. Lysates were reduced with 10 mM DTT for 30 
min at room temperature, followed by alkylation with 20 mM chloroacetamide (Sigma 
Aldrich) for 30 min at room temperature in the dark. Lysates were digested initially 
with LysC for 2 hours at 37°C. The lysates were then diluted with 100 mM ammonium 
bicarbonate, 5% acetonitrile to a final urea concentration of less than 2 M. The samples 
were digested 1:100 enzyme to protein ratio (w/w) with trypsin (Promega) overnight 
at 37°C. The next day, two additional aliquots of trypsin were added and incubated at 
37°C for four hours each.  After the digestion the samples were acidified with 
trifluoroacetic acid (TFA, Thermo Fisher Scientific) to a final concentration of 1% 
(v/v). All insoluble material was removed by centrifugation and the supernatant was 
desalted with Sep-Pak C18 cartridges (Waters, Milford, MA, USA) and lyophilised for 
2 days. 
Peptides containing the diGly remnant were enriched using K-ϵ-GG affinity resin (Cell 
Signalling Technology) according to the manufacturer's instructions. Briefly, digests 
were reconstituted in 1.4 mL of immunoaffinity purification (IAP) buffer as supplied 
by the manufacturer. One aliquot (∼40 μL packed bead volume) was washed four times 
with PBS and mixed with the peptide sample. Incubation of sample and beads was 
performed with gentle rotation at 4°C for 2 hours followed by a 30 sec 2000 × g spin 
to pellet the beads. The antibody beads were washed twice with ice-cold IAP buffer 
followed by three washes with ice-cold water. DiGly peptides were eluted from the 
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beads with the addition of 50 μL of 0.15% TFA and allowed to stand at room 
temperature for 5 min. After a 30 sec 2000 × g spin, the supernatant was carefully 
removed and retained for further analysis. A second 55-μL aliquot of 0.15% TFA was 
added to the beads followed by a 30 sec 2000 × g spin, and the supernatant was added 
to the first elution. The eluted peptides were lyophilised for 2 days and used for strong 
cationic exchange (SCX) fractionation. 
2.17.2 Strong cationic exchange fractionation of diGly peptides  
For SCX fractionation, peptides eluted from the K-ϵ-GG affinity resin were dissolved 
in 35 μL of 10 mM ammonium formate pH=2.9, 25% acetonitrile. The samples were 
sonicated and insoluble material was removed by centrifugation. Peptide separation 
and fraction collection was performed using the micro pump on an RSLCnano U3000 
(Thermo Fisher Scientific) at a flow rate of 50 μL/min. The peptides were loaded on 
15-cm Polysulfoethyl-Asp SCX column (1 mm inner diameter, 5 μm particle size, 
PolyLC). Solvent A was 10 mM ammonium formate pH=2.9, 25% acetonitrile, and 
solvent B was 500 mM ammonium formate pH=6.8, 25% acetonitrile. The samples 
were run on a linear gradient of 0-80% solvent B in 45 min, total run time was 75 min 
including column conditioning. A total of 30 fractions were collected every minute 
between 15-45 min after injection (1 fraction= 50 μL). The collected fractions were 
vacuum dried and used for liquid chromatography-mass spectrometry/mass 
spectrometry (LC-MS/MS) analysis. 
2.17.3 Liquid chromatography-mass spectrometry/mass spectrometry 
For MS analysis, peptides were resuspended in 0.1% TFA and loaded on 50-cm Easy 
Spray PepMap column (75 μm inner diameter, 2 μm particle size, Thermo Fisher 
Scientific) equipped with an integrated electrospray emitter. Reverse phase 
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chromatography was performed using the RSLCnano U3000 (Thermo Fisher 
Scientific) with a binary buffer system at a flow rate of 250 nL/min. Solvent A was 
0.1% formic acid, 5% DMSO, and solvent B was 80 % acetonitrile, 0.1% formic acid, 
5% DMSO. The diGly enriched samples were run on a linear gradient of solvent B (2- 
40%) in 90 min, total run time of 120 min including column conditioning. The nanoLC 
was coupled to a Q Exactive mass spectrometer using an EasySpray nano source 
(Thermo Fisher Scientific).  
The Q Exactive was operated in data-dependent mode acquiring HCD MS/MS scans 
(R=17,500) after an MS1 scan (R=70, 000) on the 10 most abundant ions using MS1 
target of 1x106 ions, and MS2 target of 5x104 ions. The maximum ion injection time 
used for MS2 scans was 120 ms, the HCD normalised collision energy was set at 28, 
the dynamic exclusion was set at 10 s, and the peptide match and isotope exclusion 
functions were enabled. 
2.17.4 Data processing and analysis 
Raw data files were analysed with MaxQuant software (version 1.3.0.5) as described 
previously (Cox et al., 2009). Parent ion and tandem mass spectra were searched 
against UniprotKB Mus musculus database (August 2012). A list of 247 common 
laboratory contaminants provided by MaxQuant was also added to the database. For 
the search the enzyme specificity was set to trypsin with maximum of three missed 
cleavages for the diGly datasets. The precursor mass tolerance was set to 20 ppm for 
the first search (used for mass re-calibration) and to 6 ppm for the main search. 
Carbamidomethylation of cysteines was specified as fixed modification, oxidised 
methionines and N-terminal protein acetylation were searched as variable 
modifications. Di-glycine-lysine was added to the list of variable modifications when 
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samples enriched for ubiquitinated were searched. The datasets were filtered on 
posterior error probability to achieve 1% false discovery rate on protein, peptide and 
site level. 
2.18 Mice 
2.18.1 Ethics statement 
All procedures involving mice were approved by the local ethical committee of the 
Crick at Mill Hill Laboratory and are part of a project license approved by the Home 
Office, UK, under the Animals (Scientific Procedures) Act 1986. 
2.18.2 Genotyping of TRIM21-/- mice 
A TRIM21-/- mouse (Yoshimi et al., 2009) available from the Jackson Laboratory was 
acquired and rederived into the NIMR. This mouse is on the Jackson lab C57BL/6 
background, which was maintained throughout rederivation. The pups were genotyped 
by PCR of genomic DNA from earpieces. Briefly, the earpieces were lysed in 500 µL 
lysis buffer (100 mM Tris-HCl pH 8.5, 200 mM NaCl, 5 mM EDTA, 0.2% SDS, 0.1 
mg/mL proteinase K) for 3 h at 56°C under agitation at 800 rpm. Lysates were then 
centrifuged at 16200 g for 5 min and the supernatant was thoroughly mixed with 500 
µL isopropanol. After centrifugation at 16200 g for 5 min, the pellet was dried at RT 
and resuspended in 500 µL H2O. PCR was performed as described in the literature 
(Yoshimi et al., 2009).  
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2.18.3 Infection of mice 
Wild-type (WT) and TRIM21 deficient (Yoshimi et al., 2009) mice on the C57BL/6 
background were bred and intercrossed at the Mill Hill Laboratory under specific 
pathogen-free conditions. Experiments were performed on 6 to 8-week-old females.  
For oral infections, cysts of Toxoplasma avirulent type III strain ME49 (generous gift 
from Michael Grigg, NIH, USA) were isolated from the brain of an infected Parkes 
mouse by syringe lysis of the brain. Mice were infected with 5-40 cyst resuspended in 
200 µL PBS by oral gavage.  
For intraperitoneal (i.p.) infections, Toxoplasma avirulent type II strain Pru expressing 
GFP and firefly luciferase were harvested from the peritoneum of a 4-day infected 
C57BL/6 mouse and passaged through a 26 gauge needle (Terumo). Parasites were 
washed twice with PBS and mice were injected i.p. with 5x104 parasites resuspended 
in 200 µL PBS.  
For in vivo imaging, mice were injected i.p. with 3 mg firefly D-luciferin (Perkin 
Elmer, Waltham, MA, USA), left for 10 min and imaged with an IVIS Spectrum-
bioluminescent and fluorescent imaging system (Xenogen Corporation, Caliper Life 
Sciences, Hopkinton, MA, USA) under  isoflurane anaesthesia (Abbott, Chicago, IL, 
USA). 
2.19 Blood sampling and tissue harvesting 
Blood was withdrawn at 4 and 7 days post-infection (dpi) from the saphenous vein 
after shaving the right leg and puncturing the superficial vein with a 27 gauge needle 
(Terumo). Blood was collected in microvette CB 300 (Sarstedt, Nümbrecht, Germany) 
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tubes, incubated for 1 hour at 4°C and spun 2x10 min at 5 000 rpm at 4°C before 
storage at -20°C until further use. Alternatively, blood was collected by terminal 
cardiac puncture at 7 dpi. Animals were anesthetised with 75 mg/kg ketamine 
(Vetalar®, Zoetis, Florham Park, NJ, USA) and 1 mg/kg medetomidine (Medetor®, 
Chanelle, Loughrea, Ireland) and blood was withdrawn directly from the heart with a 
25 gauge gauge needle (Terumo) and collected in 1.1 mL Z-gel microtubes (Sarstedt), 
incubated for 10 min at RT and span 10 min at 5 000 rpm before storage at -20°C until 
further use. 
Single cell suspensions were prepared from peritoneal exudate cells (PECs) obtained 
by peritoneal wash with 6 mL of PBS. Single cell suspensions were prepared from 
spleen, draining lymph nodes, mesenteric lymph nodes and Peyer’s patches by 
grinding the organs through a 40 μm filter (BD) and resuspending them in PBS + 1% 
bovine serum albumin (PBA). Red blood cells were then lysed at RT for 3 min with 1 
mL 0.86% ammonium chloride (Sigma Aldrich) and resuspended in PBA.  
2.20 Isolation of brain mononuclear cells 
Brain mononuclear cells were isolated on a Percoll gradient following the procedure 
described by Pino & Cardona (Pino and Cardona, 2011). Briefly, WT and TRIM21 
KO mice were culled at 7 dpi by overdose of pentobarbital (Virbac, Carros, France). 
10 mL of ice-cold PBS were perfused in the heart using an 18 gauge gavage needle, 
and the brain was carefully extracted and kept in 1 mL of ice-cold PBS. Brain tissues 
were disrupted through a 1 mL syringe (Terumo) and subsequently through a 19 gauge 
needle (Terumo). The cell suspension was fractionated on a 30-70% Percoll gradient 
(Sigma-Aldrich) for 30 min at 500 g without break. The mononuclear cells in the 
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interphase were washed once with PBS before resuspension in 1% PBA and 
immediately used for further experiments. 
2.21 Fluorescence Activated Cell Sorting of ex vivo cells and parasites 
2.21.1 FACS antibodies 
All antibodies used for FACS staining were purchased from BioLegend. Innate cells 
were stained with CD11c, CD11b, Ly6C, Ly6G, F4/80 and CD45. Lymphocytes were 
stained with CD3, CD4, CD8, CD19, NK1.1, TCRγδ and IFNγ. Brain- or peritoneum-
derived parasites were stained with IgG and IgM. 
Specificity Label Clone Dilution 
CD11c BV785 N418 1:200 
CD11c APC N418 1:200 
CD11b PerCP-Cy5.5 M1/70 1:200 
CD11b PE M1/70 1:200 
Ly6C PB HK1.4 1:200 
Ly6G APC-Cy7 1A8 1:200 
F4/80 APC BM8 1:200 
F4/80 PerCP-Cy5.5 BM8 1:200 
CD45 PE 30-F11 1:400 
CD3 APC-C7 17A2 1:200 
CD4 BV605 RM4-5 1:200 
CD8 PerCP-Cy5.5 53-6.7 1:100 
CD19 BV786 6D5 1:200 
NK1.1 APC PK136 1:200 
TCRγδ PE GL3 1:300 
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IFNγ PE-Cy7 XMG1.2 1:200 
IgG APC Poly4053 1:200 
IgM PerCP-Cy5.5 RMM-1 1:200 
Live/dead Zombie 
AquaTM PO / 1:200 
Table 2.13: List of antibodies used for FACS staining. 
 
2.21.2 FACS staining and analysis 
Innate cells for staining were blocked in FcγII/III block solution (Biolegend) at 4°C 
for 15 min. Innate cells and lymphocytes were then stained in 50 µL on ice for 20 min 
in presence of Zombie AquaTM fixable viability kit (BioLegend), washed with PBA 
and fixed in 4% formaldehyde at RT for 20 min. For intracellular staining, 
lymphocytes were permeabilised with Perm/Wash (BD) for 15 min at room 
temperature and stained with anti-cytokine for 30 min at 4°C.  Lymphocytes were then 
washed and resuspended in 200 mL PBA. Finally, 25 µL of CountBright absolute 
counting beads (Life Technologies) were added to both innate cells samples and 
lymphocytes samples. Samples were run and analysed immediately or kept at 4°C O/N 
before acquisition on an LSR Fortessa (BD), following the gating strategy explained 
in Figure 2.4. Data analysis was performed with the FlowJo software (Treestar, 
Ashland, OR, USA). Compensation controls were single colour stained cells from 
splenocytes.  
Parasites were isolated as described previously from either tissue culture (see 2.1.2), 
from the peritoneum and brain of a 4- or 7-day infected C57BL/6 mice (see 2.18.3). 
Parasites were stained in 100 µL for 20 min on ice, washed with PBA and fixed in 4% 
paraformaldehyde at RT for 20 min. After washing in PBA, parasites were analysed 
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immediately on an LSR Fortessa. Data analysis was performed with the FlowJo 
software (Treestar). Compensation controls were single colour stained cells from 
peritoneal exudate cells. 
2.22 Parasite counting in the brain 
The brain was removed at 7 dpi from infected animals and placed in 1 mL PBS. The 
organ was mashed with a 1 mL syringe, 10 µL of the suspension was placed on a 
coverslip and GFP-expressing parasites were counted blindly using an AxioPlan II 
fluorescent microscope (Carl Zeiss) equipped with a GFP filter. At least 4 mice per 
group were assessed for each independent experiment. 
2.23 RNA extraction from infected brains 
All steps were performed with RNAse-free tubes and using lab equipment previously 
cleaned with RNaseZap (Ambion). The brain of a 7 dpi mouse was mashed as 
described in 2.22 and spun for 5 min at 900 g. The pellet was resuspended in 1 mL 
Trizol and kept at -80°C until use. Pellets were thawed on ice and resuspended at RT 
for 5 min on a shaker before centrifugation at 8000 g for 5 min to get rid of the lipids, 
present in abundance in the brain. 200 μL chloroform was added to the supernatant 
and after gentle mixing for 15 sec and incubation at RT for 5 min, the mix was spun 
at 9000 rpm for 15 min at 4°C. The upper aqueous phase containing the extracted RNA 
was transferred to a new tube and mixed with 1:2 (v:v) Trizol and 200 μL chloroform, 
gently mixed for 15 sec, incubated at RT for 5 min before centrifugation at 9000 rpm 
for 15 min at 4°C. The upper aqueous phase containing the extracted, lipid-free RNA 
was transferred to a new tube containing 1:1 (v:v) 70% ethanol. The mix was then 
purified using the RNeasy® Mini kit (Qiagen), according to the manufacturer’s 
instructions. Briefly, the mix was transferred to a mini spin column and spun at 13000 
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rpm for 15 sec at 4°C. Membranes were washed once with 500 μL RW1 buffer and 
twice with 500 μL RPE buffer before dry-spinning at 13 000 rpm for 1 min at 4°C. 
The RNA was eluted with 30 μL RNA-free water into a new tube and samples were 
stored at -80°C. 
2.24 Real-time quantitative PCR 
cDNA was synthesised from isolated brain RNA using the RT2 First Strand kit 
(Qiagen) according to the manufacturer’s instructions. Briefly, genomic DNA was 
eliminated by mixing 1 µg RNA with 2 µL of Buffer GE (final volume of 10 mL) and 
incubating for 5 min at 42°C, then cooling immediately on ice. Reverse transcription 
of RNA to cDNA was performed at 42°C for 15 min and stopped by incubating at 
95°C for 5 min. The retrotranscription mix is detailed in Table 2.14. Finally, 91 µL 
RNase-free water was added to each reaction. 
5x Buffer BC3 4 µL 
Control P2 1 µL 
RE3 Reverse Transcriptase Mix 2 µL 
Nuclease-free water 3 µL 
Total 10 µL 
Table 2.14: Retrotranscription mix. 
Gene expression was determined in 384 plates by real-time quantitative PCR using the 
RT2 Profiler PCR array (Qiagen) for mouse cytokines and chemokines (PAMM-
150ZA) as well as mouse pain: neuropathic and inflammatory (PAMM-162ZA) 
according to the manufacturer’s instructions. Briefly, qPCR components were mixed 
as detailed in Table 2.15, and 10 µL of reaction was added per well. Each plate 
included 3 retrotranscription controls and 3 positive PCR controls. 
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2x RT2 SYBR Green Mastermix 650 µL 
cDNA synthesis reaction 102 µL 
RNase-free water 548 µL 
Total 1300 µL 
Table 2.15: RT2 qPCR reaction mix. 
 
Data were analysed by calculating the relative gene expression to the housekeeping 
gene Gapdh using the standard ∆Ct method. 
2.25 Cytokines and chemokines expression in infected mice 
2.25.1 Quantification of cytokines and chemokines by multiplex 
Blood was collected at day 3 and 7 post-infection from the saphenous vein or by 
terminal cardiac puncture, respectively. Serum was obtained after coagulation at RT 
for 30 min and centrifugation at 4°C for 10 min at 1000 g. Serum cytokines and 
chemokines analysis was performed by mouse 32-plex Discovery Assay® (Eve 
Technologies, Calgary, Alberta, Canada). 
2.25.2 Quantification of cytokines by ELISA 
Blood and peritoneal lavage were collected at 7 days post-infection as described 
previously. Wild-type or TRIM21 KO bone marrow-derived macrophages were left 
uninduced or stimulated with 100 U/mL IFNγ overnight and infected with avirulent 
Toxoplasma for 24h. Supernatants were collected and analysed by enzyme-linked 
immunosorbent assay (ELISA). Commercially available kits were used according to 
the manufacturer’s instructions to quantify the concentration of IFNα (eBioscience, 
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San Diego, CA, USA), IFNβ (PBL Assay Science, Piscataway, NJ, USA), IFNγ (R&D 
Sciences), IL-1β (BD), IL-12p40 (R&D Sciences) and TNFα (R&D Sciences). 
Standard curves and cytokine concentrations were determined using Excel (Microsoft, 
Redmond, WA, USA).  
2.25.3 Quantification of cytokines by qPCR 
Wild-type or TRIM21 KO bone marrow-derived macrophages were left uninduced or 
stimulated with 100 U/mL IFNγ overnight and infected with avirulent Toxoplasma for 
24h. Cells were washed three times in PBS and resuspended in 500 µL Trizol. RNA 
was extracted following the procedure described in 2.15 and reverse transcribed into 
cDNA using the SuperScript® VILOTM cDNA Synthesis kit (Thermo Fischer 
Scientific) according to the manufacturer’s instructions. Briefly, 50 ng RNA were used 
per assay and mixed with the reaction components as indicated in . The reverse 
transcription was performed for 10 min at 25°C, followed by an incubation for 60 min 
at 42°C and a final deactivation for 5 min at 85°C.  
5x VILOTM Reaction Mix 4 µL 
10X SuperScript® Enzyme mix 2 µL 
RNA  50 ng per reaction 
RNAse-free water to 20 µL 
Total 20 µL 
Table 2.16: SuperScript® VILOTM reverse transcription mix. 
 
The quantitative PCR was then performed using the TaqMan® Real-Time PCR Assay 
system (Applied Biosystems) according to the manufacturer’s instructions. Reaction 
mixes were made-up in 96-well plates (optical reaction plates, Applied Biosystems) as 
described in Table 2.17. 
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2x TaqMan® Master Mix 5 µL 
cDNA 2 µL 
Probe 1 µL 
RNase-free water 2 µL 
Total 10 µL 
Table 2.17: TaqMan® qPCR reaction mix. 
 
The primer-probes used are summarised in Table 2.18. The qPCR was carried out on 
an Applied Biosystem 7900HT real-time PCR machine. 






Table 2.18: TaqMan® primer-probes used for qPCR. 
 
2.26 Blood biochemistry in infected mice 
Blood was collected at day 7 post-infection by cardiac puncture. Serum was obtained 
as described above (see 2.25) and diluted 1:10 in PBS. Analysis of biomarkers for 
organ malfunction and damage was performed on a Cobas C111 analyser (Roche).  
2.27 Histology 
Following terminal cardiac puncture, animals were sacrificed at 7 dpi by an overdose 
of ketamine and medetomidine. Animals were sprayed with ethanol and the brain was 
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isolated first. Briefly, an incision was done along the neck and the skin was cut 
between the eyes and completely removed from the skull. The skull was then opened 
and the brain was carefully removed, washed once in PBS, cut in half so that the left 
hemisphere was fixed in 4% formalin and the right hemisphere was kept in 1 mL PBS 
on ice for parasites count or FACS analysis. Then, the abdomen of the mice was 
opened and entrails including guts, stomach, pancreas, spleen and kidneys were 
removed at once and fixed in 4% formalin. The rib cage was opened and the lungs 
were inflated through the trachea with 1 mL 4% formalin (Leica Microsystems). 
Trachea, lungs and heart were subsequently removed at once and fixed in 4% formalin. 
After a minimum of 48 h fixation, organs were washed in 70% ethanol and placed into 
cassette for paraffin embedding. Preparation of the samples for H&E staining was done 
in the dedicated services by Dr. Radma Mahmoud within the Crick at Mill Hill 
Laboratory, or by Richard Stone within the Crick at Lincoln Inn Fields Laboratory. 
Analyses of the slides were performed by Prof. Cheryl Scudamore at MRC Harwell or 
by Prof. Gordon Stamp at Imperial College London. 
2.28 Statistical analysis 
All statistical significance analyses were performed using Prism software (GraphPad 
Software). Comparisons of data were performed with unpaired Student’s t-test or using 
two-way ANOVA with Sidak multiple comparison correction. Survival rates were 
compared by log-rank survival analysis of Kaplan-Meier curves.  
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Figure 2.3: Verification of the RNA quality for RNA sequencing. 
The quality of RNA extracted from wild-type or TRIM21-deficient mouse embryonic fibroblasts 
infected with avirulent Toxoplasma for 1h was assessed using an Agilent 2100 Bioanalyser. All RNA 
samples present an RNA integrity number (RIN) higher than 7, meaning the RNA is not degraded and 
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Figure 2.4: Gating strategies used for the analysis of innate cells and lymphocytes. 
The graphs show FACS plots illustrating the gating strategies used to analyse innate cells (a) and 
lymphocytes (b). Innate cells were gated on side-scatter low/high and forward-scatter low/high. 
Lymphocytes were gated on side-scatter low and forward-scatter low. Flow cytometry data was 
excluded for doublets and dead cells. All future FACS plot data will have been performed following 
this gating strategy, and will thus not show the scatter plot, doublets exclusion plot and dead cell 
exclusion plot.  
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3.1 Introduction 
3.1.1 The ubiquitin system 
3.1.1.1 Overview 
Ubiquitination is a post-translational modification (PTM) event that involves the 
covalent attachment of a protein called ubiquitin (Ub) onto a protein substrate. This 
modification of the target proteins regulates their activity and function in several 
critical cellular pathways such as cell cycle (Vaysburd et al., 2013; Ciechanover et al., 
1984; Finley et al., 1994), DNA repair (Jentsch et al., 1987; Xu et al., 2009; Hofmann 
and Pickart, 1999), immune response (Deng et al., 2000) or proteasomal degradation 
(Chau et al., 1989). The importance of the ubiquitin system is also highlighted by the 
fact that ubiquitin is one of the most conserved eukaryotic proteins, with only three 
amino acids out of the seventy six residues differing between yeast and human 
ubiquitin (Graham et al., 1989). The process of ubiquitination requires the sequential 
collaboration of three groups of enzymes including a ubiquitin-activating enzyme E1, 
the ubiquitin-conjugating enzymes E2 and the ubiquitin ligases E3. These enzymes 
catalyse the covalent conjugation of ubiquitin onto the protein substrate first, then onto 
one of the internal lysine residues within the ubiquitin itself until a chain of conjugated 
ubiquitin is synthesised, resulting in the downstream possible effect on the targeted 
protein (Pickart, 2001). 
3.1.1.2 Ubiquitination 
In 2004, the Nobel Prize in Chemistry was awarded to Aaron Ciechanover, Avram 
Hershko and Irwin Rose for their discovery of the ubiquitin system (Ciechanover et 
al., 1980; Hershko et al., 1980). The ubiquitination process is performed in a well-
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orchestrated three-step enzymatic cascade (Figure 3.1). The first step is ATP-
dependent and consists in the activation of ubiquitin by the E1 ubiquitin-activating 
enzyme that forms a thiol-ester linkage between its active cysteine residue and the C-
terminal glycine present in ubiquitin. Secondly, the activated ubiquitin is transferred 
onto an active cysteine harboured by the E2 ubiquitin-conjugating enzyme. Finally, 
the substrate-specific E3 ubiquitin ligase acts as an adaptor protein between the E2 and 
the target protein and facilitates the formation of a covalent isopeptide bond between 
ubiquitin and a lysine residue of the substrate. Some protein substrates are mono-
ubiquitinated on a single lysine residue (mono-ubiquitination), while others are mono-
ubiquitinated on several lysines (multi-mono-ubiquitination) or present a chain of 
ubiquitins on one or multiple lysines (poly-ubiquitination). Indeed, once a first 
ubiquitin is covalently linked on its substrate, the process can be repeated so that 
additional ubiquitin molecules are charged via their C-terminal glycine residue to 
specific lysine residues within the previous ubiquitin. In fact, ubiquitin itself exhibits 
seven lysine residues (K6, K11, K27, K29, K33, K48 and K63), which can accept 
another ubiquitin molecule to form ubiquitin chains. Additionally, the C-terminal 
glycine of a ubiquitin molecule can also be connected to the amino-terminal 
methionine (M1) of another ubiquitin. Thus, as ubiquitination can come in different 
flavours, different ubiquitin chain types are involved in distinct cellular processes and 
signalling events so that the nature of the ubiquitin chain will dictate the fate of the 
protein substrate.  
3.1.1.3 Functions of protein ubiquitination 
Lys48- and Lys63-linked chains have been the most extensively studied. Lys48-linked 
ubiquitin chains were for a long time believed to be the main chain type. Proteins 
harbouring a polymer of ubiquitins linked via their Lys48 side chain are targeted for 
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degradation by the proteasome (Chau et al., 1989). During substrate degradation by 
the proteasome, the ubiquitin molecules are removed and recycled by enzymes called 
deubiquitinating enzymes (DUBs) associated with the 20S core of the proteasome. In 
contrast to Lys48 side chains, Lys63-linked chains are involved in promoting non-
degradative cellular events such as endocytosis (Geetha et al., 2005; Kamsteeg et al., 
2006; Duncan et al., 2006), DNA repair (Hofmann and Pickart, 1999) and immune 
signalling (Deng et al., 2000). Although Lys63 chains have been considered to 
participate in non-proteasomal functions, recent studies suggested they could possibly 
target proteins for proteasomal degradation as well (Hofmann and Pickart, 2001; Saeki 
et al., 2009). How Lys63-linked chains would only target some proteins and not all for 
degradation remains unknown, and it is still debated whether Lys63-linked chains 
serve as proteasomal signals. The remaining lysine residues (K6, K11, K27, K29 and 
K33) have all been reported to possibly target substrates for proteasomal degradation 
(Baboshina and Haas, 1996; Xu et al., 2009). Moreover, Lys6-linked chains are 
involved in DNA repair (Sobhian et al., 2007), Lys11-linked chains regulate the cell 
cycle (Jin et al., 2008), Lys29-linked chains mediate lysosomal degradation 
(Chastagner et al., 2006), and Met1-linked linear chains participate in immune 
signalling (Tokunaga et al., 2009; Rahighi et al., 2009). 
3.1.1.4 E3 ubiquitin ligases 
The human genome encodes two ubiquitin-specific E1 ubiquitin-activating enzymes 
(Kudo et al., 1991; Zhu et al., 2004), thirty-seven E2 ubiquitin-conjugating enzymes 
(Markson et al., 2009) and more than 600 E3 ubiquitin ligases (Li et al., 2008). The 
latter carry out the last step of the ubiquitination cascade and are responsible for the 
specificity of the substrate to be ubiquitinated. The E3 ubiquitin ligases can be divided 
into three main domain families: the Really Interesting New Gene (RING) finger 
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domain family, the Homology to E6-AP C-Terminus (HECT) domain family and the 
ligases resembling neither the RING nor the HECT domain families.  
RING ubiquitin ligases are the most abundant type of E3 ligases in the cell. The 
canonical E3 RING domain is a cysteine-rich globular domain that contains eight 
conserved cysteine or histidine residues, which coordinate two zinc ions in a cross-
brace structure (Freemont et al., 1991; Barlow et al., 1994; Borden et al., 1995). The 
RING domain is responsible for both binding to the N-terminal helix of the ubiquitin-
conjugating enzyme E2 and promoting the transfer of ubiquitin to the substrate at the 
same time. RING ubiquitin ligases perform the catalytic attack of the substrate lysine 
on the E2-ubiquitin thioester in one single step, resulting in direct transfer of ubiquitin 
from the E2 enzyme to the substrate (Lorick et al., 1999; Joazeiro et al., 1999; Seol et 
al., 1999; Zheng et al., 2000). The structural and conformational mechanisms 
underlying the positioning of the reactive E2-ubiquitin thioester and the acceptor 
lysine for the efficient transfer of ubiquitin still remain to be deciphered.  
In contrast to RING ubiquitin ligases, HECT ubiquitin ligases perform two distinct 
ubiquitination steps. First, ubiquitin is transferred from the active cysteine on the 
ubiquitin-conjugating E2 enzyme to a cysteine on the HECT domain. Secondly, the 
substrate lysine attacks the HECT-ubiquitin thioester to result in the ubiquitinated 
substrate (Huibregtse et al., 1995). Structural studies showed the HECT domain 
comprises two subdomains connected by a flexible linker: the N-terminal lobe that 
binds to the E2 and the C-terminal lobe that contains the catalytically active cysteine. 
The flexible linker allows conformational rearrangements between the two distal 
lobes, thereby bringing the E2-ubiquitin thioester in close proximity to the active 
cysteine (Huang et al., 1999; Verdecia et al., 2003). Once the E3-ubiquitin thioester is 
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formed, the C lobe rotates to bring the donor ubiquitin to the acceptor lysine on the 
substrate, interacting with the N lobe (Kamadurai et al., 2009; 2013; Maspero et al., 
2013). 
TRIM21, the focus of this study, is a RING ubiquitin ligase. The following section 
will present an overview of the protein, including its ubiquitin ligase properties, its 
known substrates as well as other important information necessary to understand this 
chapter. 
3.1.2 The RING ubiquitin ligase TRIM21 
3.1.2.1 The TRIM family of proteins 
The family of tripartite motif-containing (TRIM) proteins is the second largest 
subgroup of RING E3 ubiquitin ligases, with 64 members in the mouse genome and 
~100 members in the human genome (Sardiello et al., 2008; Han et al., 2011). The 
TRIM proteins, also called RBCC proteins, are characterised by a conserved N-
terminal structure comprising three protein domains: a RING (R) domain followed by 
one or two B-box (B) domains and a helical coiled-coil (CC) domain (Ozato et al., 
2008).  
The RING domain is composed of 40-60 amino acids and has a cysteine-rich 
consensus sequence reading Cys-X2-Cys-X11-16-Cys-X-His-X2-Cys-X2-Cys-X7-74-
Cys-X2-Cys, where x can be any amino acid (Borden et al., 1995). The RING domain 
has been the most widely studied, and is now known to mediate protein-protein 
interactions and exhibit E3 ligase activity. For example, the TRIM25 ubiquitin ligase 
activity is essential for the robust Lys63-linked ubiquitination and subsequent 
activation of the retinoic acid-inducible gene-I (RIG-I), leading to the production of 
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IFNβ following RNA virus infection (Gack et al., 2007). Moreover, RING-dependent 
TRIM5α auto-ubiquitination is required for proteasomal degradation of the TRIM5α-
virus complex during HIV-I infection (Diaz-Griffero et al., 2006; Rold and Aiken, 
2008; Lukic et al., 2011). 
The B-box domain exists in two different forms, B1 and B2, which consist of zinc-
binding motifs of ~40 residues. The B-boxes are exclusively found in TRIM proteins. 
Structural studies have shown B-box 1 to share some conserved ternary structures with 
the RING domain, and B-box 2 to exhibit a RING-like structure, suggesting that all 
three domains are similar and may have evolved from a common ancestral domain 
(Massiah et al., 2006; 2007). Although the B-box domains have not been widely 
studied, they have been implicated in antiviral resistance. For example, mutational 
studies have shown that B-box 2 forms high order oligomers, thereby promoting 
binding to retrovirus capsids and hence triggering HIV-1 restriction (Li and Sodroski, 
2008; Diaz-Griffero et al., 2009). 
The coiled-coil domain is formed by multiple α-helices and has been shown to be 
necessary and sufficient for the formation of homomeric and heteromeric interactions 
between TRIM proteins (Reymond et al., 2001; Cao et al., 1997; Cainarca et al., 1999). 
This allows TRIM members to form large oligomers via antiparallel helical hairpins 
that allows them to exert their functions (Sanchez et al., 2014). For example, 
dimerisation of TRIM5α is mediated by its coiled-coil domain and promotes binding 
of the TRIM protein to the viral capsid and subsequently to restrict HIV-1 (Ganser-
Pornillos et al., 2011; Sanchez et al., 2014). 
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The N-terminal RBCC domains are followed by one or several C-terminal domains 
that divide the TRIM proteins into 11 categories (Short and Cox, 2006; Ozato et al., 
2008) (Figure 3.2). As the N-terminal domain is very conserved among TRIM 
proteins, it is likely that the C-terminal domain dictates their functional diversity by 
recruiting interacting partners. The most common C-terminal feature found in TRIM 
proteins is the B30.2 motif or PRYSPRY motif. It comprises the PRY domain made 
of 61 residues followed by the SPRY domain including 120 amino acids (Grütter et 
al., 2006; Woo et al., 2006). The B30.2 motif has been shown to participate in protein-
protein interactions as well as RNA binding and is involved in the antiviral activity of 
several TRIM proteins (Nisole et al., 2005). For example, it has been shown that the 
B30.2 domain of TRIM5α binds to HIV-1 viral capsids, and one single amino acid 
substitution (R332P) in the B30.2 domain abolishes the ability of human TRIM5a to 
restrict HIV-1 (Yap et al., 2005; Stremlau et al., 2005; Nakayama et al., 2005; Perez-
Caballero et al., 2005). 
3.1.2.2 Functions of TRIM21 
Ro52 has been identified in 1988 as one of the major autoantigens in the autoimmune 
disease called Sjögren’s syndrome (Ben-Chetrit et al., 1988). The Ro52 gene has been 
mapped on human chromosome 11 (Frank et al., 1993) and mouse chromosome 7 
(Rajsbaum et al., 2008). Cloning and expression of human Ro52 allowed the discovery 
of the presence of zinc finger domains and a leucine zipper motif at the N-termini of 
the protein (Itoh et al., 1991; Chan et al., 1991). Later, structural studies revealed Ro52 
comprises an N-terminal RBCC domain and a B30.2 C-terminal domain. As such, the 
protein presents the features of a tripartite motif-containing protein and was named 
TRIM21 (Reymond et al., 2001; Ottosson et al., 2006).  
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As discussed previously in section 1.2.5, the TRIM21 B30.2 domain was shown to 
strongly bind to the Fc part of IgG, IgM and IgA (Rhodes et al., 2002; Keeble et al., 
2008; Bidgood et al., 2014). Due to this antibody-binding property, TRIM21 has been 
reported to bind to invading antibody-coated adenoviruses as well as Salmonellae in 
the cytosol, and target them for degradation by the proteasome by virtue of its RING-
dependent E3 ligase activity (Mallery et al., 2010; McEwan et al., 2013; Rakebrandt 
et al., 2014).  
TRIM21 has also been shown to mediate immune signal transduction pathways via its 
E3 ubiquitin ligase activity. TRIM21 was proposed to trigger the production of IL-
12p40 in macrophages stimulated with IFNγ and bacterial unmethylated CpG via a 
mechanism that involves the non-proteolytic ubiquitination and upregulation of the 
interferon regulatory factor IRF8 (Kong et al., 2007). Moreover, TRIM21 was 
proposed to negatively regulate NF-κB signalling in mouse embryonic fibroblasts 
following stimulation with LPS or poly(I:C), thereby downregulating the production 
of IL-1β, TNFα and IL-6 (Yoshimi et al., 2009). TRIM21 has also been reported to 
act as a negative regulator of IFNβ production by promoting the ubiquitination and 
proteasomal degradation of IRF3 upon stimulation with LPS, polyI:C, infection with 
Sendai virus (Higgs et al., 2008) or with Japanese encephalitis virus (Manocha et al., 
2014). However, another study suggested TRIM21 inhibits the degradation of IRF3 
by binding to the protein and hence abolishing the degradation-inducing interaction 
between IRF3 and a protein called Pin1 (Yang et al., 2009). TRIM21 has been reported 
to promote the ubiquitination and subsequent proteasomal degradation of IRF7 (Higgs 
et al., 2010). Following adenovirus and Salmonella infection in mouse embryonic 
fibroblasts, TRIM21 was suggested to mediate the formation of Lys63-linked chains 
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and upregulate IRF3, IRF5, IRF7, NF-κB and AP-1, thereby inducing the production 
of proinflammatory cytokines (McEwan et al., 2013). These four studies suggest 
TRIM21 can mediate both positive and negative regulatory pathways depending on 
the stimulatory conditions and the cell lines used. Moreover, this also indicates 
TRIM21 is involved in signal pathways triggered by both degradation and non-
degradation signals. Finally, TRIM21 has been demonstrated to regulate a type I 
interferon response to cytosolic dsDNA via the ubiquitination and proteasomal 
degradation of the dsDNA-sensor DDX41 (Zhang et al., 2013). All these data indicate 
TRIM21 is involved in the regulation of immune signalling following stimulation with 
several pathogens. 
3.1.3 Aims 
During the course of Toxoplasma infection in mouse, the formation of the 
autophagophore around denuded parasites and subsequent fusion with lysosomes have 
been observed by electron microscopy (Ling et al., 2006). Moreover, some autophagy 
proteins along with IRGs and GBPs have been shown to mediate clearance of 
Toxoplasma in IFNγ-stimulated cells (Zhao et al., 2008; Selleck et al., 2013; Choi et 
al., 2014; Ohshima et al., 2014). However, the sensor proteins as well as the signals 
triggering the formation of the autophagosome still remain unknown. 
Autophagy is known to participate in the clearance of other vacuolar pathogens such 
as Salmonella. In this case, the bacteria released in the host cytosol are recognised and 
targeted by ubiquitination for destruction by autophagy (Huett et al., 2012; Perrin et 
al., 2004; Fujita et al., 2013; Thurston et al., 2009; Zheng et al., 2009; Wild et al., 
2011). The Salmonella infection model hence gives some clues about which 
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recognition and targeting pathways can be involved in vacuolar pathogen recognition 
and clearance. 
The aim of this project was thus to identify new host factors involved in the restriction 
of Toxoplasma in IFNγ-induced murine cells. Ultimately, the goal was to decipher the 
molecular and organismal consequences of Toxoplasma vacuolar recognition by GBPs 
and other effector proteins. 
3.2 Results 
3.2.1 Ubiquitin accumulates in the vicinity of avirulent Toxoplasma 
Ubiquitin is involved in the clearance of intracellular pathogens. However, 
ubiquitination around the Toxoplasma vacuole has not been demonstrated yet. To 
study the possible role of ubiquitin during the course of Toxoplasma infection, I first 
assessed whether Toxoplasma or its parasitophorous vacuole could be ubiquitinated. 
Immunofluorescence for total ubiquitin in IFNγ-treated mouse embryonic fibroblasts 
reveals that ubiquitin accumulates around the PV of avirulent Toxoplasma expressing 
GFP, but does not decorate virulent Toxoplasma expressing tomato (Figure 3.3a). 
Quantitative analysis of the number of vacuoles positive for ubiquitin shows that the 
molecule accumulates at the vicinity of up to 52% of avirulent Toxoplasma, whereas 
it could not be found around any (0%) virulent parasites (Figure 3.3b). 
3.2.2 IFNγ mediates ubiquitin decoration around avirulent Toxoplasma  
Interferon gamma is the main mediator of the immune response during Toxoplasma 
infection, upregulating the expression of hundreds of genes. To determine whether the 
parasite recognition by ubiquitin is dependent on the cytokine, I next performed 
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immunofluorescent staining for total ubiquitin in IFNγ-stimulated or non-treated cells. 
I observed accumulation of ubiquitin around avirulent vacuoles only when the cells 
were induced with IFNγ (Figure 3.4a). Indeed, this accumulation of ubiquitin in the 
vicinity of avirulent Toxoplasma was dependent on stimulation with IFNγ, as the 
quantitative analysis demonstrates that less than 1% of avirulent Toxoplasma is 
decorated with ubiquitin in unstimulated cells (Figure 3.4b). In contrast, up to 52% of 
avirulent Toxoplasma were decorated with ubiquitin in IFNγ-treated cells. These 
observations suggest that the mechanism involved in the ubiquitination around 
Toxoplasma requires the presence of a cofactor whose expression and/or localisation 
to the vacuole is induced by IFNγ.  
3.2.3 GBP1 and ubiquitin colocalise to avirulent Toxoplasma 
Given the accumulation pattern of ubiquitin around avirulent Toxoplasma exclusively 
and in IFNγ-stimulated conditions only, this was reminiscent of the recruitment pattern 
of GBP1 (Virreira Winter et al., 2011). To assess the putative role of GBP1 in the 
presence of ubiquitin around the parasite, I performed colocalisation studies for 
endogenous GBP1 and total ubiquitin by immunofluorescence. As can be seen in 
Figure 3.5a, GBP1 and ubiquitin corecruit to the parasitophorous vacuole of avirulent 
Toxoplasma in IFNγ-stimulated cells. Analytical tools of the distinctive fluorescence 
signals such as the plot profile analysis (Figure 3.5b) and the 3D surface plot analysis 
(Figure 3.5c) reveal both proteins exhibit the same localisation, completely 
surrounding the avirulent parasite. 
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3.2.4 Toxoplasma virulence factors interfere with GBP1 and ubiquitin 
localisation around the vacuole  
The recruitment of GBP1 to avirulent Toxoplasma vacuoles has been reported to be 
counteracted by parasitic virulence factors secreted in the host cell cytoplasm. Two 
threonine kinases expressed by the virulent type I Toxoplasma strain, called Rop16 
and Rop18, alter the recruitment of GBP1 to avirulent PVs (Virreira Winter et al., 
2011). Rop18 has been reported to phosphorylate and hence inactivate the GTPase 
(Fentress et al., 2010; Steinfeldt et al., 2010). In order to determine whether these 
virulence factors also influence the accumulation of ubiquitin in the vicinity of 
avirulent Toxoplasma, we used the transgenic type II Pru Toxoplasma strain 
expressing the type I version of Rop16 (Pru Rop16I), as well as the transgenic type III 
CEP Toxoplasma strain expressing the type I version of Rop18 (CEP Rop18I). 
Immunofluorescence for GBP1 and ubiquitin in IFNγ-stimulated mouse embryonic 
fibroblasts first shows that GBP1 is present at avirulent ubiquitin-positive vacuoles 
only (Figure 3.6). Indeed, 47.5% of avirulent type II Pru Toxoplasma and 54% of 
avirulent type III CEP Toxoplasma are decorated with both GBP1 and ubiquitin, while 
none of them are positive for GBP1 alone. Moreover, the transgenic strains Pru Rop16I 
and CEP Rop18I show significantly reduced accumulation of GBP1 and ubiquitin 
compared to their respective parental strains, dropping to 17% and 15%, respectively 
(Figure 3.6). This suggests that Toxoplasma virulence factors interfere with the 
recruitment of both GBP1 and ubiquitin to the parasitophorous vacuoles. 
3.2.5 TRIM21 interacts with GBP1 in an IFNγ−dependent manner 
My results imply that an IFNγ-inducible factor and/or a GBP1-interacting partner is 
recruited in the vicinity of avirulent Toxoplasma, which could be an already 
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ubiquitinated protein or an E3 ubiquitin ligase. To identify an E3 ubiquitin ligase that 
could be recruited to avirulent Toxoplasma vacuoles, we searched for potential GBP1 
interactors using a mass spectrometry approach. Eva Frickel had already performed an 
immunoprecipitation of Flag-GBP1 in IFNγ-stimulated Raw 264.7 macrophages 
infected with the avirulent type II Pru Toxoplasma strain, and the putative 
immunoprecipitated proteins had been identified by mass spectrometry analysis done 
by Eric Spooner at the Whitehead Institute in Boston. The close examination of the 
generated list of putative GBP1 interaction partners lead to the identification of an E3 
ubiquitin ligase called tripartite-motif protein 21 (TRIM21), which presents a peptide 
coverage of 39% (Figure 3.7a). I then confirmed this interaction using an 
immunoprecipitation/immunoblot approach. The E3 ubiquitin ligase TRIM21 has 
been described to strongly bind to the Fc part of IgG, IgM and IgA antibodies (see 
section 1.3.5). I consequently verified the interaction in IFNγ-stimulated Raw 264.7 
cells infected with either virulent type I RH Toxoplasma or avirulent type II Pru 
Toxoplasma by immunoprecipitating for TRIM21 in order to avoid unspecific binding 
of TRIM21 to the anti-GBP1 antibody during the immunoprecipitation process. In 
order to avoid unspecific binding of proteins to the beads, the protein samples were 
precleared by incubation with the agarose beads for 3h. The remaining protein lysates, 
free of proteins unspecifically bound to the beads, were then used to perform the 
immunoprecipitation. Endogenous TRIM21 interacts with endogenous GBP1 in IFNγ-
stimulated cells independently of the presence of Toxoplasma and regardless of the 
virulence strain (Figure 3.7b). Additionally, overexpressed myc-TRIM21 interacts 
with overexpressed Flag-GBP1 (upper band) and endogenous GBP1 (lower band) in 
IFNγ-induced samples only, and independently of the virulence strain of Toxoplasma 
(Figure 3.7c). These results demonstrate the E3 ubiquitin ligase TRIM21 interacts with 
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GBP1 in a strain-independent but IFNγ-dependent manner. However, as GBP1 is 
expressed at a high level following induction with IFNγ, one cannot exclude that even 
after pre-clearing, GBP1 could unspecificaly bind to the beads rather than to TRIM21. 
One control to test for this possibility would be to perform an immunoprecipitation in 
TRIM21 KO cells. Should GBP1 only bind to TRIM21, no GBP1 should be recovered 
following preclearing, anti-TRIM21 immunoprecipitation and anti-GBP1 
immunoblot. Another approach to circumvent this issue could be to perform an 
immunoprecipitation and immunoblot for the overexpressed, tagged proteins in cells 
only expressing endogenous proteins. 
3.2.6 TRIM21 follows GBP1 recruitment to avirulent Toxoplasma 
Localisation studies were performed in mouse embryonic fibroblasts in an effort to 
gain some knowledge about the possible function of GBP1 and its TRIM21 interaction 
partner. As both proteins of interest are induced by IFNγ, the specificity of the primary 
rabbit anti-GBP1 and goat anti-TRIM21 antibodies was determined by 
immunostaining fixed cells uninduced or induced with 100U/mL IFNγ. To 
demonstrate the specificity of the secondary antibody, experiments were performed 
without the addition of the primary antibody. Briefly, cells induced with 100 U/mL 
IFNγ were fixed and immunostained with a secondary goat anti-rabbit antibody or 
donkey anti-goat antibody to ensure they do not bind non-specifically to endogenous 
mouse proteins (data not shown). 
Although our homemade GBP1 antibody has already been characterized for 
immunofluorescence microscopy (Virreira Winter et al., 2011), normal subcellular 
localisation of GBP1 was first assessed in uninfected unstimulated or IFNγ−stimulated 
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mouse embryonic fibroblasts. GBP1 was expressed uniformly in the cytoplasm of 
IFNγ-stimulated MEFs only (data not shown). Subcellular localisation of GBP1 was 
then assessed in IFNγ-stimulated cells infected with the avirulent Toxoplasma 
expressing GFP. As can be observed in Figure 3.8a (top panel), GBP1 is recruited at 
the parasitophorous vacuole of the avirulent parasite.  
Next, normal subcellular localisation of TRIM21 was assessed in uninfected 
unstimulated or IFNγ−stimulated mouse embryonic fibroblasts. TRIM21 was 
expressed uniformly in the cytoplasm of IFNγ-stimulated MEFs only (data not shown). 
Thus, I presume the commercial TRIM21 antibody is suitable for immunofluorescence 
to recognise native endogenous TRIM21 in paraformaldehyde (PFA)-fixed samples. 
Subcellular localisation of TRIM21 was then assessed in IFNγ-stimulated cells 
infected with the avirulent strain of Toxoplasma expressing GFP. As can be observed 
in Figure 3.8a (lower panel), TRIM21 is also recruited to the parasitophorous vacuole 
of the avirulent parasite. 
By quantitative analysis of the number of vacuoles positive for GBP1, I could 
reproduce published results and confirm the targeting of GBP1 to the vacuole of 55% 
of avirulent Toxoplasma in IFNγ-stimulated mouse embryonic fibroblasts, while only 
3% of virulent Toxoplasma were decorated (Figure 3.8b, top panel). Similarly, 
TRIM21 was preferentially recruited to the vacuole of avirulent Toxoplasma (26%) 
rather than of virulent Toxoplasma (1%, Figure 3.8b, lower panel). These results 
suggest TRIM21 follows the recruitment pattern of GBP1 to avirulent Toxoplasma 
vacuoles. 
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3.2.7 TRIM21 and GBP1 colocalise at avirulent Toxoplasma vacuoles 
As TRIM21 mimics the recruitment of GBP1 to avirulent vacuoles, I next studied 
whether TRIM21 was co-recruited to GBP1-positive avirulent Toxoplasma vacuoles. 
Immunofluorescence shows GBP1 and TRIM21 colocalise to the parasitophorous 
vacuole of avirulent Toxoplasma in IFNγ-stimulated cells (Figure 3.9a). Analytical 
tools of the distinctive fluorescence signals such as the plot profile analysis (Figure 
3.9b) and the 3D surface plot analysis (Figure 3.9c) reveal both proteins exhibit the 
same localisation around the avirulent parasite. Quantitative analysis of the protein 
recruitment reveals TRIM21 is mainly recruited to the parasitophorous vacuole of the 
~30% GBP1-positive Toxoplasma rather than to the 1.5% remaining GBP1-negative 
avirulent Toxoplasma (Figure 3.9d). Thus, about half of the GBP1-positive avirulent 
Toxoplasma are also decorated with TRIM21. These results suggest TRIM21 is 
preferentially recruited to GBP1-positive avirulent Toxoplasma parasitophorous 
vacuoles. 
3.2.8 TRIM21 and GBP1 form a complex in the cytoplasm and recruit to 
avirulent Toxoplasma 
Both GBP1 and TRIM21 are highly inducible by IFNγ (Degrandi et al., 2007). 
Moreover, the immunoprecipitation/immunoblot data as well as the 
immunofluorescence localisation studies strongly suggest TRIM21 and GBP1 could 
already interact in the cytoplasm upon stimulation with IFNγ, rather than forming a 
complex upon invasion of Toxoplasma in the cell. To test this hypothesis, I used the 
proximity-ligation (PL) assay, allowing to detect proteins that are in very close 
physical proximity (limiting detection distance just above 10 nm) (Söderberg et al., 
2006; Jarvius et al., 2007). I detected very limited PL signal between endogenous 
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GBP1 and TRIM21 in unstimulated cells infected with avirulent Toxoplasma (Figure 
3.10a). In contrast, I observed strong PL signals in the cytoplasm (Figure 3.10b) or 
around avirulent Toxoplasma vacuoles (Figure 3.10c) in IFNγ-stimulated mouse 
embryonic fibroblasts. These results show GBP1 and TRIM21 form a complex in the 
cytoplasm of uninfected cells upon IFNγ stimulation and relocalise together to the 
vacuole of avirulent Toxoplasma upon invasion. As discussed previously, TRIM21 has 
been described to strongly bind to the Fc part of IgG, IgM and IgA antibodies (see 
section 1.3.5). Thus, one cannot exclude that the positive signal observed is due to 
TRIM21 unspecifically binding to the anti-GBP1 antibody. An additional control to 
address this issue would be to perform the experiment in GBPchr3 cells lacking GBP1. 
Should TRIM21 only bind to GBP1 and not to the Fc part of the anti-GBP1 antibody, 
no PL signal should be observed in the absence of the GBP1 protein. 
3.2.9 TRIM21 influences GBP1 localisation to avirulent Toxoplasma 
Although both TRIM21 and GBP1 colocalise to avirulent Toxoplasma, the sequence 
and possible co-dependence of their recruitment is unknown. I next investigated the 
requirement of one of the interacting partners for the recruitment of the other to the 
avirulent vacuoles. TRIM21 recruitment was not altered in IFNγ-stimulated GBP 
DKO cells lacking all GBP1-GBP10 (Figure 3.11a). However, GBP1 recruitment to 
avirulent Toxoplasma vacuoles was partly but significantly decreased from 51% to 
36.5% in IFNγ-stimulated cells not expressing TRIM21 (Figure 3.11b). These results 
suggest that TRIM21 positively regulates the localisation of GBP1 to avirulent 
Toxoplasma vacuoles. Thus, it is likely that TRIM21 plays the role of the primary 
sensor and recruits its effector GBP1 to the avirulent Toxoplasma vacuole. However, 
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as TRIM21 only partly influences GBP1 localisation to avirulent Toxoplasma, other 
factors yet to be determined must be involved. 
3.2.10 TRIM21 and GBP1 localisation at the vacuole is altered by parasitic 
virulence factors 
I previously demonstrated that GBP1 and ubiquitin colocalisation to avirulent 
Toxoplasma vacuoles could be impaired by the secretion of virulence factors (see 
section 3.2.4). I then investigated whether parasitic virulence factors could also alter 
the recruitment of TRIM21 and GBP1. Immunofluorescence staining for GBP1 and 
TRIM21 in IFNγ-stimulated mouse embryonic fibroblasts shows that both proteins 
also colocalise to avirulent type III CEP Toxoplasma strain (Figure 3.12). However, 
the transgenic strain CEP Rop18I exhibits significantly reduced accumulation of 
GBP1 and TRIM21 compared to its parental strain, decreasing from 31.5% to 7% 
(Figure 3.12). Interestingly, the proportion of Toxoplasma vacuoles decorated with 
both TRIM21 and GBP1 compared to the proportion of total GBP1-positive avirulent 
vacuoles remains the same (50%). This suggests that Toxoplasma virulence factors 
interfere with the recruitment of both GBP1 and TRIM21 to the parasitophorous 
vacuoles. 
3.2.11 TRIM21 mediates Lys63-linked ubiquitination around avirulent 
Toxoplasma 
Distinct ubiquitin linkages have been associated with specific cellular functions. 
Lys48-linked ubiquitinated substrates have been shown to be targeted for degradation 
by the proteasome (Chau et al., 1989; Finley et al., 1994), while Lys63-linked 
ubiquitinated substrates have been shown to be involved in DNA repair and activation 
of immune signalling (Hofmann and Pickart, 2001; Deng et al., 2000). I investigated 
Chapter 3: Results 
 156 
the ubiquitin linkages present at the vicinity of avirulent Toxoplasma. 
Immunofluorescence for Lys48 ubiquitin and Lys63 ubiquitin shows both linkage 
types can be found around Toxoplasma vacuoles in IFNγ-stimulated wild-type (Figure 
3.13a) and TRIM21-deficient (Figure 3.13b) mouse embryonic fibroblasts. 
TRIM21 has been described as a RING-type E3 ubiquitin ligase that acts as a transfer 
protein between ubiquitin and the substrate to be ubiquitinated. I thus investigated the 
ubiquitination of avirulent Toxoplasma vacuoles in TRIM21-deficient cells. TRIM21-
deficiency led to a third decrease in avirulent Toxoplasma PV ubiquitination, dropping 
from 54% to 37% in TRIM21 knockout cells, suggesting TRIM21-mediated 
ubiquitination accounts at least in part for the presence of ubiquitin at the vicinity of 
the parasite (Figure 3.14a). Next, I examined the ubiquitin linkages involved in 
TRIM21-mediated avirulent Toxoplasma ubiquitination. TRIM21-deficiency did not 
affect the Lys48-linked ubiquitination of avirulent Toxoplasma (Figure 3.14a). 
However, Lys63-linked ubiquitination of avirulent Toxoplasma was decreased by half 
in TRIM21 KO cells compared to WT cells as the proportion of Lys63-linked 
ubiquitination dropped from 57% to 25%, mimicking the ubiquitination pattern of total 
ubiquitin (Figure 3.14a). This suggests the IFNγ-dependent, TRIM21-mediated 
ubiquitination of the avirulent parasites is specific to Lys63-linked polyubiquitin 
chains. 
I showed previously that TRIM21 recruitment to avirulent Toxoplasma vacuoles is not 
impaired in the absence of expression of the GBPs (see section 3.2.9). I next assessed 
the ubiquitination of avirulent Toxoplasma in IFNγ-stimulated cells lacking all GBPs. 
Total ubiquitination, Lys48-linked ubiquitination and Lys63-linked ubiquitination 
were not altered in the absence of GBPs (Figure 3.14b). In accordance with my 
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previous findings, these observations confirm that TRIM21 can decorate avirulent 
Toxoplasma vacuoles in the absence of GBP1, leading to an accumulation of ubiquitin 
at the vicinity of the parasites. 
3.2.12 TRIM21 does not mediate cell-autonomous resistance to Toxoplasma 
I next investigated the downstream effects of TRIM21-mediated avirulent Toxoplasma 
ubiquitination. Mallery et al. showed that TRIM21 binds to invading antibody-coated 
adenoviruses and targets them for degradation by the proteasome due to its E3 ligase 
activity. More recently, TRIM21 was shown to also restrict Salmonella intracellular 
infection in an antibody-dependent manner (Rakebrandt et al., 2014). I thus assessed 
whether TRIM21-mediated ubiquitination of avirulent Toxoplasma enables restriction 
of intracellular parasitic infection. The IFNγ-mediated killing of Toxoplasma parasites 
was determined by an in vitro plaque assay, which consists in measuring the number 
of plaques formed on a monolayer of uninduced vs. IFNγ-induced cells. This assay has 
been used to determine whether a single protein has an effect on the IFNγ-mediated 
clearance of Toxoplasma (Niedelman et al., 2013; Haldar et al., 2015). In both wild-
type and TRIM21-deficient mouse embryonic fibroblasts, the number of plaques 
formed following Toxoplasma infection was reduced in the IFNγ-induced samples 
compared to the uninduced samples (Figure 3.15a). Indeed, TRIM21 deficiency did 
not lead to a decrease in plaque loss, as IFNγ stimulation reduced the number of 
plaques to 66.5% in TRIM21 KO cells, whereas IFNγ-induced restriction in WT cells 
was translated by a reduction in plaques from 69.4% (Figure 3.15b). The plaque assay 
suggests TRIM21 alone does not help restrict intracellular Toxoplasma infection in 
vitro. However, as IFNγ upregulates hundreds of genes, and it cannot be excluded that 
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TRIM21 might have an effect on Toxoplasma restriction that is redundant and would 
thus be masked by the presence of another IFNγ-dependent factor. 
The clearance of Toxoplasma in IFNγ-stimulated cells is characterised by a blebbing 
and disruption of the parasitophorous vacuole membrane (Martens et al., 2005; Ling 
et al., 2006; Yamamoto et al., 2012). I thus investigated by transmission electron 
microscopy the integrity of the PVM of avirulent Toxoplasma in IFNγ-stimulated WT 
or TRIM21 KO mouse embryonic fibroblasts 2h post-infection. Disruption and 
blebbing of the PVM of avirulent Toxoplasma was not markedly impaired in TRIM21-
deficient cells (Figure 3.15c). Due to the size of Toxoplasma and to the nature of the 
transmission electron microscopy experiment, ultrastructural analysis of the 
Toxoplasma PV is always performed in a qualitative rather than quantitative way (Ling 
et al., 2006; Yamamoto et al., 2012; Selleck et al., 2013; Muniz-Feliciano et al., 2013; 
Dupont et al., 2014). The presence or absence of disruption of the vacuoles is 
considered rather than the number of intact versus broken vacuoles. Thus, our results 
suggest TRIM21 is not involved in the cell-autonomous, IFNγ-induced killing of 
Toxoplasma. 
Ubiquitination of pathogens has been shown to lead to their clearance via the 
autophagy pathway (see section 1.3.3). Toxoplasma resistance is dependent on 
autophagy proteins, and the formation of the phagophore has been observed around 
the parasite. I thus tested whether the TRIM21-mediated ubiquitination of avirulent 
Toxoplasma provides the recognition signal for the autophagy receptor p62. 
Immunofluorescence staining for p62 was performed in IFNγ-stimulated wild-type or 
TRIM21-deficient mouse embryonic fibroblasts infected with avirulent Toxoplasma. 
As can be seen in Figure 3.16, the quantitative analysis of the number of vacuoles 
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positive for p62 reveals that the adaptor protein decorates avirulent parasites to a 
similar extent in both the wildtype (44.5%) and the TRIM21 KO (33%) cells. These 
results are in accordance with the killing assay and the ultrastructural analysis of the 
vacuolar integrity, indicating that TRIM21 does not regulate the cell-autonomous, 
IFNγ-dependent restriction of avirulent Toxoplasma. 
3.2.13 TRIM21 does not regulate cytokine production in Toxoplasma-infected 
macrophages 
As TRIM21 does not mediate cell-autonomous restriction of Toxoplasma in vitro, I 
investigated whether the E3 ubiquitin ligase plays a role in immune signalling during 
Toxoplasma infection. TRIM21 has already been shown to inhibit the activation of the 
NF-kB pathway and subsequent production of TNFα, IL-1β, IL-6 and IP-10 in mouse 
embryonic fibroblasts stimulated with poly(I:C) (Keeble et al., 2008). Moreover, 
TRIM21 has been reported to induce a proinflammatory state, characterised by the 
production of TNFα, IL-6, IP-10, CCL2 and CCL4, in mouse embryonic fibroblasts 
infected with adenovirus (McEwan et al., 2013). Using RT-qPCR, I compared the 
expression of transcripts for the NF-κB transcription factor and some selected 
inflammatory cytokines (TNFα, IL-12p40, IL-10 and IL-1β) in IFNγ-stimulated wild-
type and TRIM21-deficient bone marrow-derived macrophages following infection 
with avirulent Toxoplasma. As can be seen in Figure 3.17, TRIM21-deficient cells 
show equal levels of mRNA for all the genes tested at all time points compared to the 
wild-type controls. I also assessed the secreted protein levels of the pro-inflammatory 
cytokines IFNα, IFNβ and IL-6 in wild-type and TRIM21-deficient bone marrow-
derived macrophages infected with Toxoplasma for 24h. As can be observed in Figure 
3.18, TRIM21-deficient cells exhibit similar cytokine production compared to the 
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wild-type cells. These results suggest that for the time points and proteins tested, 
TRIM21 does not regulate the production of inflammatory cytokines in vitro in 
macrophages following Toxoplasma infection. 
3.2.14 TRIM21 mediates ubiquitination of large GTPases 
Although I demonstrated TRIM21 partly mediates the Lys63-linked ubiquitination at 
the vicinity of avirulent Toxoplasma in IFNγ-stimulated cells (see section 3.2.11), it 
does not lead to cell-autonomous killing of the parasite (see section 3.2.12) nor does it 
regulate an immune response in vitro (see section 3.2.13). In order to decipher the 
consequences of the TRIM21-dependent accumulation of Lys63-linked ubiquitin to 
avirulent Toxoplasma, I investigated the potential ubiquitinated substrates of the E3 
ubiquitin ligase during Toxoplasma infection. To that end, I used the stable isotope 
labelling of amino acid in cell culture (SILAC) technique in collaboration with Dr. 
Bram Snijders and Dr. Vesela Encheva at the Crick in Clare Hall Laboratory. Briefly, 
I performed the infection of SILAC-labelled MEFs and prepared the forward and 
reverse samples. Dr. Encheva then performed the trypsin digestion, diGLY 
immunoprecipitation and LC-MS/MS of the samples.  
3.2.14.1 Identification of ubiquitinated proteins by SILAC 
SILAC is a quantitative proteomics tool that consists of in vivo isotopically labelling 
two cellular samples (in my case wild-type and TRIM21-deficient cells) with either 
heavy or light lysine and arginine residues, mixing the labelled samples together, 
digesting the proteins with trypsin and comparing the generated peptides by liquid 
chromatography coupled with mass spectrometry (LC-MS/MS). At Clare Hall, the 
method has been adapted to specifically determine ubiquitination targets and their sites 
of ubiquitination. It is based on the fact that ubiquitinated proteins subjected to trypsin 
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digestion will leave a remnant Gly-Gly (diGLY) site that can be captured using an 
anti-diGLY antibody. Thus, an additional immunoprecipitation step with the anti-
diGLY antibody post-trypsinisation allows enrichment of the sample with 
ubiquitinated peptides before LC-MS/MS analysis (Figure 3.19). 
3.2.14.2 Optimisation of culture conditions for efficient SILAC labelling 
A high incorporation rate of the labelled isotopes into the cells is a key factor for the 
success of the SILAC method. In order to ensure the highest level of incorporation, 
the cells have to undergo a theoretical 4 to 6 doublings, so that all newly synthesised 
proteins will be made up with isotopes only. The addition of labelled isotopes into the 
culture medium can alter the growth of the cells, rendering their expansion in the 
SILAC medium challenging. My primary mouse embryonic fibroblasts did not 
initially proliferate well in the SILAC medium. This issue was finally solved by using 
a SILAC-specific FCS that is dialysed at a cut-off of 1000 Da. 
Once the optimum culture conditions had been determined, wild-type mouse MEFs 
were grown for 4 to 5 doublings in “heavy” (13C-arginine, 13C-lysine and unlabelled 
proline) or “light” (12C-arginine, 12C-lysine and unlabelled proline) medium. Cells 
were mixed at a 1:1 ratio, proteins were extracted, submitted to digestion with trypsin 
and analysed by liquid chromatography coupled with mass spectrometry. The 
incorporation efficiency was assessed by plotting the peptide intensity against the log2 
ratio of the “heavy” mass-to-charge ratio over the “light” mass-to-charge ration (ratio 
H/L). Thus, a good incorporation is translated by a high H/L ratio. As can be seen on 
Figure 3.20a, both the arginine and the lysine signals are situated on the high end of 
the graph. Lysine residues exhibit a log2(16)=4, which is equivalent to an incorporation 
rate of 93.75% (as 1/16=0.0625). Similarly, arginine residues exhibit a log2(64)=6, 
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which is equivalent to an incorporation rate of 98.44% (1/64=0.0156). This indicates 
the cells divided well and incorporated the labelled isotopes enough to allow SILAC 
analysis.  
Along with the challenging culture conditions and the necessity of a high incorporation 
rate, another limiting factor in the SILAC method is the possible arginine-to-proline 
conversion. Indeed, arginine is a metabolic precursor for proline biosynthesis, and 
natural conversion of arginine to proline can occur at a high rate in the cell. This can 
lead to an unbalanced heavy isotope labelling, with a diminution of the heavy arginine 
portion and the apparition of satellite heavy proline signals. To prevent and correct the 
arginine-to-proline conversion, unlabelled proline is added to the SILAC media. 
However, the efficiency of the approach and the extent of the possible conversion have 
to be evaluated. As can be observed in Figure 3.20b, the arginine signals are evenly 
and randomly distributed on the graph, while an important arginine-to-proline 
conversion would be translated by the appearance of a cloud of arginine signals located 
on the light (e.g. left) side of the graph. This indicates that the addition of unlabelled 
proline in the SILAC culture media is sufficient to prevent the metabolic arginine-to-
proline conversion. 
3.2.14.3 TRIM21 regulates the protein level of some GBPs 
To identify the ubiquitination substrates of TRIM21, wild-type and TRIM21 KO 
mouse embryonic fibroblasts were cultivated in both “heavy” (13C-arginine, 13C-lysine 
and unlabelled proline) and “light” (12C-arginine, 12C-lysine and unlabelled proline) 
medium, induced for 16h with IFNγ and infected for 1h with avirulent Toxoplasma. 
Two samples were generated by mixing at a 1:1 ratio the “heavy” WT with the “light” 
TRIM21 KO cells (forward sample) and by mixing at a 1:1 ratio the “light” WT with 
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the “heavy” TRIM21 KO cells (reverse sample). This allows for checking of the 
reproducibility of the data and enables correlation studies between the forward and 
reverse samples.  
To control for alterations in the total abundance of proteins, a small portion of each 
mixed cell lysates was used for gross protein quantification. This enables 
determination of whether any change in ubiquitination can be attributed to a change in 
the protein abundance. The graph pictured in Figure 3.21 shows all retrieved proteins 
from the quantification analysis. As the thin blue diagonal line indicates the close 
correlation between forward and reverse samples, the closer a dot is to this line the 
greater the correlation is and thus confidence in protein quantification. The dots 
localised close to the intersection of the x and y axes represent proteins that do not 
exhibit a differential protein level. Strikingly, one protein highlighted in blue appears 
to have a higher protein level in the WT cells, and its quantification correlated well 
between the forward and reverse samples. Very interestingly, this protein is GBP1, 
implying that TRIM21 upregulates the protein level of GBP1. Moreover, analysis of 
the protein levels of other GBPs reveals that GBP2 (red dot) is present at a higher 
protein level in TRIM21 KO cells, suggesting that TRIM21 downregulates the protein 
level of GBP2 (Figure 3.21). 
A separate analysis of the protein quantification data was also performed in the 
forward sample only (Figure 3.22a) and in the reverse sample only (Figure 3.22b). On 
both graphs, GBP1 (blue dot) clearly shows a higher protein level in WT cells whereas 
GBP2 (red dot) clearly shows a higher protein level in TRIM21-deficent cells. In the 
forward sample (Figure 3.22a), another GBP represented by a green dot, namely 
GBP4, seems to exhibit a higher protein level in the WT cells, but this has not been 
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confirmed in the reverse sample. Some IRGs, represented by orange dots, appear to 
have mainly similar protein levels in both cell lines.  
3.2.14.4 TRIM21 mediates the ubiquitination of members of the family of IFNγ-
induced large GTPases 
To identify the ubiquitinated substrates of TRIM21, forward and reverse samples were 
digested with trypsin, and enrichment for ubiquitinated peptides was achieved by anti-
diGLY immunoprecipitation. DiGLY-containing peptides were analysed by liquid 
chromatography coupled with mass spectrometry. A total of 2058 diGLY sites were 
recovered from the forward WT “heavy” sample, while 1997 diGY sites were retrieved 
from the reverse WT “light” sample (Figure 3.23). 448 diGLY sites were only found 
in the forward WT “heavy” sample and 387 diGLY sites were only found in the reverse 
WT “light” sample. 221 diGLY sites were not assigned, probably due to a low signal 
to noise ratio. Finally, 1610 diGLY sites were common in the forward and the reverse 
samples and could be analysed further on the correlation plot shown in Figure 3.24. 
The graph shows the diGLY sites retrieved from the forward and reverse samples. The 
thin blue diagonal line represent the best correlation, so that the closer a dot is to this 
line the greater the correlation is and thus confidence in protein ubiquitination. The 
dots localised close to the intersection of the x and y axes represent proteins that do 
not exhibit a differential ubiquitination profile. The analysis of the family of IFNγ-
induced large GTPases reveals that the GBPs (blue, red and green dots), the IRGs 
(orange dots) and VLIG1 (pink dots) all present ubiquitination sites that correlate very 
well between the forward and reverse samples. Interestingly, GBP2 and VLIG1 seem 
to be more ubiquitinated in TRIM21-deficient cells (Figure 3.24). 
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A separate analysis of the ubiquitination sites was performed in the forward sample 
only (Figure 3.25a) and in the reverse sample only (Figure 3.25b). The further away 
from the y axis a dot is, the stronger the corresponding ubiquitination signal from mass 
spectrometry is. On both graphs, the red dots representing GBP2 cluster on the side of 
TRIM21-deficient cells, indicating GBP2 is more ubiquitinated in cells lacking 
TRIM21. Similarly, the pink dots representing VLIG1 group on the side of TRIM21 
KO cells, suggesting VLIG1 is more ubiquitinated in the absence of TRIM21. In 
contrast, the blue dots representing GBP1 cluster on the side of wild-type cells, 
implying GBP1 is more ubiquitinated in the presence of TRIM21. However, these 
latter ubiquitination sites could only be retrieved from the reverse sample. Finally, the 
ubiquitination pattern of the other GBPs and of the IRGs appear to be more consistent 
between the wild-type and TRIM21-deficient cells, indicating their ubiquitination 
status is not dependent on TRIM21. Altogether, these SILAC data identify TRIM21 
as a positive regulator of the ubiquitination of GBP1, and a negative regulator of the 
ubiquitination of GBP2 and VLIG1. 
3.2.15 TRIM21 mediates cholesterol biosynthesis 
3.2.15.1 Transcriptional analysis of Toxoplasma-infected TRIM21-deficient cells: 
quality control 
As TRIM21 appears to regulate resistance against Toxoplasma infection on a non-cell 
autonomous level, I decided to perform a transcriptional analysis by RNAseq in wild-
type and TRIM21-deficient mouse embryonic fibroblasts following Toxoplasma 
infection. Live, Toxoplasma-infected cells were sorted by flow cytometry and RNA 
was extracted as described in section 2.15. The alignment, mapping, analysis and 
visualisation of the RNAseq data were performed by Dr. Helena Ahlfors (Babraham 
Chapter 3: Results 
 166 
Institute, Cambridgeshire, UK). First, the quality of the reads was assessed using the 
FastQC tool as described in section 2.16.3. The reads were subsequently aligned to the 
mouse genome and were counted using HTSeq-count. The generated data were finally 
analysed with DESeq2. The quality of the data produced was assessed using the 
dispersion parameter. This consists in estimating the correlation of the variance, or 
“dispersion”, of the biological replicates and the mean count for each gene. First, it 
estimates a dispersion value for each gene. Second, it fits a curve through the estimates. 
Finally, it assigns to each gene a dispersion value, using a value that ranges between 
the gene estimate and the fitted value. As can be seen on Figure 3.26a, the empirical 
dispersion estimates cluster well along the fitted dispersion curve, indicating that the 
biological variance between each gene’s triplicates is minimal, and validating the 
RNAseq data. 
Second, the principal component analysis (PCA) can be used to visualise the distance 
between samples. It is a statistical ordination method that consists in determining the 
largest possible variance between data points to accordingly spread the samples onto 
the x axis of a 2D plane. Then, the second largest possible variance is identified in 
order to spread the same samples onto the y axis of the same 2D plane. The resulting 
PCA plot thus represents the optimal spread between samples and allows to determine 
how well samples cluster or differ. As can be observed in Figure 3.26b, four different 
and well-defined groups can be observed. The three replicates within each condition 
cluster together, while the distance between each condition is optimal. This suggests 
that the triplicates are of good quality and that the four conditions tested exhibit 
different and distinct gene expression profiles. 
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3.2.15.2 Differential gene expression in TRIM21-deficient mouse embryonic 
fibroblasts upon Toxoplasma infection 
The comparative analysis of the gene expression profiles in the four conditions tested 
was first performed using the MA plot. This test generates a scatter plot that represents 
the fold change gene expression (log2) between two samples versus the mean of the 
normalised counts. The graphs shown in Figure 3.27 represent the comparison of gene 
expression between two conditions at a fold change cut-off of 2 (above and below the 
blue dotted lines) and an adjusted p-value of 0.05. At the steady state, corresponding 
to the comparison between uninfected TRIM21-deficient cells and uninfected wild-
type cells, 866 genes are upregulated and 915 genes are downregulated in the TRIM21 
KO cells (Figure 3.27a). When considering the TRIM21-deficient cells only, 774 
genes are upregulated and 167 genes are downregulated following infection with 
avirulent Toxoplasma (Figure 3.27b). Similarly, if considering wild-type cells only, 
1411 genes are upregulated and 206 genes are downregulated upon infection with 
avirulent Toxoplasma (Figure 3.27c). Finally and more interestingly, 437 genes are 
upregulated and 787 genes are downregulated in TRIM21-deficient cells compared to 
wild-type cells following infection with avirulent Toxoplasma (Figure 3.27d). As this 
particular comparison corresponds to the “snapshot” that exemplifies the situation the 
Toxoplasma parasites encounter in the cell, the following gene expression analysis will 
be mainly performed in this Toxoplasma-infected TRIM21 KO versus Toxoplasma-
infected wild-type comparison .  
Finally, in order to corroborate to the proteomic data obtained by SILAC suggesting 
that TRIM21 deficiency influences the abundance of both GBP1 and GBP2 at the 
protein level, we had a closer look at their respective gene expression level. The 
expression level of Gbp1 is downregulated by a fold change of 7.7 in the TRIM21-
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deficient cells compared to the wild-type controls. Moreover, the expression level of 
Gbp2 is upregulated at a fold change of 2.4 in cells lacking TRIM21 compared to the 
WT controls.  
Gene name Gene ID 
Fold change 
(TRIM21 KO vs. WT) 
Gbp1 ENSMUSG00000040264 -7.7 
Gbp2 ENSMUSG00000028270 2.4 
Table 3.1: Gene expression levels of selected GBPs in TRIM21-deficient cells compared to wild-
type cells. 
 
Thus, the differential protein levels of GBP1 and GBP2 observed in the SILAC 
experiment could be explained by a differential expression at the genomic level, 
implying that TRIM21 somehow regulates some GBPs at the RNA level. One could 
speculate that TRIM21 could play a role in the stability or transport of GBP1 and 
GBP1 mRNAs, or alternatively could mediate the degradation of the mRNAs. The 
exact mechanism underlying this regulation remains to be investigated. 
3.2.15.3 Toxoplasma-infected TRIM21-deficient cells display an upregulated 
cholesterol biosynthesis 
Differential gene expression analysis revealed that 437 genes are upregulated and 787 
genes are downregulated in Toxoplasma-infected TRIM21-deficient mouse embryonic 
fibroblasts compared to infected wild-type controls. In order to identify the biological 
pathways and related networks these genes are involved in, we ran an Ingenuity 
Pathway Analysis (IPA) that analyses the functional connectivity of genes using 
computational algorithms from information obtained within the IPA database. 
Canonical biological pathways are scored by identifying the number of differentially 
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expressed genes that map to a specific pathway. As can be seen in Figure 3.28, IPA 
identified the 10 top canonical biological pathways whose genes are differentially 
regulated in Toxoplasma-infected TRIM21 KO cells compared to the infected WT 
cells. Strikingly, among those 10 pathways associated with differentially expressed 
genes, 2 are involved in the biosynthesis of cholesterol or its precursor, zymosterol. 
For each of these biosynthesis pathways, all genes appear to be upregulated in 
TRIM21-deficient cells following Toxoplasma infection. Interestingly, the biological 
pathway for hepatic stellate cell (HSC) activation is also differentially regulated in 
TRM21-deficient cells infected with avirulent Toxoplasma, with about half of the 
genes being upregulated and the other half of the genes being downregulated. 
Originally termed “fat-storing cells”, HSCs are hepatic cells that are responsible for 
the storage of 80-90% of the retinoid stored in the liver, as well as of a significant 
quantity of triglycerides, phospholipids, cholesterol, and free fatty acids in 
cytoplasmic lipid droplets (Friedman, 2008). During liver damage, HSCs are activated 
and these lipid droplets are lost. Furthermore, two other biological pathways found to 
be differentially regulated in infected TRIM21 KO cells are liver receptor X (LXR) 
and retinoid receptor X (RXR) activation, as well as IL-1 mediated RXR inhibition. 
LXRs have been shown to act as cholesterol sensors and modulate the expression of 
genes involved in cholesterol and lipid metabolism in response to changes in cellular 
cholesterol status (Zhao and Dahlman-Wright, 2010). RXRs are nuclear receptors that 
modulate lipids metabolism by forming activating heterodimers with other nuclear 
receptors such as LXRs and the fatty acid receptors called peroxisome proliferator-
activated receptor (PPAR). Finally, the other biological pathways differentially 
regulated in Toxoplasma-infected TRIM21-deficient cells compared to WT infected 
cells are granulocyte and agranulocyte adhesion and diapedesis, cyclic adenosine 
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monophosphate (cAMP)-mediated signalling, G-protein coupled receptor signalling 
and IL-10 signalling (Figure 3.28). 
As cholesterol biosynthesis appears to be the main biological pathway differentially 
regulated in Toxoplasma-infected TRIM21-deficient mouse embryonic fibroblasts 
compared to infected wild-type controls, the genes involved in cholesterol 
biosynthesis were retrieved and analysed with the IPA software. As can be observed 
in Figure 3.29, wild-type cells seem to downregulate the genes involved in cholesterol 
biosynthesis following Toxoplasma infection compared to uninfected wild-type. In 
contrast, at the steady state, uninfected TRIM21-deficient cells have a higher 
expression level of the genes involved in cholesterol biosynthesis when compared to 
uninfected controls, and this upregulation is exacerbated upon infection with avirulent 
Toxoplasma. Thus, these results suggest that TRIM21 mediates the downregulation of 
cholesterol biosynthesis during Toxoplasma infection, and that one major organ where 
this regulation occurs could be the liver. 
3.2.16 Discussion 
The murine host has developed immune strategies, orchestrated by the major cytokine 
interferon γ, in order to successfully contain the Toxoplasma parasite without causing 
lethal hyper-inflammation. This IFNγ-mediated response involves the recruitment of 
the two families of large GTPases p47 IRGs and p65 GBPs to the avirulent 
parasitophorous vacuole, leading to the disruption of the parasite’s replicative niche 
and its subsequent clearance by autophagy. Although Toxoplasma clearance has been 
shown to be dependent on proteins involved in the autophagy and inflammasome 
pathways, the mechanisms triggered after the disruption of the parasitophorous 
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vacuole remain unclear. The aim of this work was to identify host factors that play a 
role at the parasitophorous vacuole and mediate the restriction of Toxoplasma. 
In this thesis, I report for the first time the presence of ubiquitin at the vicinity of 
avirulent type II and type III strains of Toxoplasma (see sections 3.2.1 and 3.2.4). I 
further demonstrate that this ubiquitination around avirulent parasites is strictly 
mediated by the major cytokine IFNγ (see section 3.2.2), and that virulence factors 
secreted by the parasite in the host cytosol interfere with the decoration of the vacuole 
with ubiquitin (see section 3.2.4). As this IFNγ-dependent ubiquitin accumulation 
pattern around avirulent Toxoplasma mimics the one of the p65 guanylate-binding 
protein GBP1, I performed colocalisation studies and show that all GBP1-positive 
vacuoles are also decorated with ubiquitin (see section 3.2.3). Two different 
experimental approaches, combining immunoprecipitation with either mass 
spectrometry or immunoblot, identified the E3 ubiquitin ligase TRIM21 as a GBP1 
interaction partner (see section 3.2.5). Here, I also show that TRIM21 complexes with 
GBP1 in the cytoplasm and that both proteins colocalise to the parasitophorous 
vacuole of avirulent Toxoplasma in an IFNγ-dependent fashion (see sections 3.2.7 and 
3.2.8). This therefore makes TRIM21 a novel and the first identified interaction partner 
of GBP1 -as well as of any other GBPs- at the vacuole of avirulent Toxoplasma. As 
the formation of the TRIM21-GBP1 complex is dependent on IFNγ stimulation, an 
IFNγ-induced cofactor yet to be determined is necessary for the newly discovered 
interaction. This could be resolved in the future by performing an anti-TRIM21 
immunoprecipitation followed by a native gel electrophoresis and analysis of the 
binding partners by mass spectrometry. A confirmation of the putative new but 
necessary member of the TRIM21-GBP1 complex would then need to be performed. 
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Alternatively, the BioID technique could also be used. It would consist in fusing either 
TRIM21 or GBP1 with a promiscuous BirA biotin ligase, so that any interacting 
protein in close proximity would be biotinylated and could thus be immunoprecipitated 
with streptavidin and further identified by mass spectrometry. 
Despite their identification in 1983, little is known about the biological relevance of 
IFNγ-induced mouse guanylate binding proteins after Toxoplasma infection. Which 
cellular functions this class of IFNγ-inducible GTPases mediate is currently vaguely 
defined at best. Considering GBP1 and TRIM21 colocalise together at the PV of 
avirulent Toxoplasma, I hypothesised that the GBPs provide the cell with a recognition 
system to distinguish avirulent from virulent Toxoplasma, and they co-recruit their 
effector molecules to the vacuole to position them to exert their anti-pathogenic effect. 
This theory was initially reinforced by the observation that GBP1 and TRIM21 
corecruitment to avirulent Toxoplasma is impaired by the secretion of parasitic 
virulence factors, implying that the absence of GBP1 at the vacuole leads to an altered 
presence of TRIM21 as well (see section 3.2.10). However, localisation studies of the 
individual interaction partners in cells lacking their counterpart reveals that TRIM21 
is partly mediating the recruitment of GBP1 to avirulent vacuoles, whereas GBP1 
deficiency does not alter TRIM21 accumulation around the parasite (see section 3.2.9). 
Thus, it is likely that TRIM21 plays the role of the primary sensor and recruits its 
effector GBP1 to the avirulent Toxoplasma vacuole. 
The role of TRIM21 has mainly been described during the course of viral infection in 
the mouse. Mallery et al. who demonstrated that TRIM21 mediates an intracellular 
antibody response have disputed the dogma that antibodies do not have an intracellular 
function. They showed that TRIM21 binds to invading antibody-coated adenoviruses 
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and targets them to degradation by the proteasome due to its E3 ligase activity (Mallery 
et al., 2010), thereby enabling to control viremia in vivo (Vaysburd et al., 2013). The 
in vitro experiments reported in this work have been performed in medium 
supplemented with FCS, where antibodies can hence be present. As a result, it remains 
to be assessed whether the recruitment of TRIM21 and GBP1 to avirulent Toxoplasma 
vacuoles is dependent on antibodies. However in this study, I demonstrate that 
TRIM21 mediates Lys63-linked ubiquitination in the vicinity of avirulent Toxoplasma 
(see section 3.2.11). Interestingly, as assessed by killing assay and ultrastructural 
analysis of the integrity of the PV membrane, the TRIM21-mediated ubiquitination 
around Toxoplasma does not lead to the degradation of the parasite (see section 3.2.12) 
in contrast to its role during viral infection. TRIM21 acts on a non cell-autonomous 
level during Toxoplasma infection by a mechanism that still needs elucidation. In fact, 
assessment of the mRNA and protein levels of several inflammatory molecules did not 
indicate a role for TRIM21 in mediating immune signalling in vitro. 
Although TRIM21 is one of the GBPs partner molecules operating at the avirulent 
Toxoplasma vacuole, it is undoublty not the sole E3 ubiquitin ligase depositing 
ubiquitin at the vicinity of the parasite, as can be deduced from the remaining 
ubiquitination level around the PV in TRIM21-deficient cells (see section 3.2.11). 
These additional E3 ubiquitin ligases, as well as their recruitment kinetics and targets, 
are still to be identified and characterised. One other candidate is the E3 ubiquitin 
ligase TRAF6, that we recently shown to mediate IRGM-dependent ubiquitination of 
avirulent Toxoplasma vacuoles, thereby promoting the recruitment of the autophagy 
protein p62 and of the GBPs (Haldar et al., 2015). Thus, as p62 recruitment to avirulent 
vacuoles is not impaired in TRIM21-deficient cells, we propose that TRIM21 acts 
downstream of the E3 ligase TRAF6 and the autophagy protein p62, by complexing 
Chapter 3: Results 
 174 
with GBP1 in the cytoplasm and promoting its recruitment to TRAF6-positive and 
ubiquitin-positive Toxoplasma PVs via regulation of GBP1 ubiquitination. The 
question remains whether other ubiquitin adaptor proteins such as NDP52 are involved 
in the direction of GBPs to the vacuoles. 
TRIM21 comprises three N-terminal protein domains: a RING domain involved in 
protein-protein interactions that endows it with an E3 ligase activity, two B-box 
domains that are zinc-binding motifs and a helical coiled-coil domain important for 
protein-protein interactions (Reymond et al., 2001; Ottosson et al., 2006). TRIM21 is 
also characterised by a C-terminal B30.2/PRYSPRY domain that was shown to 
strongly bind to the Fc part of antibodies (Rhodes and Trowsdale, 2007; Keeble et al., 
2008). It is tempting to speculate that the E3 ligase activity of TRIM21 mediates the 
Lys63-linked ubiquitination at the vicinity of avirulent Toxoplasma. I have generated 
retroviral constructs for wild-type TRIM21 as well as for TRIM21 mutants lacking the 
RING domain (∆RING), the B-box domain (∆B-box) or the B30.2 domain 
(∆PRYSPRY). I have already produced the corresponding retroviruses, which will be 
used in the future to reintroduce the wild-type or mutant proteins in TRIM21-deficient 
cells to study their effect on the ubiquitination of avirulent Toxoplasma, as well as the 
recruitment of GBP1 to the vacuoles. 
Similarly, it is very appealing to define TRIM21 ubiquitination substrates around the 
avirulent Toxoplasma vacuoles, whether host or parasite proteins. Preliminary results 
from stable isotope labelling with amino acids in cell culture identified several 
members of the family of IFNγ-induced large GTPases to be differentially 
ubiquitinated in the absence of TRIM21 (see section 3.2.14.4). Indeed, GBP2 and 
VLIG1 were found to be more ubiquitinated in TRIM21-deficient mouse embryonic 
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fibroblasts, while GBP1 was less ubiquitinated. The increased ubiquitination of GBP2 
and VLIG1 could be explained by either a downregulation of a deubiquitinase activity, 
or compensatory ubiquitination by other E3 ubiquitin ligases. For example, it has been 
shown that the expression of other TRIM proteins, some of them bearing E3 ligase 
activities, is upregulated in TRIM21-deficient fibroblasts (Yoshimi et al., 2009). The 
decreased ubiquitination of GBP1 in TRIM21-deficient cells could explain the 
decreased Lys63-linked ubiquitination around avirulent Toxoplasma observed in 
TRIM21 KO cells, as well as the decreased recruitment of GBP1 to avirulent vacuoles. 
This would imply that TRIM21 mediates the recruitment of GBP1 via the 
ubiquitination process, thereby altering GBP1 antiparasitic activity. However, the 
SILAC results and the RNAseq data also show that the protein abundance of both 
GBP1 and GBP2 is altered in cells lacking TRIM21 (see section 3.2.14.3). As a 
consequence, one cannot exclude that the differential ubiquitination profile of the 
GTPases is simply due to a difference in the protein level in TRIM21-deficient cells. 
To address this, a new SILAC experiment with a targeted quantification of the GBPs 
protein levels as well as with a targeted analysis of the GBPs diGLY sites would enable 
to assess whether the ubiquitination patterns observed are real. Moreover, the 
difference in ubiquitination profiles will be confirmed by immunoprecipitating 
ubiquitinated proteins in wild-type and TRIM21 KO cells and immunoblotting for 
GBP1 or GBP2. 
Considering TRIM21 does not mediate cell-autonomous restriction of Toxoplasma, 
we performed RNAseq in order to discover what biological pathways are differentially 
regulated in Toxoplasma infected TRIM21-deficient mouse embryonic fibroblasts 
compared to infected wild-type cells. Very strikingly, multiple regulators of the 
cholesterol biosynthesis pathway are upregulated in infected TRIM21 KO cells. 
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Additionally, pathways related to the activation of hepatic stellate cells and the 
activation of the liver X receptor, involved in cholesterol storage and metabolism, 
respectively, appear to be also differentially regulated in TRIM21-deficient cells 
infected with avirulent Toxoplasma. It is thus likely that TRIM21 downregulates the 
biosynthesis of cholesterol, possibly mainly in the liver which is the organ where 
cholesterol is sequestrated. This is of particular importance, as Toxoplasma has been 
reported to be auxotroph for cholesterol (Coppens et al., 2000). As a consequence, 
TRIM21 could act at the transcriptional level by downregulating the level of 
cholesterol available, thereby impairing Toxoplasma replication.  
Finally, the possible role of TRIM21 during Toxoplasma infection remains to be 
investigated in human cells. Earlier this year, TRIM21 has been identified as one of 
eight E3 ubiquitin ligases present at the Legionella-containing vacuoles in human 
macrophages (Bruckert and Abu Kwaik, 2015). Preliminary data in the Frickel 
laboratory suggest avirulent Toxoplasma is decorated with Lys63-linked ubiquitin in 
IFNγ-stimulated non-hematopoietic cells (personal communication, Dr. Barbara 
Clough, unpublished data). It would thus be interesting to assess whether TRIM21 
recruits to avirulent vacuoles in human cells and mediates the IFNγ-dependent Lys63-
linked ubiquitination like it does in the mouse cells. Shall TRIM21 prove to decorate 
Toxoplasma vacuoles in human cells, its precise role could be further studied by 
knocking out the Trim21 gene using the recently developed CRISPR technology. 
In summary, I have identified the E3 ubiquitin ligase TRIM21 as the first GBP1 
interaction partner at the vacuole of avirulent Toxoplasma. Mediating the 
ubiquitination of GBP1 and its recruitment to the vacuole, TRIM21 is an important 
effector molecule in the IFNγ-induced non cell-autonomous resistance to Toxoplasma 
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in the in vitro mouse model (Figure 3.30). This complex and cooperative mechanism 
between TRIM21 and GBP1 highlights a new host defence mechanism against the 
intracellular pathogen. The consequences of the deletion of the newly discovered 













Figure 3.1: The ubiquitination process. 
Ubiquitination is an ATP-dependent post-translational modification process by which a molecule of 
ubiquitin is attached to a substrate protein. Ubiquitin is activated by an E1 ubiquitin-activating enzyme, 
resulting in the formation of a thioester linkage between the C-terminus of ubiquitin and an active 
cysteine on the E1 enzyme. As an E2 ubiquitin-conjugating enzyme binds to both the E1 enzyme and 
the activated ubiquitin, the ubiquitin is then transferred to an active cysteine on an E2 enzyme. Finally, 
an E3 ubiquitin ligase enzyme interacts with both the E2 enzyme and the substrate. The E3 ubiquitin 
ligase catalyses the transfer of ubiquitin from the E2 enzyme to the target protein, resulting in an 
isopeptide bond between the C-terminal glycine of the ubiquitin molecule and a lysine on the substrate 
protein. The process is repeated until a ubiquitin chain is formed. The ubiquitin-labelled protein is then 
either degraded into peptides by the proteasome, releasing free ubiquitin molecules, or it can regulate 
cellular processes such as the cell cycle or the immune response. Enzymes called deubiquitinases 
(DUBs) remove ubiquitin molecules from the substrate, thereby recycling the cellular pool of ubiquitin 
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Figure 3.2: Schematic structures of the human TRIM proteins. 
TRIM proteins all comprise a RING (R) domain, one or two B-box (B) domains and one coiled-coil 
(CC) domain. They are classified (C-I to C-XI) according to their C-terminal features. COS: cos-box; 
FN3: fibronectin type III repeat; ACID: acid-rich region; PHD: PHD domain; BROMO: bromodomain; 
FIL: filamin type I G domain; NHL: NCL1, HT2A and LIN41 domain; MATH: meprin and TRAF 
homology domain; ARF: ADP-ribosylation factor family domain; TM: transmembrane region. 
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Figure 3.3: Ubiquitin accumulates at the vicinity of avirulent Toxoplasma. 
a) Representative immunofluorescence confocal images of IFNγ-stimulated mouse embryonic 
fibroblasts infected with avirulent Toxoplasma expressing GFP (top panel) or virulent Toxoplasma 
expressing tomato (lower panel) and stained with ubiquitin (FK2, Enzo Life Sciences). Ubiquitin 
decorates avirulent, but not virulent Toxoplasma vacuoles. MEFs were induced with 100 U/mL IFNγ 
overnight and infected for 1h with Toxoplasma. Cells were fixed in 3% paraformaldehyde and stained 
with goat anti-mouse antibody (Molecular Probes). Nuclei were stained with Hoechst. Scale bar is 2 
μm. b) Quantification of ubiquitin-positive parasite-containing PVs in IFNγ-stimulated MEFs infected 
with virulent or avirulent Toxoplasma. Ubiquitin decorates avirulent, but not virulent Toxoplasma 
vacuoles. For each strain, at least 100 vacuoles of invaded Toxoplasma were checked for ubiquitin 
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Figure 3.4: IFNγ mediates accumulation of ubiquitin at the vicinity of avirulent Toxoplasma. 
a) Representative immunofluorescence confocal images of mouse embryonic fibroblasts infected with 
avirulent Toxoplasma expressing GFP with (top panel) or without (lower panel) IFNγ stimulation and 
stained with ubiquitin (FK2, Enzo Life Sciences). Ubiquitin decorates avirulent Toxoplasma vacuoles 
in IFNγ-stimulated cells only. MEFs were induced with 100 U/mL IFNγ overnight and infected for 1h 
with Toxoplasma. Cells were fixed in 3% paraformaldehyde and stained with goat anti-mouse antibody 
(Molecular Probes). Nuclei were stained with Hoechst. Scale bar is 2 μm. b) Quantification of ubiquitin-
positive parasite-containing PVs in MEFs infected with avirulent Toxoplasma with or without IFNγ 
stimulation. Ubiquitin decorates avirulent Toxoplasma vacuoles in IFNγ-stimulated cells only. For each 
strain, at least 100 vacuoles of invaded Toxoplasma were checked for ubiquitin recruitment. Data pooled 
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Figure 3.5: GBP1 and ubiquitin colocalise to avirulent Toxoplasma vacuoles. 
a) Representative immunofluorescence confocal images of IFNγ-stimulated mouse embryonic 
fibroblasts infected with avirulent Toxoplasma and co-stained for GBP1 (home-made antibody) and 
ubiquitin (FK2, Enzo Life Sciences). GBP1 and ubiquitin colocalise to avirulent Toxoplasma vacuoles 
in IFNγ-stimulated cells. MEFs were induced with 100 U/mL IFNγ overnight and infected for 1h with 
avirulent Toxoplasma. Cells were fixed in 3% paraformaldehyde and stained with a goat anti-rabbit 
antibody and goat anti-mouse antibody (Molecular Probes), respectively. Nuclei were stained with 
Hoechst. Scale bar is 2 μm. Plot profile analysis b) and 3D surface plot analysis c) show GBP1 and 


























Figure 3.6: Toxoplasma virulence factors interfere with GBP1 and ubiquitin colocalisation to the 
vacuole. 
Quantification of ubiquitin- and/or GBP1-positive parasite-containing vacuoles in IFNγ-stimulated 
mouse embryonic fibroblasts infected with the canonical avirulent Toxoplasma type II (Pru) and type 
III (CEP) strains, as well as with avirulent Toxoplasma type II strain transgenic for the virulent version 
of type I Rop16 (Pru Rop16I), and avirulent Toxoplasma type III strain transgenic for the type I version 
of Rop18 (CEP Rop18I). Transgenic avirulent strains expressing virulence factors show less GBP1 and 
ubiquitin colocalisation compared to their respective parental strain. For each strain, at least 100 
vacuoles of invaded Toxoplasma were checked for ubiquitin recruitment. Data pooled from two 
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Figure 3.7: TRIM21 interacts with GBP1 in an IFNγ-dependent manner. 
a) Immunoprecipitation and subsequent MS/MS analysis were performed on IFNγ-stimulatedRAW 
264.7 cells overexpressing Flag-GBP1 and infected with avirulent Toxoplasma. Unique peptides 
recovered from TRIM21 are shown in red. The number of unique peptides recovered, the total number 
of unique amino acids (# AA), and the percentage of peptide coverage are indicated in the table.       b) 
Immunoprecipitation of endogenous TRIM21 followed by immunoblot analysis of endogenous GBP1 
in IFNγ-stimulated Raw 264.7 cells infected with virulent RH or avirulent Pru Toxoplasma. c) 
Immunoprecipitation of myc-tagged TRIM21 followed by immunoblot analysis for GBP1 was 
performed in IFNγ–stimulated Raw 264.7 cells overexpressing Flag-GBP1 and myc-TRIM21 and 
infected with virulent RH or avirulent Pru Toxoplasma. Cells uninduced or induced with 100 U/mL 
IFNγ were infected for 1h with virulent RH strain or avirulent Pru strain of Toxoplasma and lysed in 
0.5% NP-40 lysis buffer. Proteins were then IP’ed with anti-TRIM21 (Santa-Cruz Biotechnology) or 
anti-myc antibody (Cell Signaling). 10 µg of input and 7.5 µL of IP were loaded on each gel. IBs 





























Figure 3.8: TRIM21 follows the recruitment pattern of GBP1 to avirulent Toxoplasma 
parasitophorous vacuoles. 
a) Representative immunofluorescence confocal images of IFNγ-stimulated mouse embryonic 
fibroblasts infected with avirulent Toxoplasma expressing GFP and stained for endogenous GBP1 (top 
panel; home-made antibody) or TRIM21 (bottom panel; Santa-Cruz Biotechnology). Both GBP1 and 
TRIM21 individually recruit to avirulent Toxoplasma in IFNγ-stimulated cells. MEFs were induced 
with 100 U/mL IFNγ overnight and infected for 1h with avirulent Toxoplasma. Cells were fixed in 3% 
paraformaldehyde and stained with a goat anti-rabbit antibody or rabbit anti-goat antibody (Molecular 
Probes), respectively. Nuclei were stained with Hoechst. Scale bar is 2 μm. b) Quantification of GBP1 
(top panel) and TRIM21 (bottom panel) localisation on the parasite-containing vacuoles. Both GBP1 
and TRIM21 recruit to avirulent Toxoplasma in an IFNγ-dependent manner. For each staining, at least 
100 vacuoles of invaded Toxoplasma were checked for GBP1 or TRIM21 recruitment. Data pooled 
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Figure 3.9: TRIM21 is preferentially recruited to GBP1-positive avirulent parasitophorous 
vacuoles of Toxoplasma. 
a) Representative immunofluorescence confocal images of IFNγ-stimulated mouse embryonic 
fibroblasts infected with avirulent Toxoplasma and co-stained for GBP1 (home-made antibody) and 
TRIM21 (Santa-Cruz Biotechnology). GBP1 and TRIM21 colocalise to avirulent Toxoplasma vacuoles 
in IFNγ-stimulated cells. MEFs were induced with 100 U/mL IFNγ overnight and infected for 1h with 
avirulent Toxoplasma. Cells were fixed in 3% paraformaldehyde and stained with a goat anti-rabbit 
antibody and rabbit anti-goat antibody (Molecular Probes), respectively. Nuclei were stained with 
Hoechst. Scale bar is 2 μm. Plot profile analysis b) and 3D surface plot analysis c) show GBP1 and 
TRIM21 exhibit a similar localisation pattern and colocalise around the avirulent Toxoplasma vacuole. 
d) Quantification of GBP1 and TRIM21 co-recruitment to the parasite-containing vacuoles. TRIM21 
mainly recruits to GBP1-positive avirulent Toxoplasma in an IFNγ-stimulated cells. For each staining, 
at least 100 vacuoles of invaded Toxoplasma were checked for GBP1 and/or TRIM21 recruitment. Data 


















































Figure 3.10: TRIM21 and GBP1 complex in the cytoplasm and recruit together to avirulent 
Toxoplasma vacuoles. 
Confocal images of the IFNγ-dependent GBP1 and TRIM21 cytoplasmic (a+b) and vacuolar (c) 
complex. Proximity-ligation assay was performed in mouse embryonic fibroblasts with (b, c) or without 
(a) stimulation with 100 U/mL IFNγ. Cells were infected for 1h with avirulent Toxoplasma expressing 
GFP (a, c), fixed in 3% paraformaldehyde and stained with rabbit anti-GBP1 (home-made) and goat 
anti-TRIM21 (Santa-Cruz Biotechnology) before ligation and polymerisation of the secondary 
antibodies (Olink Bioscience). Red signals indicate positive proximity-ligation between GBP1 and 
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Figure 3.11: TRIM21 positively regulates GBP1 recruitment to avirulent Toxoplasma. 
a) Quantification of TRIM21 localisation on the parasite-containing PVs in WT vs. GBPchr3/chr5 (GBP 
DKO, lacking all GBPs) mouse embryonic fibroblasts. Cells were induced with 100 U/mL IFNγ 
overnight and infected for 1h with avirulent Toxoplasma. Data were pooled from two independent 
experiments. Mean + SEM, unpaired t-test. b) Quantification of GBP1 localisation on the parasite-
containing vacuoles in WT vs. TRIM21 KO mouse embryonic fibroblasts. Cells were induced with 100 
U/mL IFNγ overnight and infected for 1h with avirulent Toxoplasma. Data pooled from two 























Figure 3.12: Toxoplasma virulence factors interfere with GBP1 and TRIM21 colocalisation at the 
vacuole. 
Quantification of TRIM21- and/or GBP1-positive parasite-containing vacuoles in IFNγ-stimulated 
mouse embryonic fibroblasts infected with the canonical avirulent Toxoplasma type III (CEP) strain 
and avirulent Toxoplasma type III strain transgenic for the type I version of Rop18 (CEP Rop18I). The 
transgenic avirulent strain expressing the virulence factor Rop18I shows less GBP1 recruitment as well 
as less GBP1 and TRIM21 colocalisation compared to the parental strain. For each strain, at least 100 
vacuoles of invaded Toxoplasma were checked for ubiquitin recruitment. Data pooled from two 
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Figure 3.13: Lys48 and Lys63 ubiquitin decorate avirulent Toxoplasma vacuoles. 
Representative immunofluorescence confocal images of IFNγ-stimulated WT (a) or TRIM21 KO (b) 
mouse embryonic fibroblasts infected with avirulent Toxoplasma expressing GFP and stained for Lys48 
ubiquitin (left panel; Merck Millipore) or Lys63 ubiquitin (right panel; Merck Millipore). Lys48 
ubiquitin and Lys63 ubiquitin decorate avirulent Toxoplasma vacuoles in IFNγ-stimulated cells. MEFs 
were induced with 100 U/mL IFNγ overnight and infected for 1h with avirulent Toxoplasma. Cells were 
fixed in 3% paraformaldehyde and stained with a goat anti-rabbit antibody (Molecular Probes). Nuclei 
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Figure 3.14: Lys63-linked ubiquitination around avirulent Toxoplasma vacuoles is significantly 
mediated by TRIM21. 
a) Quantification of ubiquitin- (Ub), Lys63 ubiquitin- and Lys63 ubiquitin-positive parasite-containing 
vacuoles in IFNγ-stimulated WT vs. TRIM21 KO mouse embryonic fibroblasts infected with avirulent 
Toxoplasma. TRIM21 deficiency induces a decrease in total ubiquitin and Lys63 ubiquitin 
accumulation at avirulent Toxoplasma vacuoles in IFNγ-stimulated cells. Data were pooled from three 
independent experiments. Mean + SEM, ** p<0.005, **** p<0.0001, 2-way ANOVA. b) 
Quantification of ubiquitin-, Lys63 ubiquitin- and Lys63 ubiquitin-positive avirulent Toxoplasma 
vacuoles in IFNγ-stimulated WT vs. GBPchr3/chr5 (GBP DKO, cells lacking all GBPs) mouse embryonic 
fibroblasts infected with avirulent Toxoplasma. Deletion of the GBPs does not influence the 
accumulation of ubiquitin at avirulent Toxoplasma vacuoles. Data pooled from two independent 
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Figure 3.15: TRIM21 does not mediate cell-autonomous control of Toxoplasma infection in vitro. 
a) IFNγ-induced parasite killing was assessed by quantification of the number of avirulent Toxoplasma-
forming plaques after 3 days on IFNγ-stimulated or unstimulated WT vs. TRIM21 KO mouse 
embryonic fibroblasts. IFNγ mediates the killing of avirulent Toxoplasma in both WT and TRIM21 KO 
cells. Data pooled from three independent experiments. Mean +SEM, **** p<0.0001, 2-way ANOVA. 
b) Quantification of the number of avirulent Toxoplasma-forming plaques after 3 days on IFNγ-
stimulated WT vs. TRIM21 KO mouse embryonic fibroblasts compared to unstimulated cells. 
IFNγ mediates the killing of avirulent Toxoplasma in both WT and TRIM21 KO cells. Data pooled from 
three independent experiments. Mean +SEM, unpaired t-test. c) Ultrastructural analysis of avirulent 
Toxoplasma PVM in IFNγ-stimulated WT vs. TRIM21 KO mouse embryonic fibroblasts. Cells were 
induced with 100 U/mL IFNγ overnight and infected for 1h with avirulent Toxoplasma before analysis 
by electron microscopy. The lower images are enlarged views from the upper images. Red arrows 
indicate blebbing and disruption of the parasitophorous vacuole. Deletion of TRIM21 does not impair 
the disruption of Toxoplasma parasitophorous vacuole in IFNγ-induced cells. Scale bar is 200 nm. 























Figure 3.16: TRIM21 does not mediate the recruitment of the autophagy adaptor p62 to avirulent 
Toxoplasma. 
The graph shows quantification of the localisation of p62 on the parasite-containing vacuoles in IFNγ-
stimulated mouse embryonic fibroblasts. Deletion of TRIM21 does not impair p62 recruitment to 
avirulent Toxoplasma vacuoles in IFNγ-stimulated cells. MEFs were induced with 100 U/mL 
IFNγ overnight and infected for 1h with avirulent Toxoplasma. Data pooled from two independent 
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Figure 3.17: TRIM21-deficient bone marrow macrophages exhibit equal mRNA levels of selected 
inflammatory cytokines and transcription factor following Toxoplasma infection. 
Wild-type (WT) or TRIM21 KO bone marrow-derived macrophages were induced with 100 U/mL 
IFNγ overnight and infected with avirulent Toxoplasma for several time points. Cells were then lysed 
in tri-reagent and RNA was purified and reverse-transcribed to cDNA as described in the Experimental 
Procedure. The level of expression of the depicted genes was determined by qRT-PCR relative to the 
expression of the housekeeping gene Hprt. At all times post-infection, TRIM21-deficient cells do not 
exhibit differential mRNA expression of inflammatory cytokines or transcription factor. Data shown 




Chapter 3: Results 
 195 
 
Figure 3.18: TRIM21-deficient bone marrow macrophages exhibit equal protein levels of selected 
inflammatory cytokines following Toxoplasma infection. 
Wild-type (WT) or TRIM21 KO bone marrow-derived macrophages were left uninduced or stimulated 
with 100 U/mL IFNγ overnight and infected with avirulent Toxoplasma for 24h. Supernatants were 
collected and analysed by enzyme-linked immunosorbent assay (ELISA) as described in the 
Experimental Procedure. Graphs show the level of expression of the depicted proteins. TRIM21-
deficient cells do not exhibit differential protein expression of inflammatory cytokines. Data 
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Figure 3.19: Workflow for detection and analysis of ubiquitinated proteins by SILAC. 
Schematic representation of the experimental steps performed for the identification of putative TRIM21 
ubiquitination substrates. Wildtype and TRIM21-deficient mouse embryonics fibroblasts were 
cultivated in “heavy” (13C-arginine, 13C-lysine and unlabelled proline) or “light” (12C-arginine, 12C-
lysine and unlabelled proline) medium for a minimum of 4-6 doublings to allow for a good incorporation 
of the heavy or light isotopes. Cells were induced for 16h with 100 U/mL of IFNγ and infected with 
avirulent Toxoplasma for 1h. Cells were mixed at a 1:1 ratio, proteins were extracted and submitted to 
digestion with trypsin. Ubiquitinated peptides harbouring diGLY sites were immunoprecipitated with 
an anti-diGLY antibody, and enriched ubiquitinated peptides were analysed by liquid chromatography 
coupled with mass spectrometry. UHPLC: ultra-high performance liquid chromatography; MS: mass 
spectrometry; m/z: mass-to-charge ration; Ub: ubiquitin. Adapted and reprinted with permission from 
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Figure 3.20: Assessment of the heavy isotope integration and arginine-to-proline conversion in 
cells for stable isotope labelling with amino acids in cell culture. 
Wild-type mouse embryonic fibroblasts were cultivated in “heavy” (13C-arginine, 13C-lysine and 
unlabelled proline) and “light” (12C-arginine, 12C-lysine and unlabelled proline) for a minimum of 4-6 
doublings to allow for a good incorporation of the heavy or light isotopes. a) Assessment of sufficient 
incorporation was performed using the log2 heavy/light (H/L) ratio and shows a lysine incorporation of 
93.75% (as log2(16)=4 and 1/16=0.0625) and an arginine incorporation of 98.44% (as log2(64)=6 and 
1/64=0.0156), indicating the cells had doubled enough to enable for a successful incorporation. b) 
Assessment of arginine-to-proline conversion was performed using the log2 heavy/light (H/L) ratio and 
































Figure 3.21: GBP1 and GBP2 exhibit differential protein levels in TRIM21-deficient mouse 
embryonic fibroblasts. 
Wild-type and TRIM21 KO mouse embryonic fibroblasts were cultivated in “heavy” (13C-arginine, 13C-
lysine and unlabelled proline) or “light” (12C-arginine, 12C-lysine and unlabelled proline) medium, 
induced for 16h with IFNγ and infected for 1h with avirulent Toxoplasma. A small portion of cell lysate 
was used for gross protein quantification before SILAC analysis. The graph shows all retrieved proteins 
from the quantification analysis. The thin blue diagonal line indicates the close correlation between 
forward (WT heavy/KO light) and reverse (WT light/KO heavy) samples. GBP1 (blue dot) is present 
at a higher protein level in WT cells, whereas GBP2 (red dot) is present at a higher protein level in 
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Figure 3.22: Quantification of the GBPs and IRGs protein levels in wild-type versus TRIM21-
deficient mouse embryonic fibroblasts. 
Wild-type and TRIM21 KO mouse embryonic fibroblasts were cultivated in “heavy” (13C-arginine, 13C-
lysine and unlabelled proline) or “light” (12C-arginine, 12C-lysine and unlabelled proline) medium, 
induced for 16h with IFNγ and infected for 1h with avirulent Toxoplasma. A small portion of cell lysate 
was used for gross protein quantification before SILAC analysis in both the forward (a, WT heavy/KO 
light) and reverse (b, WT light/KO heavy) experiment. The graphs show all retrieved proteins from the 
quantification analysis. GBP1 (blue dot) is present at a higher protein level in WT cells in both forward 
(a) and reverse (b) samples, whereas GBP2 (red dot) is present at a higher protein level in TRIM21 KO 
cells in both forward (a) and reverse (b) samples. Some immunity-related GTPases (IRGs, orange dots) 




























Figure 3.23: Venn diagram of the Gly-Gly-containing peptides retrieved by LC-MS/MS. 
Cell lysates of wild-type and TRIM21 KO mouse embryonic fibroblasts cultivated in “heavy” (13C-
arginine, 13C-lysine and unlabelled proline) or “light” (12C-arginine, 12C-lysine and unlabelled proline) 
medium, induced for 16h with IFNγ and infected for 1h with avirulent Toxoplasma, were digested with 
trypsin to reveal Gly-Gly (diGLY) sites remnant on digested ubiquitinated proteins. Enrichment of the 
diGLY sites was performed by immunoprecipitation with an anti-diGLY antibody, and diGLY-
containing peptides were analysed by liquid chromatography coupled to mass spectrometry (LC-
MS/MS). More diGLY sites were obtained from the WT heavy sample (2058 sites) than from the WT 





































Figure 3.24: Forward and reverse SILAC experiments show consistent ubiquitination of the 
members of the family of IFNγ-induced large GTPases. 
Cell lysates of wild-type and TRIM21 KO mouse embryonic fibroblasts cultivated in “heavy” (13C-
arginine, 13C-lysine and unlabelled proline) or “light” (12C-arginine, 12C-lysine and unlabelled proline) 
medium, induced for 16h with IFNγ and infected for 1h with avirulent Toxoplasma, were digested with 
trypsin to reveal Gly-Gly (diGLY) sites remnant on digested ubiquitinated proteins. Enrichment of the 
diGLY sites was performed by immunoprecipitation with an anti-diGLY antibody, and diGLY-
containing peptides were analysed by liquid chromatography coupled to mass spectrometry (LC-
MS/MS). The graph shows all retrieved diGLY sites from both forward (WT heavy/KO light) and 
reverse (WT light/KO heavy) samples. The thin blue diagonal line indicates the close correlation 
between forward and reverse samples. GBP1 (blue dot), GBP2 (red dots), other GBPs (green dots), 
IRGs (orange dots) and VLIG1 (pink dots) all retrieved diGLY sites indicating of ubiquitinated lysines, 
which correlate well between the two samples. GBP2 and VLIG1 have more ubiquitinated lysines in 
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Figure 3.25: Members of the family of IFNγ-induced large GTPases exhibit differential 
ubiquitination status in TRIM21-deficient cells. 
Cell lysates of wild-type and TRIM21 KO mouse embryonic fibroblasts cultivated in “heavy” (13C-
arginine, 13C-lysine and unlabelled proline) or “light” (12C-arginine, 12C-lysine and unlabelled proline) 
medium, induced for 16h with IFNγ and infected for 1h with avirulent Toxoplasma, were digested with 
trypsin to reveal Gly-Gly (diGLY) sites remnant on digested ubiquitinated proteins. Enrichment of the 
diGLY sites was performed by immunoprecipitation with an anti-diGLY antibody, and diGLY-
containing peptides were analysed by liquid chromatography coupled to mass spectrometry (LC-
MS/MS). The graphs show all retrieved diGLY sites from both forward (a, WT heavy/KO light) and 
reverse (b, WT light/KO heavy) samples. GBP2 (red dots) and VLIG1 (pink dots) have more 
ubiquitinated lysines in TRIM21 KO cells, as indicated in both forward (a) and reverse (b) samples. 
GBP1 (blue dots) shows less ubiquitinated lysines in TRIM21 KO cells as indicated in the reverse (b) 
sample. The ubiquitinated lysines on the other GBPs (green dots) and on the IRGs (orange dots) appear 
more consistent between WT and TRIM21 KO cells. 
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Figure 3.26: Quality control of the RNAseq raw data generated from wild-type and TRIM21-
deficient mouse embryonic fibroblasts with or without infection with avirulent Toxoplasma.  
Wild-type and TRIM21-deficient cells were stimulated for 16h with 100 U/mL IFNγ and infected or 
not with avirulent Toxoplasma for 1h. 100 000 live, uninfected or Toxoplasma-infected cells were sorted 
by flow cytometry and RNA was extracted as described in the Experimental procedure section. Each 
condition performed in triplicates. a) The graph shows the empirical (black dots) and fitted (red line) 
dispersion values plotted against the mean of the normalised counts. The dispersion of the nucleotide 
sequence counts obtained cluster around the red line and indicate a good coverage. b) The graph shows 
the principal component analysis (PCA) of the gene expression profiles in the 4 conditons tested: WT 
uninfected (light green), Toxoplasma-infected WT (dark green), TRIM21 KO uninfected (light blue) 
and Toxoplasma-infected TRIM21 KO (dark blue). PCA indicates triplicates within each condition 
cluster nicely together and all 4 conditions tested present different gene expression profiles. Graphs 










Chapter 3: Results 
 204 
 
Figure 3.27: Comparison of the differential gene expression across the four RNAseq samples 
generated. 
The graphs are MA plots that show the scatter plots of the fold change (log2) gene expression between 
two conditions against the mean of the normalised counts. The blue dots represent the genes 
differentially expressed with an adjusted p-value of 0.05. The two dotted blue lines represent the limits 
to define the genes whose expression has a fold change greater than 2 between the conditions compared. 
The 4 comparisons are: uninfected TRIM21 KO against uninfected wild-type (a), Toxoplasma-infected 
TRIM21 KO against uninfected TRIM21 KO (b), Toxoplasma-infected wild-type against uninfected 
wild-type (c) and Toxoplasma-infected TRIM21 KO against Toxoplasma-infected wild-type (d). 
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Figure 3.28: Cholesterol biosynthesis is substantially upregulated in Toxoplasma-infected 
TRIM21-deficient mouse embryonic fibroblasts. 
The graph represents the Ingenuity pathway analysis of differentially expressed genes in avirulent 
Toxoplasma-infected TRIM21-deficient mouse embryonic fibroblasts compared to infected wild-type 
controls. The top 10 biological pathways associated with differentially expressed genes between 
Toxoplasma-infected TRIM21 KO cells and wild-type cells are shown. Top axis represents the 
percentage overlap between input genes and genes in the pathway. Bottom axis denotes Benjamini-
Hochberg corrected –log(p-value), represented by the gold line, for pathway association. Upregulated 
genes are coloured in red, downregulated genes are coloured in green. Among the top 10 biological 
pathways associated with differentially expressed genes, 2 are involved in the biosynthesis of 








Chapter 3: Results 
 206 
 
Figure 3.29: Differential expression of genes involved in cholesterol biosynthesis in Toxoplasma-
infected TRIM21-deficient and wild-type mouse embryonic fibroblasts. 
Heat map shows hierarchical clustering of the 13 genes involved in the biosynthesis of cholesterol 
identified as differentially expressed in TRIM21-deficient mouse embryonic fibroblasts infected with 
avirulent Toxoplasma. Data show the log2 value of each triplicate within the 4 conditions tested, from 
left to right: uninfected TRIM21 KO, Toxoplasma-infected WT and Toxoplasma-infected TRIM21 KO. 
Downregulated genes are coloured in white, upregulated genes are coloured in red. Colour range 
denotes intensity of expression. Genes involved in cholesterol biosynthesis are upregulated at the steady 
state in uninfected TRIM21-deficient cells compared to uninfected wild-type controls, and this 



















Figure 3.30: TRIM21 regulates Lys63 ubiquitination and recruitment of GBP1 to avirulent 
Toxoplasma vacuoles.  
Following infection with Toxoplasma, interferon gamma (IFNγ) is the main cytokine produced. 
Signalling through its receptor (IFNγR), IFNγ activates the signal transducer and activator of 
transcription 1 (STAT1). This nuclear transcription factor in turn upregulates the expression of the 
immunity-related GTPases (IRGs), guanylate-binding proteins (GBPs) and TRIM21. The IRGs recruit 
to the avirulent Toxoplasma PV and mediate its disruption. GBP1 complexes with the E3 ubiquitin 
ligase TRIM21 in the cytoplasm and, following Lys63-linked ubiquitination, they recruit to the PV of 
avirulent Toxoplasma. TRIM21 also downregulates the biosynthesis of cholesterol, which is essential 
for the growth of the auxotroph Toxoplasma parasite. As Toxoplasma can be coated with antibodies and 
retain them once it has invaded the cell, the breakage of the PV could release the immunoglobulins in 
the host cytosol where they could serve as danger-associated molecular pattern (DAMP). Whether the 
Fc receptor TRIM21 binds to the unmasked antibody-coated Toxoplasma remains unclear. Similarly, 
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4.1 Introduction 
4.1.1 TRIM21 knockout mouse models 
In order to study the function of a protein, the mouse model can be an invaluable tool. 
Knocking out the activity of a gene in a mouse, by disrupting or replacing it, provides 
precious hints or evidence about what that gene normally does. As far as TRIM21 is 
concerned, two knockout mouse models have been generated and published in 2009. 
In the first model, Espinosa et al. disrupted the Trim21 gene by targeting exons 5 to 8. 
They reported their TRIM21 knockout mice to develop a profound lupus-like disease 
characterised by an aberrant cytokine response in all immune cells that involves the 
Th17 pathway (Espinosa et al., 2009). However, as their targeting strategy results in 
exons 1 to 4 to remain in the mouse genome and as the START codon is situated in 
exon 3, the possibility that a truncated TRIM21 protein harbouring the E3 RING 
ubiquitin ligase domain, the B-box domain and a part of the coiled-coil domain is still 
expressed could explain the observed phenotype. Moreover, the PGK-neo cassette 
used for embryonic stem cell selection has not been removed in this TRIM21 knockout 
model and could account for the inflammatory phenotype. In the second model, 
Yoshimi et al. disrupted the Trim21 gene by replacing exons 3 to 5 with EGFP, thereby 
including the translation start site. The absence of TRIM21 was confirmed at the 
protein level, and their mouse model does not develop any abnormal developmental 
or physiological phenotype. It is of note that although the composition of the immune 
cells population and their immune response was comparable to that of wild-type mice, 
the production of IL-1β, TNFα, IL-6, and CXCL10 was enhanced in TRIM21-
deficient fibroblasts (Yoshimi et al., 2009). The latter TRIM21 knockout mouse has 
now been established as the reference model to study TRIM21 in vivo. 
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4.1.2 TRIM21 in viral in vivo infection 
Yoshimi et al.’s TRIM21 knockout mouse model has recently been used to study the 
role of the protein during infection with mouse adenovirus 1 (MAV-1). Indeed, 
Vaysburd et al. reported that TRIM21-deficient mice are more susceptible to MAV-1 
infection and exhibit higher viral load in the brain but no differential serum 
inflammatory cytokine production compared to wild-type controls. In addition, this 
TRIM21-dependent mediation of adenoviral infection was shown to be linked to the 
intracellular Fc binding property of the protein, as TRIM21-deficient mice injected 
with protective antisera still succumb to fatal viral infection whereas wild-type mice 
can control viremia and are hence rescued by serum passive transfer (Vaysburd et al., 
2013). Altogether, these results highlight the role of TRIM21 in the humoral response 
to mouse adenovirus infection. This study remains the sole in vivo investigation of the 
role of TRIM21 during any infection to date. 
4.1.3 Aims 
Initial work reported in this thesis has centered on the impact of TRIM21 during 
Toxoplasma infection in vitro, highlighting its role in Lys63-linked ubiquitination of 
avirulent Toxoplasma vacuoles, in the regulation of some GBPs and in mediating 
cholesterol biosynthesis. However, the biological relevance for TRIM21 during 
Toxoplasma infection at the organismal level remains to be elucidated. The importance 
of TRIM21 in eukaryotic infection models is poorly addressed in the literature. What 
phenotype do TRIM21-deficient mice develop upon Toxoplasma infection? Can they 
also control parasite burden in vivo? What correlates with the absence of TRIM21 at 
the avirulent Toxoplasma vacuole? This section investigates the consequences of the 
deletion of TRIM21 in the in vivo mouse model of Toxoplasma infection. 
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4.2 Results 
4.2.1 Oral infections with Toxoplasma cysts 
The major natural route of infection with Toxoplasma in humans is oral with 
bradyzoite cysts or oocysts, after ingesting contaminated food or water. In the rodent 
animal model, this is mimicked by orally infecting the mice with bradyzoites of a type 
II avirulent strain of Toxoplasma called ME49, a clone of the type II Pru strain used 
previously. In order to reproduce the most biologically relevant model of infection, I 
first infected wild-type controls and TRIM21-deficient mice per os with 10 or 40 cysts 
and followed the outcome by assessing the overall condition of the animals. TRIM21-
deficient mice were generated on the C57BL/6 genetic background, which are 
naturally susceptible to oral infection with Toxoplasma and usually succumb during 
the acute phase (Munoz et al., 2011). Following oral infection with 10 or 40 avirulent 
Toxoplasma ME49 cysts, both the wild-type and TRIM21-deficient animal had to be 
sacrificed 7 days post-inoculation. This suggests that TRIM21 knock out does not 
confer a disadvantage during Toxoplasma infection. The production of 32 cytokines 
in the serum of wild-type and TRIM21-deficient mice was assessed at 3 and 7 days 
post-infection for both infectious doses tested. TRIM21-deficient mice infected with 
40 Toxoplasma cysts exhibit a slight but significantly decreased level of the neutrophil 
chemoattractant LIX at 3 days post-infection, as well as a slight but significantly 
increased level of the monocyte chemotactic protein 1 (MCP-1) at 7 days post-
infection (Figure 4.1). Moreover, TRIM21-deficient mice infected with 10 
Toxoplasma cysts exhibit slight but significantly lower levels of IL-9 and macrophage 
colony-stimulator factor (M-CSF) at 3 days post-infection, as well as a slight but 
significantly decreased level of IL-1β at 7 days post-infection (Figure 4.2). As these 
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cytokine profiles differ according to the infectious dose, this suggests that the response 
to infection is modulated depending on the parasite dose inoculated. However, since 
both TRIM21-deficient and wild-type mice succumb to acute Toxoplasma infection, 
no conclusions on the immunological mechanism can be drawn from these results. 
Finally, a very low infection dose of 5 avirulent Toxoplasma ME49 cysts was 
inoculated into experimental mice. As can be seen on Figure 4.3, although the animals 
survived the infection longer than after infection with 10 or 40 cysts, both wild-type 
and TRIM21-deficient mice succumb to infection at a very similar rate and presented 
a similar weight loss (Figure 4.3). This indicates that TRIM21 does not negatively 
impact the resistance to Toxoplasma infection in the oral infection mouse model. 
However, TRIM21 KO animals often appeared sicker, presenting stronger 
manifestations of the typical signs of Toxoplasma infection such as ruffled fur, 
hunched position and even immobility. However, as it is difficult to assess whether 
TRIM21 enhances susceptibility during Toxoplasma infection in the mouse model 
where the wild-type controls are already susceptible, the oral infection was abandoned 
and the intraperitoneal route of infection was favoured for the rest of the study. 
4.2.2 Intraperitoneal infections with Toxoplasma tachyzoites 
4.2.2.1 TRIM21-deficient mice infected intraperitoneally are susceptible to 
Toxoplasma infection 
As opposed to oral infection, mice on the C57BL/6 background are resistant to 
peritoneal infection with Toxoplasma during the acute phase of the infection (Munoz 
et al., 2011). However, bradyzoite cysts and oocysts ingested orally both convert to 
tachyzoites in the host’s gut. As a result, intraperitoneal infection of tachyzoites is 
another commonly used in vivo mouse model. Thus, wild-type and TRIM21-deficient 
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mice were infected intraperitoneally with 5x104 avirulent type II Toxoplasma 
tachyzoites genetically engineered to express firefly luciferase. In contrast to the wild-
type controls, TRIM21-deficient mice are highly susceptible to infection and succumb 
during the acute phase of the infection, at 7 to 10 days post-inoculation. At 10 days 
post-infection, 77% of the TRIM21-deficient mice had succumbed to infection while 
83% of the control mice had survived (Figure 4.4a). Both wild-type and TRIM21-
deficient mice show a similar pattern of weight loss (Figure 4.4b), but TRIM21-
deficient mice exhibit a significantly higher clinical score (characterised by 
piloerection, hunching and reduced motility) from day 7 post-infection on (Figure 
4.4c). These results suggest TRIM21 participates in the resistance against Toxoplasma 
infection in vivo.  
4.2.2.2 TRIM21-deficient mice can mostly control parasite replication in the 
periphery 
The different mouse knockout models infected with Toxoplasma so far generally 
succumb to infection due to an unchecked parasite replication, sometimes 
accompanied with a cytokine storm (Yarovinsky, 2014). In order to determine the 
cause of TRIM21-deficient mice death, I followed the progression of the parasite 
burden in infected mice using in vivo imaging. As the Toxoplasma strain is engineered 
to express firefly luciferase, mice were injected with the enzyme’s substrate luciferin 
during the acute phase of infection at days 3, 5 and 7 post-inoculation. The higher the 
parasite load, the higher the luminescence signal measured is in infected animals. As 
can be seen in Figure 4.5, wild-type and TRIM21-deficient mice already present a high 
parasite load at day 3 of infection. At 5 days post-infection, TRIM21-deficient mice 
exhibit a significantly higher parasite burden compared to wild-type controls, but this 
difference disappears at 7 days post-infection when the knockout mice start dying. 
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These results indicate that TRIM21-deficient mice can mostly control Toxoplasma 
replication in the periphery, and is in accordance with the in vitro plaque assay data 
(see section 3.2.12). 
4.2.2.3 TRIM21-deficient mice exhibit a decreased level of serum pro-
inflammatory cytokines 
TRIM21 mediates the upregulation of IL-12p40 expression, a cytokine important for 
innate immunity in macrophages and involved in the stimulation of IFNγ production 
via interaction and ubiquitination of IRF8 (Kong et al., 2007). TRIM21 has also been 
shown to downregulate NF-B signalling in embryonic fibroblasts, leading to higher 
expression of pro-inflammatory cytokines (Yoshimi et al., 2009). Apart from 
unchecked parasite replication, infection with Toxoplasma can lead to a lethal hyper-
immune response. Thus, I hypothesised that TRIM21 confers resistance to 
Toxoplasma infection by controlling cytokine levels to mediate immune responses 
rather than through direct labelling of the parasite for degradation. Therefore, I 
assessed the protein levels of cytokines and chemokines in the serum at 3 and 7 days 
post-infection. At the first time point corresponding to the early stage of infection, no 
difference was observed in the levels of serum pro-inflammatory cytokines (Figure 
4.6). However at 7 days post-infection, corresponding to the time when mice start to 
succumb to the parasitic infection, TRIM21-deficient mice exhibit lower levels of 
IFNγ, IL-6, IL-10, IL-12p40, IFNγ-inducible protein 10 (IP-10) and MCP-1. 
Additionally, TRIM21-deficient mice show significantly decreased levels of regulated 
on activation, normal T cell expressed and secreted protein (RANTES) and of TNFα 
(Figure 4.6), cytokines and chemokines that are all induced by the NF-B-mediated 
cytokine production signalling pathway.  
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Moreover, analysis by enzyme-linked immunosorbent assay (ELISA) of the protein 
levels of selected cytokines in the serum of mice infected for 7 days further confirmed 
the downregulation of IFNγ in TRIM21-deficient mice, while the levels of the type I 
interferons IFNα and IFNβ are not impacted by the absence of TRIM21 (Figure 4.7a). 
Interestingly, the level of IL-1β was significantly lower in the serum of TRIM21-
deficient mice when measured by ELISA (Figure 4.7a). Finally, the protein levels of 
IFNγ, IL-12p40 and TNFα are not different in the peritoneum of TRIM21-deficient 
mice compared to wild-type controls, whereas the decreased level of IL-1β in the 
serum is also present in the peritoneum of TRIM21-deficient mice infected for 7 days 
(Figure 4.7b). These results suggest TRIM21 mediates resistance to Toxoplasma 
infection in vivo by inducing the production of pro-inflammatory cytokines, mainly in 
the serum. 
4.2.2.4 TRIM21-deficient mice do not exhibit a differential recruitment of 
immune cells to the sites of infection 
The components of the immune system can be divided in two categories. The primary 
lymphoid organs consist of the bone marrow and the thymus. The secondary lymphoid 
organs consist of the spleen, the lymph nodes and the Peyer’s patches. In order to 
determine what cells could be involved in the dramatic survival phenotype as well as 
the differential level of cytokines in the serum, we performed a phenotyping of the 
immune cells in the peritoneum and the secondary lymphatic organs by flow 
cytometry. First, different populations of innate cells were analysed in a total of 4 
independent experiments. The frequency and total cell number of neutrophils, 
dendritic cells, macrophages and inflammatory monocytes were determined each time, 
but no tendency or significant difference could be reproduced twice so that the analysis 
of the innate cells did not lead to any conclusive result. An example of the analysis can 
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be seen in Figure 4.8. Second, different populations of lymphocytes were analysed in 
a total of 2 to 4 independent experiments. The frequency and total cell number of B 
cells, T cells, NK cells, CD4 T cells, CD8 T cells, NK IFNγ+ cells, CD4 IFNγ+ cells 
and CD8 IFNγ+ cells were determined in each experiment in the peritoneum (Figure 
4.9), the spleen (Figure 4.10), the Peyer’s patches (Figure 4.11), the mesenteric lymph 
nodes (Figure 4.12) and the draining lymph nodes (Figure 4.13). Similarly to the innate 
cells, no tendency or significant difference in the frequency of cell number could be 
reproduced twice, thus the phenotyping of the lymphocytes did not lead to any 
conclusive results. Examples of the analysis performed for each organ can be seen 
from Figure 4.9 to Figure 4.13. These results suggest it is likely that there is no clear 
and definite impact of TRIM21 deficiency on the proliferation, recruitment or 
activation of the immune cell populations during Toxoplasma infection. 
4.2.2.5 TRIM21 deficiency does not lead to immunopathology  
As TRIM21-deficient mice exhibit a high mortality characterised by an increased 
parasite burden at 5 days post-infection and a decrease in serum inflammatory 
cytokines at 7 days post-inoculation, I checked for tissue and organ damage or 
malfunction by measuring the level of specific biomarkers in the serum of mice 
infected for 7 days. The panel of biomarkers included detection of liver damage and 
abnormal function (albumin, alanine aminotransferase, aspartate aminotransferase and 
bilirubin), tissue damage (lactate and lactate dehydrogenase), kidney failure (urea), 
pancreas failure (lipase), lipid metabolism (cholesterol, low density lipoprotein 
cholesterol, and triglycerides). As can be seen in Figure 4.14, no abnormal level in any 
biomarker was detected in TRIM21-deficient mice compared to wild-type controls.  
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These observations were further confirmed by histopathology. Livers, spleens, lungs 
and brains from wild-type and TRIM21-deficient mice infected for 7 days with 
avirulent Toxoplasma were sent for pathology examination. Prof. Cheryl Scudamore 
(MRC Harwell) could not detect any abnormal levels of liver peritonitis, inflammation 
and necrosis (Figure 4.15a), and examination revealed equal levels of spleen 
peritonitis, extramedullary haematopoiesis and apoptosis (Figure 4.15b). Moreover, 
Prof. Gordon Stamp (Imperial College London) did not report any abnormal pathology 
in lungs and brains of TRIM21-deficient mice (data not shown). Altogether, these 
results imply TRIM21-deficient mice do not succumb to Toxoplasma infection from 
organ damage or failure. 
4.2.2.6 TRIM21-deficient mice exhibit higher parasite load and decreased 
number of microglia in the brain 
So far TRIM21 deficiency has been shown to lead to an increased parasite load at the 
periphery at 5 days post-infection, accompanied with a decreased level of 
inflammatory cytokines in the serum at 7 days post-infection. However, this does not 
lead to immunopathology in the periphery. As Toxoplasma tachyzoites ultimately 
migrate to the brain where they convert into the slow replicating bradyzoites, I 
assessed the number of parasites in this organ. Although the overall parasite burden 
has been investigated by in vivo imaging, it does not include what is happening in the 
brain due to the fact that the luminescence signal cannot be detected through the skull. 
Brains were isolated at 7 days post-infection and the GFP-expressing Toxoplasma 
were counted in wild-type and TRIM21-deficient samples in a blind fashion. In a 
consistent manner, TRIM21-deficient mice that presented rough physical conditions 
typical of infection with Toxoplasma exhibit higher parasite counts than healthy wild-
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type animals (Figure 4.16a). Thus, TRIM21-deficient mice cannot control the parasite 
replication in or migration to the brain. 
Furthermore, the immune cell populations in the brain of mice infected for 7 days with 
avirulent Toxoplasma were analysed by flow cytometry. In two independent 
experiments, the total number of microglial cells was consistently decreased in 
TRIM21-deficient mice, and this was associated with a frequency of microglia that 
was strongly decreased in one experiment (Figure 4.16b). As both naïve wild-type and 
TRIM21-deficient mice present the same number of microglial cells, it is likely that 
this population of resident myeloid cells of the central nervous system does not 
proliferate following Toxoplasma infection in the absence of TRIM21. Although a 
significant increase in the frequency of infiltrate cells can be observed in Figure 4.16b, 
the reverse phenomenon was seen in the previous experiment (data not shown). As far 
as the lymphocyte population is concerned, a significant increase in the frequency and 
total number of CD3+ T cells, as well as a significant decrease in the frequency of 
CD4+ T cells, were observed in TRIM21-deficient cells in one experiment (Figure 
4.16c), while the reverse was spotted in the previous experiment. Thus, the 
phenotyping of infiltrate cells and lymphocytes remains inconclusive for now. 
4.2.2.7 TRIM21-deficient mice present decreased transcripts involved in the 
immune inflammatory response 
To understand what happens in the brain of a TRIM21-deficient mouse infected with 
avirulent Toxoplasma compared to a wild-type control, I performed a transcriptional 
analysis of the genes encoding for cytokines and chemokines or involved in 
neuroinflammation. A total of 164 targets were screened by quantitative PCR, out of 
which four show a significantly decreased expression level in infected TRIM21-
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deficient animals (Figure 4.17). Indeed, type I interferon alpha (Ifna2), the pro-
inflammatory cytokine IL-6 (Il6), the leukocyte adhesion regulator integrin alpha M 
(Itgam) and the immune modulatory peptide prokineticin 2 (Prok2) all exhibit lower 
mRNA levels in the brain of mice lacking TRIM21. This indicates that the higher 
parasite burden and the lower number of microglial cells in the brain of TRIM21-
deficient mice is accompanied by a decreased transcriptional expression of genes 
involved in the immune inflammatory response. The expression profile of the 
remaining genes analysed can be found in the Appendix. 
4.3 Discussion 
So far, the role of TRIM21 has only been described during the course of viral infection 
in the mouse model. TRIM21 has been reported to bind to invading antibody-coated 
adenoviruses and target them to degradation by the proteasome due to its E3 ligase 
activity (Mallery et al., 2010), as well as to modulate the production of pro-
inflammatory cytokines during viral infection (McEwan et al., 2013), thereby enabling 
to control viremia in vivo (Vaysburd et al., 2013). Our in vitro findings suggest 
TRIM21 participates in the response to Toxoplasma infection by mediating the 
ubiquitination status of the guanylate binding proteins around the parasitophorous 
vacuole. However, the consequences of these observations remain unclear. The aim of 
this work was to shed light on the consequences of TRIM21 deficiency during murine 
Toxoplasma infection at the organismal level. 
In this thesis, I report for the first time the role of TRIM21 in in vivo resistance against 
a eukaryotic intracellular pathogen. Indeed, I show that TRIM21-deficient mice are 
highly susceptible to infection with Toxoplasma. Mice infected intraperitoneally with 
an avirulent strain of the parasite succumb during the acute phase of the infection, 
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between day 7 and 10. This kinetic strongly resembles the survival rate observed in 
IFNγ- and IL-12-deficient mice, the two known major mediators of the resistance 
against the apicomplexan parasite (Scharton-Kersten et al., 1996; Gazzinelli et al., 
1994; Yap et al., 2000). Moreover, this survival pattern also mimics the one already 
reported in MyD88- and UNC93B-deficient mice, two proteins downstream of the 
TLR response and essential for activation of immune signalling (Scanga et al., 2002; 
Sukhumavasi et al., 2008; Melo et al., 2010). Thus, this places TRIM21 as another, 
new important player in the control of Toxoplasma infection. 
Several parameters were investigated in this work in order to assess the cause of death 
in TRIM21-deficient mice infected with avirulent Toxoplasma. In vivo imaging 
allowed to follow the evolution of the parasite replication and showed TRIM21-
deficient mice exhibit a higher parasite burden at 5 days post-infection, before the 
critical point when mice start succumbing to infection. At 7 days post-inoculation, the 
death of infected mice lacking TRIM21 correlates with a higher parasite load in the 
brain. This unchecked parasite replication is accompanied with a significant decrease 
in the total number of microglial cells and in the transcriptional expression levels of 
inflammatory cytokines in the brain. My results also show that TRIM21-deficient mice 
present a significantly lower secretion of inflammatory cytokines in the serum and do 
not exhibit any abnormal pathology. Taken together, these data suggest TRIM21 
mediates the upregulation of inflammatory cytokines necessary to control avirulent 
Toxoplasma replication. Failing to do so leads to an increased parasite burden in the 
periphery and subsequently in the brain, where microglia appear not to activate and 
proliferate. The exact mechanisms by which TRIM21 regulates the production of 
inflammatory cytokines as well as what causes the defect in microglia activation 
remain to be elucidated. As TRIM21 has been reported to regulate the antiviral 
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response by the production of Lys63-ubiquitin chains (McEwan et al., 2013), I 
hypothesise that the E3 ubiquitin ligase activity of TRIM21 is essential also to mediate 
immune signalling during Toxoplasma infection. This could be investigated in the 
future by the generation of a mouse line expressing a mutant TRIM21 protein lacking 
the RING E3 ubiquitin ligase domain. 
One controversial property of TRIM21 recently brought to the fore is its ability to bind 
to intracellular antibody-coated adenoviruses (Mallery et al., 2010). Toxoplasma has 
also been reported to retain antibodies once inside the host cell (Dubremetz et al., 
1985). In the lab, preliminary work showed that avirulent Toxoplasma tachyzoites 
isolated from the peritoneum of a C57BL/6 mouse are mainly coated with IgG, while 
parasites isolated from the peritoneum of µMT mice lacking B cells and hence 
circulating antibodies, do not harbour any antibody (Figure 4.18a, c). Very 
interestingly, these preliminary data also show that avirulent Toxoplasma isolated 
from the immune privilege brain of a C57BL/6 mouse are mainly coated with IgM 
(Figure 4.18b, c). How this differential antibody decoration influences the immune 
response to the parasite at the site of infection remains unknown. As B cell-deficient 
mice die of a high parasite load in the brain (Kang et al., 2000), it is tempting to 
hypothesise that TRIM21 and antibodies act in concert during Toxoplasma infection, 
such that TRIM21 could sense antibody-coated parasites like it does detect 
adenoviruses. However, this hypothesis would prove to be difficult to test in vivo, as 
even backcrossing TRIM21-deficient mice on the µMT genetic background would not 
help determine the individual or combined role of TRIM21 and antibodies. 
In summary, I have identified TRIM21 as an important mediator of in vivo resistance 
against a eukaryotic pathogen, Toxoplasma. TRIM21-deficient mice succumb to 
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avirulent Toxoplasma infection during the acute phase, and the death correlates with 
an enhanced parasite load in the brain accompanied with decreased inflammatory 
cytokines and microglial cells. The newly discovered implication of TRIM21 in 
Toxoplasma infection suggests that resistance mechanisms yet to be determined 
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Figure 4.1: Production of serum cytokines in TRIM21-deficient mice following infection with 40 
cysts of avirulent Toxoplasma. 
The serum of wild-type and TRIM21-deficient mice infected per os with 40 cysts of avirulent 
Toxoplasma was collected at 3 and 7 days post-infection (dpi). Cytokine levels were measured using 
multiplex at Eve Technology as described in the Experimental Procedure. TRIM21-deficient mice show 
decreased levels of serum LIX at 3 dpi, and decreased levels of MCP-1 at 7 dpi. Mean + SEM, * p<0.05, 
unpaired t-test. 
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Figure 4.2: Production of serum cytokines in TRIM21-deficient mice following infection with 10 
cysts of avirulent Toxoplasma. 
The serum of wild-type and TRIM21-deficient mice infected per os with 10 cysts of avirulent 
Toxoplasma was collected at 3 and 7 days post-infection (dpi). Cytokine levels were measured using 
multiplex at Eve Technology as described in the Experimental Procedure. TRIM21-deficient mice show 
decreased levels of serum M-CSF at 3 dpi, and decreased levels of IL-1β at 7 dpi. Mean + SEM, * 
p<0.05, unpaired t-test. 
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Figure 4.3: Survival of TRIM21-deficient mice infected with a low dose of avirulent Toxoplasma 
cysts. 
Wild-type and TRIM21-deficient mice were infected per os with 5 cysts of avirulent Toxoplasma. The 
survival of infected mice was monitored (a) as well as the evolution of the body weight (b). Mice 
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Figure 4.4: TRIM21-deficient mice are highly susceptible to intraperitoneal Toxoplasma infection. 
Wild-type and TRIM21-deficient mice were infected intraperitoneally with 5x104 avirulent 
Toxoplasma. The survival of infected mice was monitored (a) as well as the evolution of the body 
weight (b). The clinical score, assessed by piloerection, a hunched position and immobility, was 
measured throughout the time of the experiment (c). Mice lacking TRIM21 infected peritoneally with 
avirulent Toxoplasma are very susceptible to Toxoplasma infection and present higher clinical score 
compared to wild-type controls. Survival curves were compared by log-rank survival analysis of 
Kaplan-Meier curves, **** p<0.0001. Weight curve and clinical score are represented by mean + SEM, 
** p<0.01, *** p<0.001, **** p<0.0001, 2-way ANOVA. 
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Figure 4.5: TRIM21-deficient mice exhibit higher parasite burden in the periphery. 
Wild-type and TRIM21-deficient mice were infected intraperitoneally with 5x104 avirulent 
Toxoplasma. (a) The evolution of the firefly luciferase-expressing parasite load was controlled by in 
vivo imaging after injection of luciferin at 3, 5 and 7 days post-infection (dpi) as described in the 
Experimental Procedure. (b) Mice lacking TRIM21 infected peritoneally with avirulent Toxoplasma 
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Figure 4.6: Production of serum cytokines in TRIM21-deficient mice following infection with 
5x104 avirulent Toxoplasma. 
The serum of wild-type and TRIM21-deficient mice infected intraperitoneally with avirulent 
Toxoplasma was collected at 3 and 7 days post-infection (dpi). Cytokine levels were measured using 
multiplex at Eve Technology as described in the Experimental Procedure. TRIM21-deficient mice show 
decreased levels of serum eotaxin, RANTES and TNFα at 7 dpi. Data were pooled from three 
independent experiments. Mean + SEM, * p<0.05, unpaired t-test. 
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Figure 4.7: Production of selected serum and peritoneum cytokines in TRIM21-deficient mice 
following infection with 5x104 avirulent Toxoplasma. 
Wild-type and TRIM21-deficient mice infected intraperitoneally with avirulent Toxoplasma were 
sacrificed at 7 days post-infection (dpi) and serum (a) as well as peritoneal lavage (b) were collected. 
Cytokine levels were measured by enzyme-linked immunosorbent assay (ELISA) as described in the 
Experimental Procedure. TRIM21-deficient mice show decreased levels of serum IFNγ and IL-1β 7 
dpi. Mice lacking TRIM21 also show decreased levels of IL-1β in the peritoneum at 7 dpi. Data were 
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Figure 4.8: Analysis of innate cell populations in TRIM21-deficient mice infected with avirulent 
Toxoplasma. 
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Wild-type and TRIM21-deficient mice infected intraperitoneally with avirulent Toxoplasma were 
sacrificed at 7 days post-infection (dpi). Immune cells were isolated from the peritoneal exudate (PECs), 
spleen, Peyer’s patches (PP), mesenteric lymph nodes (mLN) and draining lymph nodes dLN). Innate 
cell populations were analysed by flow cytometry as described in the Experimental Procedure. (a) 
Representative fluorescence-activated cell sorting (FACS) plots of the live, single innate cell 
populations in wild-type and TRIM21-deficient mice following avirulent Toxoplasma infection. (b) 
Example of quantitative analysis of the innate cell populations in wild-type and TRIM21-deficient mice 
following avirulent Toxoplasma infection by frequency (left panel) and total cell number (right panel). 
Data were chosen from 2 to 4 independent experiments. Mean + SEM, * p<0.05, ** p<0.01, 2-way 
ANOVA. 
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Figure 4.9: Analysis of lymphocyte populations in the peritoneal exudate of TRIM21-deficient 
mice infected with avirulent Toxoplasma. 
Wild-type and TRIM21-deficient mice infected intraperitoneally with avirulent Toxoplasma were 
sacrificed at 7 days post-infection (dpi). Lymphocytes were isolated from the peritoneal exudate and 
lymphocyte populations were analysed by flow cytometry as described in the Experimental Procedure. 
(a) Representative fluorescence-activated cell sorting (FACS) plots of the live, single lymphocyte 
populations in the peritoneal exudate of wild-type and TRIM21-deficient mice following avirulent 
Toxoplasma infection. (b) Example of quantitative analysis of the lymphocyte populations in the 
peritoneal exudate of wild-type and TRIM21-deficient mice following avirulent Toxoplasma infection 
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by frequency (left panel) and total cell number (right panel). Data were chosen from 2 to 4 independent 
experiments. Mean + SEM, 2-way ANOVA. 
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Figure 4.10: Analysis of lymphocyte populations in the spleen of TRIM21-deficient mice infected 
with avirulent Toxoplasma. 
Wild-type and TRIM21-deficient mice infected intraperitoneally with avirulent Toxoplasma were 
sacrificed at 7 days post-infection (dpi). Lymphocytes were isolated from the spleen and lymphocyte 
populations were analysed by flow cytometry as described in the Experimental Procedure. (a) 
Representative fluorescence-activated cell sorting (FACS) plots of the live, single lymphocyte 
populations in the spleen of wild-type and TRIM21-deficient mice following avirulent Toxoplasma 
infection. (b) Example of quantitative analysis of the lymphocytes populations in the spleen of wild-
type and TRIM21-deficient mice following avirulent Toxoplasma infection by frequency (left panel) 
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and total cell number (right panel). Data were chosen from 2 to 4 independent experiments. Mean + 
SEM, ** p<0.01, 2-way ANOVA. 
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Figure 4.11: Analysis of lymphocyte populations in the Peyer’s patches of TRIM21-deficient mice 
infected with avirulent Toxoplasma. 
Wild-type and TRIM21-deficient mice infected intraperitoneally with avirulent Toxoplasma were 
sacrificed at 7 days post-infection (dpi). Lymphocytes were isolated from the Peyer’s patches and 
lymphocytes populations were analysed by flow cytometry as described in the Experimental Procedure. 
(a) Representative fluorescence-activated cell sorting (FACS) plots of the live, single lymphocyte 
populations in the Peyer’s patches of wild-type and TRIM21-deficient mice following avirulent 
Toxoplasma infection. (b) Example of quantitative analysis of the lymphocyte populations in the 
Peyer’s patches of wild-type and TRIM21-deficient mice following avirulent Toxoplasma infection by 
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frequency (left panel) and total cell number (right panel). Data were chosen from 2 to 4 independent 
experiments. Mean + SEM, * p<0.05, *** p<0.001, **** p<0.0001, 2-way ANOVA. 
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Figure 4.12: Analysis of lymphocytes population in the mesenteric lymph nodes of TRIM21-
deficient mice infected with avirulent Toxoplasma. 
Wild-type and TRIM21-deficient mice infected intraperitoneally with avirulent Toxoplasma were 
sacrificed at 7 days post-infection (dpi). Lymphocytes were isolated from the mesenteric lymph nodes 
and lymphocyte populations were analysed by flow cytometry as described in the Experimental 
Procedure. (a) Representative fluorescence-activated cell sorting (FACS) plots of the live, single 
lymphocyte populations in the mesenteric lymph nodes of wild-type and TRIM21-deficient mice 
following avirulent Toxoplasma infection. (b) Example of quantitative analysis of the lymphocyte 
populations in the mesenteric lymph nodes of wild-type and TRIM21-deficient mice following avirulent 
Toxoplasma infection by frequency (left panel) and total cell number (right panel). Data were chosen 
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Figure 4.13: Analysis of the lymphocyte populations in the draining lymph nodes of TRIM21-
deficient mice infected with avirulent Toxoplasma. 
Wild-type and TRIM21-deficient mice infected intraperitoneally with avirulent Toxoplasma were 
sacrificed at 7 days post-infection (dpi). Lymphocytes were isolated from the draining lymph nodes and 
lymphocyte populations were analysed by flow cytometry as described in the Experimental Procedure. 
(a) Representative fluorescence-activated cell sorting (FACS) plots of the live, single lymphocyte 
populations in the draining lymph nodes of wild-type and TRIM21-deficient mice following avirulent 
Toxoplasma infection. (b) Example of quantitative analysis of the lymphocyte populations in the 
draining lymph nodes of wild-type and TRIM21-deficient mice following avirulent Toxoplasma 
infection by frequency (left panel) and total cell number (right panel). Data were chosen from 2 to 4 
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Figure 4.14: TRIM21-deficient mice infected with avirulent Toxoplasma do not develop organ 
dysfunction or damage. 
Wild-type and TRIM21-deficient mice infected intraperitoneally with avirulent Toxoplasma were 
sacrificed at 7 days post-infection (dpi). Blood was collected and levels of selected serum biomarkers 
were measured on the Cobas C111 analyser as described in the Experimental procedure. TRIM21-
deficient mice do not exhibit organ dysfunction or damage following infection with avirulent 
Toxoplasma. ALB2: albumin; ALTL: alanine aminotransferase; ASTL: aspartate aminotransferase; 
BILTS: bilirubin; CHOL2: cholesterol; GLU2: glucose; LACT2: lactate; LDHI2: lactate 
dehydrogenase; LDLC: low density lipoprotein cholesterol; LIPC: lipase; TRIGL: triglycerides; UREL: 
urea. Mean + SEM, unpaired t-test. 
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Figure 4.15: TRIM21-deficient mice infected with avirulent Toxoplasma do not develop abnormal 
pathology. 
Wild-type and TRIM21-deficient mice infected intraperitoneally with avirulent Toxoplasma were 
sacrificed at 7 days post-infection (dpi). Liver and spleen were fixed in neutral buffered formalin and 
processed for histology as described in the Experimental Procedure. Analysis of pathology in the liver 
(a) and the spleen (b) was performed on hematoxylin and eosin slides by Prof. Cheryl Scudamore. 
TRIM21-deficient mice do not exhibit abnormal liver and spleen pathology following infection with 
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Figure 4.16: TRIM21-deficient mice exhibit a higher parasite burden and a decreased microglia 
population in the brain following avirulent Toxoplasma infection. 
Wild-type and TRIM21-deficient mice infected intraperitoneally with avirulent Toxoplasma were 
sacrificed at 7 days post-infection (dpi). Brains were isolated and used for the determination of the 
parasite load or analysis of the immune cell populations. (a) Quantitative analysis of the number of 
GFP-expressing Toxoplasma tachyzoites in the brain of wild-type and TRIM21-deficient mice at 7 dpi. 
Data pooled from three independent experiments. Mean + SEM, *** p<0.001, unpaired t-test. (b) Innate 
cells were isolated from the brain and innate cell populations were analysed by flow cytometry as 
described in the Experimental Procedure. The plots are representative fluorescence-activated cell 
sorting (FACS) plots of the live, single innate cell populations in the brain of wild-type and TRIM21-
deficient mice following avirulent Toxoplasma infection. The graphs are quantitative analyses of innate 
cell populations in the brain of wild-type and TRIM21-deficient mice following avirulent Toxoplasma 
infection by frequency (left panel) and total cell number (right panel). Data representative of two 
independent experiments. Mean + SEM, **** p<0.0001, 2-way ANOVA. (c) Lymphocytes were 
isolated from the brain and lymphocyte populations were analysed by flow cytometry as described in 
the Experimental Procedure. The plots are representative FACS plots of the live, single lymphocyte 
populations in the brain of wild-type and TRIM21-deficient mice following avirulent Toxoplasma 
infection. The graphs are quantitative analyses of lymphocyte populations in the brain of wild-type and 
TRIM21-deficient mice following avirulent Toxoplasma infection by frequency (left panel) and total 
cell number (right panel). Data representative of two independent experiments. Mean + SEM, * p<0.05, 
*** p<0.001, **** p<0.0001, 2-way ANOVA. 
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Figure 4.17: TRIM21-deficient mice exhibit decreased levels of transcripts  involved in the brain 
immune inflammatory response to avirulent Toxoplasma infection. 
Wild-type and TRIM21-deficient mice infected intraperitoneally with avirulent Toxoplasma were 
sacrificed at 7 days post-infection (dpi). Brains were isolated, RNA was isolated and gene expression 
was assessed by quantitative polymerase chain reaction as described in the Experimental Procedure. 
Mice lacking TRIM21 present significantly lower levels of transcripts involved in the inflammatory 
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Figure 4.18: Analysis of the antibody coating of in vivo Toxoplasma tachyzoites. 
Toxoplasma tachyzoites were isolated from the peritoneum and/or brain of infected mice and their 
potential antibody coating was analysed by flow cytometry as described in the Experimental Procedure. 
(a) Antibody coating profiles of Toxoplasma tachyzoites purified from the peritoneum of C57BL/6 mice 
(upper panel) or B cells-deficient mMT mice (lower panel) at 4 days post-infection. Fluorescence-
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activated cell sorting (FACS) plots are representative of at least 4 independent experiments. In the 
presence of circulating antibodies, Toxoplasma parasites are mainly coated with IgG. (b) Antibody 
coating profiles of Toxoplasma tachyzoites purified from the brain (upper panel) or peritoneum (PECs, 
lower panel) of C57BL/6 mice at 7 days post-infection. FACS plots are representative of at least 3 
independent experiments. Toxoplasma tachyzoites are coated with IgM in the brain and with IgG in the 
peritoneum. (c) Quantitative analysis of the antibody coating profile of Toxoplasma tachyzoites in the 
peritoneum (PECs) and brain of C57BL/6 mice at 7 days post-infection. Data representative of three 
independent experiments. Toxoplasma tachyzoites are coated with IgM in the brain and with IgG in the 
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During Toxoplasma infection, IFNγ is the main cytokine produced and it orchestrates 
the immune response that involves the recruitment of the two families of large 
GTPases, the p47 IRGs and p65 GBPs to the avirulent parasitophorous vacuole. This 
accumulation of large GTPases leads to the disruption of the avirulent Toxoplasma 
vacuole and its subsequent clearance by autophagy. The mechanisms by which the 
GBPs are recruited to the vacuole, as well as the downstream effectors triggered after 
the disruption of the parasitophorous vacuole remain unclear. The aim of this work 
was to identify new host factors that play a role at the parasitophorous vacuole and 
contribute to mediating the restriction of Toxoplasma. 
In the first part of this study, I showed for the first time that ubiquitin decorates the 
parasitophorous vacuole of avirulent Toxoplasma in an IFNγ-dependent manner. The 
E3 ubiquitin ligase TRIM21 was identified as the first putative interaction partner of 
GBP1 during Toxoplasma infection. The IFNγ-mediated GBP1-TRIM21 cytoplasmic 
complex recruits to the avirulent Toxoplasma vacuole. TRIM21 has been shown bind 
to invading antibody-coated adenoviruses and targets them to degradation by the 
proteasome due to its E3 ligase activity (Mallery et al., 2010), thereby enabling to 
control viremia in vivo (Vaysburd et al., 2013). The in vitro experiments reported in 
this work have been performed in medium supplemented with FCS, where antibodies 
can hence be present. As a result, it remains to be assessed with antibody-free medium 
and parasites versus antibody-coated parasites whether the recruitment of TRIM21 and 
GBP1 to avirulent Toxoplasma vacuoles is dependent on antibodies. Additionally, 
TRIM21 regulates Lys63-linked ubiquitination in the vicinity of the vacuole, but the 
in vitro studies suggest TRIM21 does not participate in the restriction of Toxoplasma 
in mouse embryonic fibroblasts or in the regulation of immune signalling in 
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macrophages. Very interestingly, ubiquitinated proteins identified in this study include 
GBP1 and GBP2 proteins. Moreover, the TRIM21-mediated regulation of the GBPs 
appear to be both at the transcriptional and the protein level, with GBP1 being 
downregulated while GBP2 being upregulated. These results will be confirmed in the 
future by quantitative polymerase chain reaction, and point to TRIM21 having a role 
in regulating the differential biological function of GBP1 and GBP2 during 
Toxoplasma infection that still needs to be elucidated. As the SILAC results and the 
RNAseq data show that the protein abundance of both GBP1 and GBP2 is altered in 
cells lacking TRIM21, one cannot exclude that the differential ubiquitination profile 
of the GTPases is simply due to a difference in the protein level in TRIM21-deficient 
cells. To address this, a new SILAC experiment with a targeted quantification of the 
GBPs protein levels as well as with a targeted analysis of the GBPs diGLY sites would 
enable assessment of whether the ubiquitination patterns observed are real. Moreover, 
the difference in ubiquitination profiles will be confirmed by immunoprecipitating 
ubiquitinated proteins in wild-type and TRIM21 KO cells and immunoblotting for 
GBP1 or GBP2. As GBP1 recruitment is partly dependent on the presence of TRIM21, 
it is likely the E3 ubiquitin ligase mediates a ubiquitination cascade that GBP1 is 
dependent on. The IRGs- and GBPs-mediated disruption of the vacuole could possibly 
unmask abnormally localised intracellular antibodies coating Toxoplasma. Both the 
presence of intracellular antibodies in Toxoplasma infection and a binding to these by 
TRIM21 with the functional consequences this would trigger remain unclear. Finally, 
TRIM21 strikingly and mainly transcriptionally downregulates one specific biological 
pathway that is the biosynthesis of cholesterol. As Toxoplasma is auxotroph for 
cholesterol and hence relies on its host as a source for the molecule, this could be a 
mean by which TRIM21 fights against Toxoplasma. 
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In the second part of this work, I report that TRIM21-deficient mice are highly 
susceptible to Toxoplasma infection, hence highlighting the important role of the 
protein in resistance against the parasitic infection. Mice lacking TRIM21 succumb 
during the acute phase of the infection, between day 7 and 10 post-inoculation. The 
death of the animals is preceded by an increased parasite burden in the periphery at 5 
days post-infection, and the death correlates with a higher parasite load in the brain at 
day 7 post-infection. Although TRIM21-deficient mice do not develop any abnormal 
pathology or differential immune cell populations in the periphery, they exhibit a 
decreased production of inflammatory cytokines in the serum. This lower immune 
response is also reflected in the brain, where the transcriptional levels of genes 
involved in the immune response and the number of microglial cells are both 
decreased. One property of TRIM21 recently brought to the fore is its ability to bind 
to intracellular antibody-coated adenoviruses (Mallery et al., 2010). As far as 
Toxoplasma is concerned, the presence of antibodies inside the vacuole at the surface 
of the parasite following invasion remains unclear. It is generally accepted that a 
fraction of the Toxoplasma-derived surface-exposed proteins are shed or not carried 
into the cell due to sieving at the Tight Junction during parasite invasion (Walzer and 
Genta, 1989). With regards to bound antibodies, electron microscopy of anti-P30 (the 
major Toxoplasma surface protein) coated parasites left to invade HeLa cells 
demonstrated that most of the parasite surface-attached antibody was shed, however, 
some escape was noted and a minor fraction of the parasites were faintly labelled with 
anti-P30 antibody intracellularly (Dubremetz et al., 1985). In terms of viral 
neutralisation, it has been calculated that 1.6 antibodies per virus particle suffice for 
TRIM21 activity in the presence of interferon (MacEwan et al., 2012). It is thus 
conceivable that very few residual antibodies bound to the parasite could trigger the 
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activity of TRIM21. I showed in preliminary work that avirulent Toxoplasma 
tachyzoites isolated from the peritoneum of a C57BL/6 mouse are mainly coated with 
IgG, while parasites isolated from the peritoneum of µMT mice lacking B cells and 
hence circulating antibodies, do not harbour any antibody. These preliminary data also 
show that avirulent Toxoplasma isolated from the immune privilege brain of a 
C57BL/6 mouse were mainly coated with IgM. How this differential antibody 
decoration influences the immune response to the parasite at the site of infection 
remains unknown. As B cell-deficient mice die of a high parasite load in the brain 
(Kang et al., 2000), it is tempting to hypothesise that TRIM21 and antibodies act in 
concert during Toxoplasma infection, such that TRIM21 could sense antibody-coated 
parasites like it does detect adenoviruses. However, this hypothesis would prove to be 
difficult to test in vivo, as even backcrossing TRIM21-deficient mice on the µMT 
genetic background would not help determine the individual or combined role of 
TRIM21 and antibodies. 
Altogether, the data gathered during this study indicate TRIM21 is an important player 
in the resistance against Toxoplasma infection in the mouse model, acting on both the 
regulation of the immune response to the parasite and the restriction of the parasite 
replication. How this dual function is achieved remains to be further determined. First, 
TRIM21-mediated Lys63-linked ubiquitination at the vicinity of avirulent Toxoplasma 
could be responsible for the differential downstream immune signalling outcome. It is 
thus essential to determine the consequence of ubiquitination around the avirulent PV, 
whether it be by mediating the recruitment of other effectors to the vacuole or by 
regulating other E3 ligases or deubiquitinases. Second, it is tempting to speculate that 
the TRIM21-mediated ubiquitination of the GBPs as well as the downregulation of the 
cholesterol biosynthesis both impact on the ability of the parasite to successfully thrive 
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in the host. It is imperative to continue deciphering the precise role of the different 
GBPs at the Toxoplasma vacuole in order to understand how their TRIM21-mediated 
differential ubiquitination and expression level can affect the response to Toxoplasma 
infection. The importance of TRIM21 in the regulation of cholesterol metabolism 
during Toxoplasma infection could be further investigated by confirming the 
differential cholesterol levels in vivo by immunobloting, polymerase chain reaction 
and mass spectrometry, but also by treating the animals with statins, molecules that 
inhibit hydroxyl methyl glutaryl-CoA reductase, an enzyme crucial for the production 
of cholesterol in the liver (Endo et al., 1976). Should TRIM21-mediated 
downregulation of the cholesterol be important for the restriction of Toxoplasma, 
TRIM21-deficient mice treated with statins would present reduced levels of 
cholesterol and could be rescued. Moreover, the discrepancy between the in vivo 
imaging (where TRIM21-deficiency leads to a higher parasite load) and the in vitro 
plaque assay (where TRIM21-deficient cells can contain Toxoplasma replication) 
could be explained by the fact that the latter has been performed in the presence of 
serum-containing cholesterol, thereby allowing the parasite to grow and replicate 
happily in TRIM21-deficient cells. The plaque assay will be reproduced in the near 
future in the presence of a lipoprotein-free serum in order to determine whether the 
outcome of the experiment will be different. 
To conclude, I have demonstrated in this work the importance of TRIM21 in the 
resistance against Toxoplasma infection, acting on both the restriction of the parasite 
itself as well as on the regulation of the inflammatory response. Further investigations 
will help understand the proper mechanisms underlying these two properties. 
However, I could hypothesise that by upregulating the production of inflammatory 
cytokines and downregulating the biosynthesis of cholesterol, TRIM21 participates in 
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the control of Toxoplasma replication, avoiding a high parasite burden in the periphery 
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Figure A. 1: List of the transcripts in the brain of Toxoplasma-infected wild-type and TRIM21-
deficient mice analysed by quantitative polymerase chain reactions. 
Wild-type and TRIM21-deficient mice infected intraperitoneally with avirulent Toxoplasma were 
sacrificed at 7 days post-infection (dpi). Brains were isolated, RNA was extracted and gene expression 
was assessed by quantitative polymerase chain reaction as described in the Experimental Procedure. 
Mean + SEM, unpaired t-test. 
 
 
